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Abstract 
Coagulation plays an important role in the haemostatic process, forming a blood 
clot to prevent blood loss. Changes in formation, structure or breakdown of 
these clots can result in the pathogenesis of thrombotic disorders. These 
imbalances can be caused by changes to the fibrin(ogen) molecule, 
inflammation and levels of other plasma proteins. This thesis focusses on 
different mechanisms that effect clot structure, and how these prevent or 
promote disease, with the aim of uncovering new pathways to target 
therapeutically. 
This study revealed the vast range of physiological fibrinogen γ’ levels present 
in 1164 patients, fluctuating between 0.8 % and 39.5 % of total fibrinogen. 
Furthermore, it demonstrated that changes of fibrinogen γ’ levels within this 
physiological range plays an important role in modulating clot structure, with 
fibrinogen γ’ significantly increasing height and volume of clots under flow. It 
also found that the FXIII-B Arg95 variant is associated with an increased risk of 
AAA, suggesting a possible role for FXIII in AAA pathogenesis. It showed how 
PNH patients with increased clone size have a more thrombotic phenotype, with 
faster forming, more stable clots, but these changes do not appear to be caused 
by changes in the fibrin clot. In addition, it showed that the antithrombotic 
effects of eculizumab treatment appear to function in part due to a reduction in 
fibrinogen and thrombin levels. And finally the discovery of a remarkable aspect 
of blood clotting in which fibrin forms a protective film at the air-blood interface 
covering the external surface of the clot, retaining blood cells and providing an 
instant barrier against microbial invasion. 
Together these data provide new insight into some of the main modulators of 
clot structure, providing previously unknown mechanisms of haemostasis and 
possible new pathways to target in the prevention and treatment of thrombosis 
and infection. 
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Chapter 1 - Introduction  
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The coagulation and fibrinolytic cascades play important roles in both the 
prevention of blood loss and infection control. Damage to the vessel wall and 
exposure of the subendothelium triggers complex pathways that result in the 
formation of a blood clot that helps to prevent blood loss. Imbalances in the 
formation, stability or breakdown of these clots can result in the 
pathogenesis of thrombotic or bleeding disorders. 
1.1 Haemostasis 
The ultimate goal in the haemostatic process is to prevent the loss of blood. 
This is achieved by blocking breaches in the vessel wall with the formation of 
a blood clot. This occurs through a chain of enzymatic reactions known as 
the coagulation cascade. The initial step, primary haemostasis, occurs due 
to the activation and aggregation of platelets to form a platelet plug. This is 
followed by secondary haemostasis, which refers to the formation of the 
fibrin 3D network, which helps to stabilise the platelet plug. This occurs 
through two pathways, the ‘Extrinsic’ or ‘Tissue Factor’ pathway which is 
triggered by tissue factor (TF), or the ‘Intrinsic’ or ‘Contact Factor’ pathway 
which is triggered by the exposure of collagen or a negatively charged 
surface, activation of prekallikrein, high molecular weight kininogen (HMWK) 
and Factor XII (FXII). 
1.1.1 Coagulation initiation 
Upon injury to the vessel wall, endothelial cells in close proximity to the site 
of injury become activated. This results in P-selectin being released from the 
Weibel-Palade storage bodies (WPB) and becoming exposed on the cell 
surface (McEver et al., 1989). Exposure of the subendothelium immediately 
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begins to activate platelets, with P-selectin also being exposed on the 
platelet surface from within the alpha granules, where it plays an important 
role in the initial adhesion and rolling of platelets to areas of injury and 
inflammation. Activated platelets also begin to adhere to the exposed 
collagen and fibronectin via GPVI and α2β1 (Roskam et al., 1959). 
Simultaneously von Willebrand Factor (vWF) is released from the body of 
endothelial cells and platelets. This plays two roles, under high shear rates 
(arterial flow) vWF recruits platelets to the site of injury by binding collagen in 
the subendothelium and glycoprotein Ib (GPIb) on the platelet surface 
(Bergmeier et al., 2006). vWF also binds to glycoprotein IIb/IIIa (GPIIb/IIIa) 
on the activated platelet surface which helps to increase platelet aggregation 
(Naimushin and Mazurov, 2004). Tissue factor, a transmembrane 
glycoprotein, is expressed on stromal fibroblasts and smooth muscle cells 
and is exposed upon vascular injury. Circulating Factor VII (FVII) binds to TF 
forming an active TF-FVIIa complex, which can then activate Factor X (FX). 
Factor Xa (FXa) activates prothrombin to thrombin, and this small quantity of 
thrombin feeds back to propagate further thrombin production in the 
amplification phase (Monroe and Hoffman, 2006). 
1.1.2 Thrombin amplification 
Thrombin produced from FXa activation leads to the activation of Factor V 
(FV) and Factor XI (FXI). Thrombin also releases Factor VIII (FVIII) from its 
circulating complex with vWF and activates it. FVIIIa then comes together 
with Factor IXa (FIXa) and calcium on platelet surfaces to form a tenase 
complex, which activates FX (Dahlback, 2000). 
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The tenase complex goes on to produce vast quantities of FXa, this forms a 
partnership with FVa forming the prothrombinase complex. The 
prothrombinase complex results in a thrombin burst, producing large 
quantities of thrombin (Dahlback, 2000). The thrombin produced continues 
to activate FV, FVIII and FXI resulting in further thrombin production. The 
activation of FXI results in the activation of Factor IX (FIX) which also 
contributes to thrombin production. The thrombin produced goes on to 
convert fibrinogen to fibrin and activate Factor XIII (FXIII) to help stabilise the 
clot. 
1.1.3 Intrinsic pathway 
The intrinsic pathway is initiated by the exposure of collagen or other 
negatively charged surfaces to FXII. Small amounts of FXII are auto-
activated and along with HMWK, leads to the activation of prekallikrein (PK) 
to kallikrein (Kaplan et al., 2002, Renne et al., 2012). Further activation of 
FXII by kallikrein, and PK by FXIIa results in a positive feedback loop. The 
generated FXIIa subsequently activates FXI. FXIa activates FIX, which along 
with FVIII, activates FX (Smith et al., 2015), leading to the activation of 
prothrombin. 
Both the intrinsic and extrinsic pathways continue their feedback loops with 
activation of FV, FVIII and FIX producing more thrombin, until they are 
downregulated by anticoagulants or the fibrinolysis pathways. 
1.1.4 Fibrinogen to fibrin 
Fibrinogen is the third most abundant of human plasma proteins, and 
normally circulates at around 2-4 mg.ml-1. Fibrinogen expression can be 
upregulated in response to pro-inflammatory agents such as interleukin-6 
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and other cytokines, resulting in increased plasma levels (Dalmon et al., 
1993, Lane et al., 1991). Increased levels of fibrinogen are associated with 
cardiovascular disease including stroke, peripheral vascular disease, 
pulmonary embolism and abdominal aortic aneurysms (AAA) (Danesh et al., 
2005, Bartlett et al., 2009, Klovaite et al., 2013, Parry et al., 2009). Whether 
these elevated fibrinogen levels are part of the cause or an effect of the 
disease is still unknown. 
Fibrinogen is a 340 kDa complex glycoprotein made up of three pairs of 
polypeptide chains, Aα, Bβ and γ held together by 29 disulfide bonds 
(Doolittle, 1984, Henschen and McDonagh, 1986). It is 45 nm long, 
consisting of three globular regions, two D regions at each end and one E 
region in the centre connected by α-helical coiled-coil rods (Hall and Slayter, 
1959, Weisel et al., 1985). The C-terminal ends of the Aα-chains extend out 
from the D regions in a coiled-coil, ending in the αC globular region (Weisel 
and Medved, 2001). The N-terminal ends of the Aα- and Bβ-chains, 
fibrinopeptide A and B, are located in the central E region. 
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Figure 1 Structure of fibrinogen and conversion to fibrin. A, A diagram of 
fibrinogen structure. Fibrinogen consists of three pairs of polypeptide chains, Aα, 
Bβ and γ held together by 29 disulfide bonds. All three chains converge in a central 
E region, which contains the cleavage sites for thrombin (Fibrinopeptides A and B). 
The chains extend out of this central E region through a coil-coiled region to the D 
regions, where the beta and gamma chains reach their C-terminus. The alpha chain 
extends beyond this D region, as the alpha-C chain. B, Fibrinopeptide A is cleaved 
by thrombin from fibrinogen which aggregate via knob-hole interactions forming 
oligomers and then protofibrils. Fibrinopeptide B is then cleaved by thrombin, 
releasing the αC regions, which allows lateral aggregation to occur forming fibres. 
Factor XIIIa initially crosslinks γ chains, followed by α chains. Branch points are 
initiated by the divergence of two protofibrils. Adapted from Weisel (2005). 
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Fibrin polymerization is initiated when the fibrinopeptides are cleaved 
specifically by thrombin, a serine protease (Figure 1). The newly exposed 
‘‘knobs’’ in the E region, due to fibrinopeptide removal, interact with the 
‘‘holes’’ that are always exposed in the D regions (Doolittle, 1984, Shainoff 
and Dardik, 1983). This results in the conversion of soluble fibrinogen to an 
insoluble fibrin polymer. These tightly controlled binding interactions result in 
fibrin polymerizing in a repeating 22.5 nm half-staggered conformation 
producing oligomers that lengthen into protofibrils (Weisel, 1986, Fowler et 
al., 1981). Protofibrils laterally aggregate, enhanced by αC regions, to form 
fibres, forming a branching 3D network that is essential for haemostasis 
(Hantgan and Hermans, 1979, Weisel and Medved, 2001). Finally FXIII, also 
activated by thrombin, covalently binds together fibrin molecules through 
specific glutamine-lysine residue interactions via isopeptide bonds 
(Henschen and McDonagh, 1986, Lorand, 2001). This helps to stabilize the 
clot against mechanical, and proteolytic interventions. The mechanical 
properties of clots are essential to fibrin’s functions in haemostasis.  
A blood clot is only a temporary plug during haemostasis, so mechanisms 
are in place to remove fibrin and remove the clot after it has served its 
purpose. The breakdown of fibrin occurs when the zymogen plasminogen is 
activated to the active enzyme plasmin by tissue-type plasminogen activator 
(tPA), which results in the digestion of fibrin at specific lysine residues 
(Marder et al., 1969). This process is augmented by the co-localization of 
plasminogen and tPA on fibrin (Thorsen, 1992). As fibrin cleavage occurs 
new binding sites for plasminogen and tPA are created when new C-terminal 
lysine residues are exposed (Suenson et al., 1984). This leads to a positive 
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feedback mechanism that accelerates lysis ensuring a rapid and efficient 
breakdown of the clot. 
1.1.5 Factor XIII 
Factor XIII is a protransglutaminase consisting of two A-subunits, which 
contain the active site, and two B-subunits, which protect the hydrophobic A 
subunits, arranged as a heterotetramer (Schwartz et al., 1973). The 
activation of FXIII begins with thrombin cleaving a 37 amino acid activation 
peptide from the A-subunit. The presence of calcium then leads to the 
dissociation of the B-subunits, exposing the activated enzyme FXIIIa  
(Ariens et al., 2002). The activated FXIII plays a vital role in stabilising the 
fibrin clot by crosslinking fibrin monomers together and also crosslinking 
anti-fibrinolytic proteins, such as alpha-2-antiplasmin (α2AP) into the clot. 
Crosslinking of fibrin occurs through the α- and γ-chains, with γ-chain 
crosslinking happening first between Gln398 or 399 of one molecule and 
Lys406 on another molecule during protofibril formation (Duval et al., 2014, 
Spraggon et al., 1997). This is followed by slower α-chain crosslinking 
between Gln221, Gln328 and Gln355 in one molecule with one of 15 Lys 
residues in another molecule during lateral aggregation (Lorand, 2001). 
Crosslinking by FXIIIa leads to a clot with increased density and thinner 
fibres that is harder to break down (Smith et al., 2013), increases fibre 
stiffness and reduces deformation (Duval et al., 2014) and slows fibrinolysis 
(Mutch et al., 2010b). FXIIIa also crosslinks α2AP (Tamaki and Aoki, 1981), 
plasminogen activator inhibitor-2 (PAI-2) (Ritchie et al., 2001) and thrombin 
activatable fibrinolysis inhibitor (TAFI)(Valnickova and Enghild, 1998). 
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1.1.6 Changes in clot structure 
The role of altered fibrin clot structure in cardiovascular disease has been 
the focus of many previous studies (Bridge et al., 2014). Some of the main 
characteristics of fibrin clots that have been analysed previously include fibre 
density and thickness, fibre branching, protofibril packing (protein density of 
fibre), clot permeability and viscoelastic properties (Table 1). Changes in 
these structural properties have been linked to increased thrombotic risk. 
Increased fibrinogen concentration has been shown to be a risk factor for 
CVD (van Holten et al., 2013), and is one of the major modulators of fibrin 
clot structure. Increasing fibrinogen concentration is thought to effect 
polymerisation resulting in an increased fibre density and thickness 
(Standeven et al., 2005). Elevated fibrinogen levels have been shown to 
reduce time to vascular occlusion in vivo, and increase clot fibrin content, 
network density and resistance to fibrinolysis in a murine model (Machlus et 
al., 2011). Alterations in the molecular structure of fibrinogen have also been 
shown to play a role in clot structure. Splice variant fibrinogen γ’ (discussed 
in more detail in chapter 1.2) has been shown to result in clots with thinner 
fibres, reduced protofibril packing, increased number of fibre branch points 
and reduced pore size (Cooper et al., 2003, Domingues et al., 2016). 
Another common fibrinogen sequence variant, Fib-β Arg448Lys also effects 
clot structure resulting in clots with thinner fibres, smaller pores and 
increased stiffness that are more resistant to lysis (Ajjan et al., 2008). 
However fibrinogen alone does not account for all alterations to clot 
structure. Another major factor in alterations to clot architecture is thrombin 
concentration. Low thrombin concentrations (< 1 nM) lead to clots with thick, 
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loosely woven fibres, while high concentrations (> 100nM) lead to clots with 
thin, densely packed fibres (Wolberg, 2007). Thrombin concentration during 
coagulation varies from < 1nM up to > 500 nM, although low levels of 
thrombin (~ 2 nM) are sufficient for fibrin polymerisation (Brummel et al., 
2002). Thrombin concentration has also been shown to modulate protofibril 
packing, with increased thrombin concentrations resulting in a decrease in 
protofibril packing (Domingues et al., 2016). Thrombin generation is mostly 
localized to the cell surface and this leads to spatial heterogeneity in clot 
structure correlated with the distance of fibrin from the cell surface 
(Campbell et al., 2008).  
As previously mentioned FXIII has also been shown to influence clot 
structure, with fibrin crosslinking resulting in fibrin clots with increased 
density, reduced pore size and thinner fibres, with increased resistance to 
lysis (Hethershaw et al., 2014). However, changes to FXIII have also been 
associated with changes to fibrin clot structure. FXIII-A Val34Leu results in 
faster activation of FXIII by thrombin, with the resulting clots forming faster 
with thinner and smaller pores (Ariens et al., 2000, Schroeder et al., 2001). 
Blood flow has also been shown to profoundly affect clot structure, leading to 
fibrin fibres aligning in the direction of flow, increasing clot stiffness in that 
direction (Gersh et al., 2010). One study reported thick fibres in the direction 
of flow, with thinner interconnecting fibres (Campbell et al., 2010). 
Platelets can alter clot properties via proteins they release, particularly at 
sites of platelet aggregation. Platelet factor 4 release is associated with the 
formation of a compact clot structure (Amelot et al., 2007). Polyphosphates 
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lead to the formation of tight fibre aggregates interspaced with large pores 
(Mutch et al., 2010a). 
Table 1 Modifiers of fibrin clot structure. 
 
1.1.7 Fibrinolysis 
Fibrin breakdown mainly occurs through cleavage by plasmin. Plasmin is 
produced when plasminogen is activated by tissue- or urokinase-type 
plasminogen activators. This process is upregulated 1000-fold in the 
presence of fibrin by providing a surface for co-localisation of tPA and 
plasminogen (Collen, 1980b). Fibrinolysis is inhibited directly by inhibition of 
plasmin through α2AP and α2-macroglobulin (α2M), and indirectly through 
plasminogen activator inhibitor-1 (PAI-1) which blocks plasmin production, 
and through TAFI, which cleaves C-terminal lysines in fibrin inhibiting the 
fibrin enhancement of plasmin generation (Figure 2) (Collen, 1980a, 
Cesarman-Maus and Hajjar, 2005). 
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Figure 2 The fibrinolysis cascade. Plasminogen is converted to plasmin by tissue 
plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). 
Plasmin breaks down fibrin. Fibrinolysis is prevented or slowed by the inhibition of 
plasmin by alpha-2-antiplasmin (α2AP) and α2-macroglobulin (α2M), or through 
plasminogen activator inhibitor-1 (PAI-1) and thrombin activatable fibrinolysis 
inhibitor (TAFI) preventing plasmin generation. Adapted from Bridge et al. (2014). 
1.2 Fibrinogen γ’ 
Fibrinogen is the product of three closely linked genes: fibrinogen α (FGA), 
fibrinogen β (FGB) and fibrinogen γ (FGG) which are located in a region of 
approximately 50 kb on chromosome 4q31.3 (Kant et al., 1985). Many 
common mutations, splice variations and post translational modifications 
make fibrinogen a very heterogeneous protein. One of the most common 
heterogeneities is fibrinogen γ’. This fibrinogen variant is the result of a 
splice variation in the γ-chain, leading to a bulky negatively charged 
extension at the C-terminus of the γ-chain in about 10-12 % of total 
fibrinogen (Figure 3). This extension produces numerous functional effects, 
related to protein binding and modulation of fibrin network formation. 
Clinically, fibrinogen γ′ levels have been associated with thrombotic 
diseases, but the relationship with arterial and venous thrombosis appear 
different. In view of this splice variant being present in all individuals so far 
and its functional effects, many studies have investigated the role of 
fibrinogen γ′ in pathophysiology. 
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Figure 3 The bulky extension of fibrinogen γ’. A Fibrinogen molecule with the 
location and proposed model of the γ′-chain. A, The 20 amino acid extension of the 
γ′-chain is located at the C-terminus of the γ-chain (red) and may extend up to 30 to 
40 Å or more from the D region. B, When fibrinogen polymerizes through D–E–D 
interactions, the γ′ extension is at the D–D interface and could stretch to the E 
region of a neighbouring molecule affecting longitudinal polymerization (colours 
represent progression from N-terminus (blue) through to C-terminus (red) for each 
chain). The fibrinogen molecule crystal structure was taken from Kollman et al 
(Kollman et al., 2009) and the γ′-chain extension was created using PyMOL 
Molecular Graphics System (New York, NY). From Macrae et al. (2014). 
 
1.2.1 Splicing mechanisms and genetics 
In 1972, Mosesson et al discovered fibrinogen γ’ when noticing a subspecies 
of fibrinogen with a γ-chain that had a higher molecular weight (Mosesson et 
al., 1972). They also showed that fibrinogen’s heterogeneity in size and 
charge was due to this minor variation of the γ-chain. Over the next few 
years other groups made similar findings calling it a number of different 
names including γB, γ′, or γ57.5. (Francis et al., 1980, Fornace et al., 1984, 
Peerschke et al., 1986) The predominant wildtype γA chain is made up of 10 
exons and 9 introns. Normally polyadenylation occurs at the polyadenylation 
site (AATAAA) downstream of exon 10. However, the variant γ′-chain is 
produced when an alternative processing and polyadenylation site in the 
ninth intron is used instead. This results in the precursor mRNA being 
terminated and polyadenylated within the ninth intron (Chung et al., 1983, 
Chung and Davie, 1984). This alternative precursor matures into the mRNA 
that codes for the 20 unique amino acids at the terminal end of the γ′-chain 
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(γ′408–427; VRPEHPAETEYDSLYPEDDL), substituting the 4 γA amino 
acids (γA408– 411) of exon 10 (Wolfenstein-Todel and Mosesson, 1980, 
Wolfenstein-Todel and Mosesson, 1981)(Figure 4). 
 
 
Figure 4 Alternative FGG pre-mRNA processing. The predominant γA chain is 
formed when polyadenylation occurs at the polyadenylation site 2 (pA2) 
downstream of exon 10. The γ′-chain is formed when an alternative polyadenylation 
site 1 (pA1), which occurs in the ninth intron, is selected. This precursor molecule 
matures into the mRNA that codes for the 20 unique amino acids at the terminal 
end of the γ′-chain, substituting the 4 γA amino acids of exon 10. From Macrae et 
al. (2014). 
 
1.2.2 Thrombin interactions 
Fibrinogen γ′ has been shown to bind thrombin with high affinity through 
exosite II on thrombin (Lovely et al., 2003), while thrombin exosite I interacts 
with the fibrinogen E region, where the fibrinopeptides reside. When bound 
to thrombin, fibrinogen γ′ adopts a β-turn structure between residues 422 
and 425 (Sabo et al., 2006, Pineda et al., 2007). Within these residues there 
are two negatively charged, sulphated tyrosines that are particularly 
important for thrombin binding. When bound to thrombin, γ′ Tyr418 is 
positioned in a groove between Lys235, Lys236, and Arg126, and γ′ Tyr422 
closely interacts with Lys240 within exosite II (Pineda et al., 2007). These 
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interactions consolidate the high affinity interaction of fibrinogen γ′ with 
thrombin. 
The interaction of γ′ with thrombin is normally associated with thrombin 
inhibition. In fact, fibrinogen γ′ was also called antithrombin I in view of its 
inhibitory effect on thrombin (de Bosch et al., 2002). However, the effects of 
fibrinogen γ′ on thrombin activity are complex. It is thought that the 
antithrombin I activity of fibrinogen γ′ is due to the sequestering of thrombin 
via γ′ into the forming fibrin clot, reducing the amount of thrombin in the 
remaining plasma solution. Furthermore, the presence of the γ′ sequence 
was found to reduce fibrinopeptide B (FpB) cleavage, which resulted in 
reduced lateral aggregation of the fibrin fibres (Cooper et al., 2003). 
However, γ′ has no effect on fibrinopeptide A (FpA) cleavage, and when 
bound to γ′, thrombin is also relatively protected against inhibition by 
antithrombin and heparin (Cooper et al., 2003, Moaddel et al., 2000, 
Fredenburgh et al., 2008). It appears therefore that thrombin activity remains 
normal when thrombin is associated with fibrin(ogen) γ′, at least toward 
some of the above-mentioned substrates. Finally, the presence of fibrinogen 
significantly increases thrombin generation in plasma, and the fibrinogen γ′ 
variant is particularly capable in this respect, largely by decreasing α2M-
dependent thrombin degradation (Kremers et al., 2014). The binding of γ′ to 
thrombin does not just inhibit thrombin activity, but rather modulates the 
activity of thrombin by localizing it to the growing fibrin clot and by protecting 
it against degradation. 
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1.2.3 Interactions with other proteins and pathways 
FXIII is a zymogen of the transglutaminase FXIIIa that helps to stabilize 
blood clots in both mechanical aspects (Lorand, 2001) and its resistance to 
lysis (Gaffney and Whitaker, 1979, Siebenlist and Mosesson, 1994). It is 
known that FXIII associates with fibrinogen (Kd 10-8 M), and on the basis of 
this affinity constant, it is thought that practically all FXIII in circulation is 
bound to fibrinogen (Greenberg and Shuman, 1982). FXIII co-purifies with 
fibrinogen γA/γ′ on anion-exchange chromatography, and when separated 
from fibrinogen γA/γA, FXIII was only found in the second peak of γA/γ′ 
(Mosesson and Finlayson, 1963). Fibrinogen γA/γ′ has been shown to bind 
to the B-subunit of plasma FXIII with 20-fold higher affinity than fibrinogen 
γA/γA (Siebenlist et al., 1996). However, two studies have opposed this, with 
one showing no difference in FXIII binding between γA/γ′ and γA/γA 
fibrinogen (Gersh et al., 2006). The second more recent study found that the 
FXIII zymogen binds to fibrinogen residues γ390-396 via the B subunits 
(Byrnes et al., 2016). They also suggest that all excess plasma FXIII-B2 
circulates bound to fibrinogen, suggesting that this may reveal part of a 
stepwise mechanism that leads to production of fibrinogen/FXIII-A2B2 
complexes. The effects of γ′ fibrin on FXIII activation and crosslinking have 
not been fully established. One study shows that γA/γ′ increases the 
activation kinetics of FXIII leading to enhanced FXIII A- and B-subunit 
dissociation (Moaddel et al., 2000). Three other studies all have opposing 
views on the effect of fibrinogen γA/γ′ on FXIII crosslinking, suggesting it 
upregulates (Moaddel et al., 2000), downregulates (Siebenlist et al., 2001) or 
has no effect at all (Allan et al., 2012) on the crosslinking of the fibrinogen γ-
chain. 
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Fibrinogen γ′ has also been shown to cause effects on other proteins in the 
coagulation system. Its interaction with thrombin has been shown to inhibit 
FVIII and FV activation, which also depend on binding with thrombin exosite 
II (Lovely et al., 2007, Omarova et al., 2013a). Fibrinogen γ’ has also been 
shown to increase plasma activated Protein C sensitivity and increase 
histidine-rich glycoprotein binding (Omarova et al., 2013b, Vu et al., 2011). 
The carboxy-terminal end of the fibrinogen γA-chain is involved in binding to 
the platelet integrin GPIIb/IIIa (Hawiger et al., 1982, Kloczewiak et al., 1982). 
The γ′-chain lacks the γA residues 408 to 411 required for platelet adhesion 
(Harfenist et al., 1984). This results in the γ′-chain reducing thrombin-
induced platelet aggregation in both static and flow conditions and in vivo 
γA:γ′ ratios have been shown to modify platelet activation (Lancellotti et al., 
2008). Platelets do not contain γA/γ′ fibrinogen, the reason for this is 
currently unknown and further studies are needed to elucidate why α-
granules only contain γA/γA fibrinogen (Francis et al., 1984). 
1.2.4 Fibrinogen γ′ effects on clot structure  
Changes in fibrin clot architecture have been closely associated with 
cardiovascular disease (CVD), and are thought to contribute to their 
pathogenesis and progression (Undas and Ariens, 2011). The structural 
changes that occur with fibrinogen γ′ have been found to associate with 
some CVDs. Elevated levels have been described in patients with 
myocardial infarction (MI) (Mannila et al., 2007), coronary artery disease 
(CAD) (Lovely et al., 2002), and acute phase ischemic stroke (Cheung et al., 
2008), while a reduction in levels has been related to increased risk of 
venous thrombosis (Uitte de Willige et al., 2005). In view of these 
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associations with CVD, it is important to fully elucidate the role of fibrinogen 
γ′ on fibrin clot structure. There have been several studies that have 
demonstrated that fibrinogens γA/γA and γA/γ′ display different clotting 
characteristics. Plasma purified γA/γ′ fibrin has been shown to clot at a 
slower rate, and form clots with thinner fibrin fibres and smaller pores than 
γA/γA fibrin (Cooper et al., 2003, Siebenlist et al., 2005). Using 
microrheometer magnetic tweezers, γA/γ′ were shown to have reduced 
stiffness and increased viscosity compared to γA/γA clots both in the 
presence and absence of cross-linking by FXIIIa (Allan et al., 2012). This 
suggested that the γA/γ′ fibres are softer and more viscous and could result 
in increased propensity to embolize. Early stages of clot formation were 
studied and showed that fibrinogen γA/γ′ produced shorter oligomers 
compared with fibrinogen γA/γA, which may help to explain the highly 
branched γA/γ′ fibrin fibres. A model was suggested whereby shorter, more 
numerous protofibrils could lead to earlier gelling of γ′ clots. Subsequently, 
this produces γA/γ′ clots that are composed of thinner, shorter fibres 
interspersed by large pores. 
The rate at which thrombin removes the fibrinopeptides plays a role in 
clotting characteristics. FpB release has been shown to be decreased in 
γA/γ′ compared to γA/γA fibrinogen (Cooper et al., 2003, Kim et al., 2014). 
The timing of FpB release coincides with lateral aggregation of protofibrils 
and a delay in its release γA/γ′ could affect fibre thickness. In turbidity 
experiments, γA/γ′ fibrin clots produced with reptilase, a snake venom 
enzyme that release FpA but not FpB, showed decreased polymerization 
rates and reduced maximum absorbance. This demonstrates that the effects 
of γ′ on fibrin structure are independent of the electrostatic binding between 
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fibrinogen γ′ and exosite II in thrombin, and that the negatively charged 
region in fibrinogen γ′ directly influences fibrin formation (Allan et al., 2012). 
Clots containing fibrinogen γ′ are more resistant to breakdown by the 
fibrinolytic pathway. Fibrinolysis assays in the presence of FXIII have shown 
that plasma purified γA/γ′ fibrin is more resistant to fibrinolysis than γA/γA 
fibrin (Falls and Farrell, 1997). This was thought to be due to increased FXIII 
cross-linking and that γA/γ′ fibrinogen localizes FXIII to the fibrin clot to 
increase its stability. Reduced fibrinolysis rates with γA/γ′ have also been 
attributed to delayed FpB release, which results in delayed activation of 
plasminogen (Kim et al., 2014). The effects of γA/γ′ fibrinogen on lysis have 
also been shown in patient plasma, with patients with increased γA/γ′ levels 
presenting delayed clot lysis (Pieters et al., 2013).  
1.3 Abdominal Aortic Aneurysms 
An Abdominal Aortic Aneurysm is a permanent, localised dilatation of the 
descending abdominal aorta. The aorta is classed as aneurysmal when it is 
1.5 times its normal diameter or greater than 3 cm (Johnston et al., 1991). 
AAA commonly occurs in men over the age of 65 and accounts for up 1.8 % 
of all deaths in England and Wales (Parry et al., 2009). The natural 
progression of an untreated AAA is rupture with the risk increasing 
significantly as the size of the aneurysm increases (Brewster et al., 2003). 
Currently, the only treatment available is surgical intervention and the 
placement of a stent, which is offered electively once the AAA reaches the 
intervention threshold. This threshold is currently set at 55 mm, where the 
risk of rupture exceeds the risk of mortality from surgery (Filardo et al., 
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2012). An AAA rupture occurs when the stress on the aortic wall becomes 
too great and the aortic wall dissects. Two thirds of patients who experience 
a ruptured AAA end up dying before they reach hospital, and only 40-50 % 
of those that reach hospital survive (Dillavou et al., 2006). Even with a 
screening program in place in the UK for men over the age of 65, ruptured 
AAA is still responsible for over 6000 deaths per year. 
Studies have shown that some of the risk factors for AAA include smoking, 
and male gender and that diabetes mellitus is protective against AAA 
(Lederle et al., 1997). A genetic familial link has been suggested in AAA, 
where at least one first degree relative has also developed an AAA (Larsson 
et al., 2009, Linne et al., 2012). A number of candidate genes have been 
suggested as a means of inheritance, but no individual gene has been 
implicated (Sandford et al., 2007). AAA is a multifactorial disease, and it is 
likely that the disease and its progression is due to both genetic and 
environmental factors. Previous studies have indicated family history of AAA 
as a risk factor (Johansen and Koepsell, 1986), and strong links between 
AAA development and MMP9 (Duellman et al., 2012). Environmental factors 
such as smoking and obesity are known to be significant risk factors for the 
development of AAA (Blanchard et al., 2000, Stackelberg et al., 2013). 
1.3.1 Formation and progression of AAA 
Formation and progression of AAAs is not yet fully understood. In the 
presence of AAA it has been shown that matrix metalloproteinases (MMPs), 
other proteases from aortic smooth muscle cells and macrophages are 
secreted into the extracellular matrix. This leads to the proteolytic breakdown 
of the elastin and collagen that provide the structure of the aortic wall. There 
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is also an increase in the infiltration of lymphocytes and macrophages (Rizas 
et al., 2009), a loss of smooth muscle cells (Thompson et al., 1997) and 
neovascularisation (Thompson et al., 1996) occurring within the aortic wall. 
Studies have demonstrated that in AAA patients there is an increase in 
elastase and collagenase expression including MMP-2, -9, and -12 and 
MMP-1 and MMP-13 (Annabi et al., 2002, Curci et al., 1998, Knox et al., 
1997, Mao et al., 1999, Reeps et al., 2009). The role of inflammation and 
immune response have also been linked to AAA formation and progression. 
The increase in the number of macrophages and lymphocytes may lead to 
an increase in the number of cytokines that are released, and these can 
activate proteases leading to the breakdown of the aortic wall (Lindholt and 
Shi, 2006). The infiltration mechanisms of the leucocytes is not fully 
understood, but it has been suggested that elastin degradation products may 
act as a chemoattractant (Ailawadi et al., 2003). The influence of 
biomechanical stress on the aortic wall is thought to contribute to the 
progression of AAA expansion. With reduced elastin within the aortic wall, 
the aorta becomes much stiffer (He and Roach, 1994), and with fewer 
smooth muscle cells it becomes less resistant to pressure of arterial flow. 
The stress on the aortic wall was found to correlate with aortic diameter but 
also to asymmetry of the vessel, possibly due to disturbed flow within the 
aneurysm (Vorp et al., 1998). Figure 5 shows a schematic representation of 
the current understanding of AAA pathophysiology. 
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Figure 5 The pathophysiology of abdominal aortic aneurysms. A schematic 
diagram presenting the events that contribute to the formation and development of 
an AAA. A, A normal aortic wall with the three layers of intima, media and 
adventitia. The combination of collagen, elastin and smooth muscle cells help to 
maintain wall integrity. B, Following damage to the aortic wall leukocytes are 
recruited into the aortic media. Macrophages are activated and begin to release 
proinflammatory molecules, such as cytokines and reactive oxygen species. 
Macrophages also begin to produce pro-MMPs which are activated in the 
extracellular space. The active MMPs proceed to degrade elastin and collagen and 
over many years the degradation of elastin and collagen, the strain and tension 
from arterial blood pressure gradually leads to aortic dilatation. Smooth muscle cells 
and fibroblasts attempt to repair the damage, and this results in the deposition of 
disordered collagen. However, smooth muscle cells become senescent and 
undergo apoptosis resulting in the loss of smooth muscle cells. In an advanced 
AAA the medial layer of the aortic wall is found to be thinner.  
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1.3.2 The intra-luminal thrombus 
Around 75 % of larger aneurysms have been shown to possess an intra-
luminal thrombus (ILT) (Wang et al., 2002). Its role in AAA formation and 
progression is not fully understood. The ILT is not a stagnant structure and 
active secretion of proteolytic factors such as plasmin result in constant 
remodelling at the luminal surface (Houard et al., 2007). This results in the 
clot being biologically active. The wall underlying the ILT has been shown to 
have decreased tensile strength (Vorp and Vande Geest, 2005) and 
decreased wall thickness (Kazi et al., 2003). This in part, is thought to be 
due to the release of proteolytic factors which contribute to the thinning of 
the vessel wall (Folkesson et al., 2011, Fontaine et al., 2002, Coutard et al., 
2010). Increased plasmin production results in increased MMP activation, 
and a faster rate of collagen and elastin breakdown resulting in quicker 
aneurysm growth. (Carrell et al., 2006). This was supported by a study that 
showed an increase in ILT thickness resulted in increased MMP levels and 
elastin breakdown within the aortic wall (Koole et al., 2013). The ILT is also 
thought to mediate the weakening of the aortic wall by creating localised 
hypoxia, which intensifies as thrombus thickness increases (Vorp et al., 
2001). A couple of observational studies have found that larger ILTs are 
associated with a greater rate of AAA expansion and risk of rupture, and that 
this increased rate leads to higher risk of rupture (Wolf et al., 1994, 
Stenbaek et al., 2000). However, the mechanisms behind the effect of the 
ILT on expansion rate are still not fully understood. To highlight this, a 
number of studies have demonstrated a protective effect of the ILT, showing 
it to be protective against rupture by altering stress distribution and 
decreasing peak wall stress, providing a ‘cushioning’ effect to the underlying 
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wall (Inzoli et al., 1993, Mower et al., 1997, Wang et al., 2002). Although it 
appears that this protective effect is far outweighed by the negative 
influences of the ILT, with one study finding that the ILT is usually found at 
the point of AAA rupture (Simao da Silva et al., 2000). 
The ILT is made up of fibrin, platelets, erythrocytes, leucocytes and 
neutrophils. It is usually composed of three distinct layers: The luminal layer, 
which is a vibrant red due to large numbers of fresh erythrocytes. This is the 
main location of remodelling and protease activity. The medial layer, which is 
yellow/pink in colour. And the abluminal layer which is a dark yellow-brown 
and is closest to the aortic wall. This can nicely be seen in a cross section of 
very large ILT that was removed from a patient with a 12 cm abdominal 
aortic aneurysm in Figure 6A.  
 
 
Figure 6 Intra-luminal thrombus. A, An ILT was removed from a patient having an 
open repair on a 12 cm abdominal aortic aneurysm. B, A cross section of this clot 
was taken and prepared for scanning electron microscopy (SEM). 
 
A cross section of this clot was prepared for scanning electron microscopy 
(SEM, Figure 6B) and the clot was imaged from the luminal surface across 
to the aortic wall (Figure 7). This figure shows how heterogeneous the ILT is 
from luminal surface to the aortic wall, and the continuous network of 
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interconnected canaliculi (channels and pores) can be seen traversing 
through the clot. This allows for the movement of proteases and fluid through 
the ILT (Adolph et al., 1997). 
 
Figure 7 Cross section of an intra-luminal thrombus. A cross section of an ILT 
was imaged from the luminal surface to the aortic wall using scanning electron 
microscopy (SEM). Scale bar – 20 μm.  
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1.4 Paroxysmal Nocturnal Heamoglobinuria 
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare disorder of 
haematopoietic stem cells. It occurs due to an acquired mutation in the X-
linked phosphatidylinositol glycan class A gene (PIG-A). The PIG-A gene 
codes for an enzyme involved in the formation of the N-acetylglucosaminyl 
phosphatidylinositol biosynthetic protein which is necessary for the first step 
in the biosynthesis of glycosylphosphatidyinositol (GPI) anchors (Miyata et 
al., 1993). GPI, a glycolipid moiety, anchors numerous proteins to the cell 
surface, with more than 12 GPI-anchored proteins (GPI-APs) located on 
haemopoietic cells (Brodsky, 2014). Mutations in this gene result in stem cell 
progeny (mature blood cells) lacking complement regulatory proteins on their 
surface and leads to them being vulnerable to complement attack (Brodsky, 
2014). Thrombosis is the most common cause of morbidity and mortality in 
PNH and accounts for between 40-67 % of deaths. Forty percent of these 
patients have suffered a thromboembolic event before diagnosis and 29-44 
% of patients suffer at least one event throughout the course of their disease 
(Socie et al., 1996). Despite playing such a large role in PNH, the 
mechanisms involved in PNH driven thrombosis are poorly understood, and 
so elucidating a link between PNH and thrombosis is important to improve 
the treatment of these patients. Multiple proposed mechanisms behind the 
increased incidence of thrombosis suggest a prothrombotic state in 
conjunction with platelet abnormalities and impaired fibrinolysis (Hill et al., 
2013, Grunewald et al., 2003). 
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1.4.1 Pathophysiology 
The incidence of PNH is very rare, estimated at 0.1 – 0.2/ 100,000 persons 
per year (Devalet et al., 2015). Studies have shown that a small number of 
GPI anchor deficient cells are present in the blood of healthy controls as well 
as in patients with PNH (Bessler et al., 1994). This suggests that the 
presence of a mutation in the PIG-A gene alone is not sufficient to allow the 
PNH clone to dominate. The process by which the clonal expansion of the 
mutated PIG-A stem cells in PNH patients occurs is not fully understood.  
Two combined hypotheses exist to explain the clonal expansion of PNH 
cells; one involves immune selection-mediated expansion and the second 
predicts that dominant PNH clones acquire a growth advantage (Nakakuma 
and Kawaguchi, 2003). The UL16 binding protein 1 (ULBP1), a stress-
induced ligand for the natural killer cell receptor NKG2D, is a GPI-linked 
glycoprotein thought to be lost on PNH stem cells. Loss of ULBP1 may 
prevent their destruction of ULBP1 deficient stem cells by NKG2D+ 
lymphocytes allowing for immune-escape from ULBP-NKG2D engagement 
in the bone marrow (Kawaguchi and Nakakuma, 2007). PIG-A mutant cells 
have been demonstrated to be less sensitive to T lymphocytes and, along 
with leukemic cells with the same mutation, possess increased resistance to 
natural killer cells (Kawaguchi and Nakakuma, 2007, Hanaoka et al., 2006). 
The growth phenotype is thought to be due to upregulation of early growth 
response factor 1 gene (EGR-1) and ectopic expression of the high mobility 
transcription factor coding genes HMGA2 (Inoue et al., 2006, Lyakisheva et 
al., 2002, Murakami et al., 2012).  
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The two most significant GPI-APs thought to play a major role in the 
pathophysiology of PNH are complement regulatory proteins CD55 and 
CD59 (Schubert and Roth, 2015). CD55 prevents complement proteins C4b 
and C3b from catalysing the conversion of C2 and Factor B to active C2a 
and Bb, preventing the formation of C4b2a and C3bBb (both forms of C3 
convertase). CD59 inhibits the formation of the membrane attack complex 
(MAC), formed as a product of the complement cascade, preventing pore 
formation and cell lysis (Rollins and Sims, 1990). Without these complement 
regulatory proteins, complement attack leads to erythrocyte lysis, platelet 
activation and a loss of thrombotic modulators on granulocytes, causing 
many of the symptoms of PNH (Jankowska et al., 2011, Hugel et al., 1999, 
Wiedmer et al., 1993) (Figure 8). 
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1.4.2 Clinical presentation 
Patients can present with ‘classical’ PNH characterized by clinical and 
laboratory evidence of intravascular haemolysis with no clinical evidence of 
an underlying bone marrow disorder. Others have evidence of haemolytic 
PNH as well as clinical evidence of bone marrow disorder, such as 
myelodysplasia or aplastic anaemia. A further group may be defined as 
’subclinical PNH’ where a small proportion of PNH cells are found but with 
no evidence of haemolysis or thrombosis (Parker et al., 2005). The presence 
of PNH cells are identified using flow cytometry, determining the proportion 
of GPI negative granulocytes, monocytes and erythrocytes (Parker et al., 
2005). The proportion of PNH granulocytes are normally used as a marker of 
disease severity as the numbers of granulocytes is not affected by 
haemolysis or transfusions. PNH RBCs are labelled type I, II or III; type I 
cells have normal expression of GPI-APs, type II have partial deficiency and 
type III lack all GPI-Aps (Hill et al., 2007b).  
Clinical manifestations of PNH are variable; the main symptoms include 
intravascular haemolysis, thrombosis and anaemia, however, other 
symptoms may be present (Brodsky, 2014). Schrezenmeier et al. analysed 
1610 patients and showed the proportion of symptoms, such as fatigue (80 
%), dyspnea (64 %), haemoglobinuria (62 %), abdominal pain (44 %), chest 
pain (33 %) and impaired renal function (14 %), with only 16 % of patients 
having a history of thrombotic events (Schrezenmeier et al., 2014). However, 
it has been shown that the presence of subclinical thrombosis is significantly 
underestimated (Hill et al., 2007a). 
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Thrombosis is the most serious complication associated with PNH. Venous 
thrombosis accounts for 85 % of cases, arterial in 15 % of cases and cases 
involving thrombosis at more than one site at the same time occurring in 
20.5 % of cases (Devalet et al., 2015). Thrombosis is thought to be able to 
occur at any site, with deep vein thrombosis (DVT), pulmonary embolism 
(PE), MI or cerebral vascular attack all commonly observed complications 
(Moyo et al., 2004). There appears to be an increased incidence of 
thrombosis at atypical sites, such as the hepatic vein resulting in Budd-Chiari 
syndrome, occurring in 40-44 % of PNH patients, in addition to thrombosis in 
the vasculature of the central nervous system, mesenteric, dermal veins and 
the cavernous sinus (Ziakas et al., 2007). The proportion of PNH cells and 
clone size has also been associated with thrombotic complications. It has 
been shown that patients with more than 50 % of their granulocytes affected 
by PNH have a 44 % risk of thrombosis over 10 years, but in patients with 
less than 50 % PNH granulocytes, the risk was only 5.8 % (Hall et al., 2003). 
Moyo et al. showed a 1.64 increase in odds ratio of developing thrombosis 
for every 10 % increase in the proportion of PNH cells (Moyo et al., 2004). 
These findings correlate with other studies which have shown that the 
occurrence of thrombosis is noticeably elevated in PNH patients with a 
proportion of PNH cells as low as 10 % when compared to normal 
population controls (Hoekstra et al., 2009, Fowkes et al., 2003). 
1.4.3 Induction of a prothrombotic state 
The mechanisms behind thrombus formation in PNH are complex and 
subject to continued research. Interactions between the complement system, 
platelets and coagulation are thought to explain some of the increased risk 
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of thrombosis. The multifactorial and variable nature of the disease mean 
that a combination of several factors may contribute to the increased 
incidence of thrombus formation and associated mortality (Figure 8). 
1.4.3.1 Platelet activation 
Platelets have been reported to play a significant role in thrombus formation 
in PNH patients, by both contributing to a prothrombotic state and initiating 
clot formation (Gralnick et al., 1995). Due to the deficiency of CD55 and 
CD59, lysis of platelets would be expected leading to thrombocytopenia, 
however, the lifespan of platelets in PNH patients is normal (Devine and 
Rosse, 1987). Rather than complement resulting in the lysis of platelets, an 
intrinsic mechanism of adaption and resistance to complement attack has 
been shown which contributes to the prothrombotic state (Wiedmer et al., 
1986). Increased deposition of MAC (C5b-9) on the membrane of platelets, 
results in morphological changes (Hugel et al., 1999). The loss of platelet 
membrane phospholipid asymmetry through the action of adenosine 
triphosphate (ATP) -dependent enzymes, gelsolin, aminophospholipid 
translocase, lipid scramblase and calpain allow for cytoskeletal and 
phospholipid bilayer changes (Bevers et al., 1999). The now activated 
platelet secretes α-granules, and in conjunction with membrane 
depolarization, α-granules fuse with the platelet membrane (Blair and 
Flaumenhaft, 2009). This results in exocytosis of the vesiculated MAC and 
the production of prothrombotic platelet-derived microparticles (PMPs), 
which are also thought to contribute to thrombosis (Hugel et al., 1999). 
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1.4.3.2 Haemolysis 
Intravascular haemolysis is responsible for causing a large number of the 
symptoms in PNH (Figure 8), and many of these are due to the release of 
free haemoglobin. Free haemoglobin is normally cleared by haptoglobin, 
haemopexin and the scavenger CD163. These clearing mechanisms are 
overwhelmed in PNH and lead to the accumulation of high levels of free 
haemoglobin in the plasma, which then leads to the depletion of nitric oxide 
(NO) (L'Acqua and Hod, 2015). The subsequent excess of haemoglobin 
leads to visible haemoglobinuria, while the depletion of NO, a potent 
vasodilator, results in vasoconstriction, decreased regional blood flow and 
muscular contraction, causing chest and abdominal pain, amongst other 
symptoms (Hill et al., 2013). Free haemoglobin can also lead to a 
prothrombotic state, with recent studies showing that it can rapidly stimulate 
the release of WPBs from the vascular endothelium resulting in the release 
of vWF and P-selectin onto the surface of endothelial cells, stimulating 
coagulation and the complement cascade (Ballarin et al., 2011, Belcher et 
al., 2014). Free haemoglobin has also been observed to directly bind to vWF 
exposed on the endothelium which increases the affinity of vWF for the 
glycoprotein Ib (GPIb) receptor on the surface of platelets (Da et al., 2015). 
Free haemoglobin can also inhibit ADAMTS13, reducing vWF cleavage, 
further promoting a prothrombotic state (Zhou et al., 2009, Studt et al., 
2005). In agreement with this, animal and human studies have both 
demonstrated that the infusion of haemoglobin or haem into the blood 
stream resulted in a prothrombotic state, with animal models showing 
increased platelet aggregation and adhesion to the endothelium of an injured 
vessel wall (Olsen et al., 1996) and healthy volunteers presenting with 
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thrombophlebitis, vascular inflammation and obstruction (Simionatto et al., 
1988). It has also been suggested that the increased oxidative status of PNH 
cells may be due to increased haemoglobin levels. Haemoglobin is known to 
produce reactive oxygen species (ROS), and these can go on to cause 
phospholipid disorganisation, induce cytotoxicity, promote inflammation and 
enhance platelet activation (L'Acqua and Hod, 2015, Iuliano et al., 1994). 
The lysis of erythrocytes have been reported to produce microparticles as a 
result of MAC-induced apoptosis (Kozuma et al., 2011). Although, other 
studies have shown that the concentration of erythrocyte derived 
microparticles were much lower than platelet derived microparticles (Hugel 
et al., 1999), and are at similar levels to healthy controls (Simak et al., 2006), 
so their contribution to thrombosis in PNH may be minimal.  
1.4.3.3  Reciprocal activation of complement and coagulation 
Thrombin has been observed to independently activate complement proteins 
C3 and C5 (Huber-Lang et al., 2006). Plasmin, an enzyme involved in fibrin 
clot degradation and stimulated by fibrin itself, has also recently been shown 
to cleave C5 (Leung and Morser, 2016). This suggests a feedback 
mechanism in which thrombin generation, fibrin deposition and fibrinolysis 
may in turn activate the complement system, which reciprocally leads to 
more platelets and coagulation activation, exacerbating the thrombotic 
response. 
1.4.3.4 Fibrin clot structure 
Previous studies have shown that individuals with an increased risk of 
thrombosis form fibrin clots with an altered fibrin network (Bridge et al., 
2014). Their clots are formed of thinner, more tightly packed fibrin fibres that 
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are stiffer, more resistant to mechanical deformation, and have an increased 
resistance to fibrinolysis. Resistance to fibrinolysis is due to the increased 
number of fibres that need to be lysed and a reduced permeation of the lytic 
enzymes into the denser clot structure (Collet et al., 2000). There have been 
no studies to date that have investigated clot structure in patients with PNH. 
Abnormal clot structure could be an additional mechanism by which the risk 
of thrombosis is increased in PNH. Complement activation and factors have 
previously been associated with effects on fibrin clot structure and function. 
Alternative complement pathway activation has been associated with the 
production of denser, more tightly packed clots (Shats-Tseytlina et al., 
1994); furthermore, C3 has been shown to be incorporated into the fibrin 
clot, leading to thinner fibrin fibres and a stiffer clot with increased resistance 
to fibrinolysis (Howes et al., 2012). Mannan-binding lectin serine protease 1 
(MASP-1) has been shown to influence clot formation and activate FXIII, 
leading to an increased resistance of the clot to fibrinolysis (Hess et al., 
2012). Other unidentified mechanisms of complement activation may also 
play a role in clot structure and function.  
1.4.3.5 Animal models 
The use of mouse models to replicate the thrombotic phenotype caused by 
the deficiency of CD55 and CD59 in PNH has proven difficult to replicate. 
Generating the thrombotic phenotype via PIG-A mutations has also proven 
difficult. Two models, one in murine embryonic stem cells and another in a 
mouse model have attempted to inactivate the PIG-A gene, giving rise to 
blood cells with the PNH phenotype (Rosti et al., 1997, Tremml et al., 1999). 
In both cases this mutation of the PIG-A gene did not lead to the expansion 
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of the PNH clone, suggesting other additional factors are required for PNH 
symptoms. Limited knowledge of the clonal expansion mechanism has made 
it difficult to create animal models in which the thrombotic mechanisms in 
PNH can be analysed. 
1.4.3.6 Treatment 
The current treatment for PNH is a monoclonal antibody directed against C5, 
called eculizumab (Seregina et al., 2015). It helps prevent C5 cleavage to 
C5a and C5b, stopping uncontrolled complement system activation by 
inhibiting the terminal steps of the complement cascade, and reducing 
complement mediated complications, such as thrombosis. Studies have 
shown a reduction in thromboembolic incidents from 7.37 to 1.07 events per 
100 patient’s years when observing patients pre and post eculizumab 
treatment (Hillmen et al., 2007). Eculizumab’s therapeutic effects are 
reduced with a heterozygous C5 Arg885His polymorphism (Nishimura and 
Kanakura, 2015), and this has led to the development of Coversin, another 
C5 inhibitor for the treatment of PNH and other complement-mediated 
disorders (Weston-Davies et al., 2014). 
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1.5 Hypotheses 
Fibrin(ogen) plays many important roles in the human body. Physiologically, 
fibrinogen contributes to the prevention of blood loss through clot formation, 
and plays a role in infection control. Pathologically, however fibrinogen may 
play a role in forming thrombi in the vasculature leading to heart attacks or 
strokes. I hypothesize that by examining the role of fibrin(ogen) in the 
different settings of thrombosis and haemostasis I will uncover new 
mechanisms that promote or prevent disease, improving our understanding 
of the complex mechanisms underpinning diseases of bleeding and 
thrombosis. 
1. Fibrinogen γ’. Previous studies of fibrinogen γ’ have shown it plays a 
role in clot structure and breakdown, but many of these studies have 
been on purified protein comparing 100 % fibrinogen γ’ to 100 % 
fibrinogen γA in static conditions. I hypothesise that effects of 
fibrinogen γ’ will persist at physiological levels, with differences in clot 
formation, structure and breakdown being seen in patient samples 
with different fibrinogen γ’ levels. Fibrinogen γ’ will also form clots with 
different structural properties from fibrinogen γA when clots are 
formed under flow conditions. 
2. Fibrin film. A major conundrum after decades of fibrin polymer 
research is that fibrin fibres in blood clots appear endless, with little 
evidence of fibre ends. Thus, the mechanisms and structures that 
determine the external boundary of an extravascular (haemostatic) 
blood clot are unknown. I hypothesise that the structures at the 
external boundaries of clots will differ from the normal fibrin fibre 
- 38 - 
network. The architecture of this interface is important because it 
forms a distinction between host and the environment. 
3. Fibrinogen and FXIII in AAA. Analysis of genetic polymorphisms of 
FXIII and Fibrinogen in AAA patients will help to identify high risk 
genotypes and potential disease mechanisms. 
4. Clotting in PNH. Patients with an increased cardiovascular risk 
present with altered clot structures. I hypothesise that patients with 
PNH will also present with an altered clot structure, and patients with 
a larger clone size will have denser clots and increasing fibrinolysis 
resistance, and this may contribute to the disease mechanism. 
Patients on eculizumab will possess hallmarks of a less pro-
thrombotic fibrin clot structure. 
1.6 Aims 
1. Fibrinogen γ’ 
a. Measure fibrinogen and fibrinogen γ’ in a large number of 
patient samples and select three groups of patients with low, 
normal and high levels of fibrinogen γ’. 
b. Carry out clot structure assays on the three groups and 
compare them with purified and repleted plasma clots with 
similar fibrinogen γ’ levels. 
c. Carry out rotational thromboelastometry (ROTEM) assays on a 
selection of patients with known fibrinogen γ’ levels. 
d. Investigate the role of fibrinogen γ’ on clot structure under flow. 
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2. Fibrin film 
a. Investigate the edge of clots and characterise structures that 
form at external boundaries. 
b. Uncover how these structures form and elucidate any roles 
they may have. 
3. Fibrinogen and FXIII in AAA 
a. In view of the central role of FXIII and fibrinogen in thrombus 
formation and the complications of ILT in AAA, investigate 
genetic polymorphisms of FXIII and Fibrinogen in AAA to 
identify high risk genotypes and potential disease mechanisms. 
b. Measure fibrinogen levels, fibrinogen γ' levels and fibrinogen γ' 
percentage in AAA and control patients, and investigate its 
relationship with AAA size, clinical outcomes. 
4. Clotting in PNH 
a. Analyse fibrin clot structure and function in PNH patients and 
how it is effected by clone size. 
b. Investigate the anti-thrombotic effects of eculizumab treatment 
on clot structure. 
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Chapter 2 - Experimental Design, Materials and Methods 
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2.1 General methods 
2.1.1 Materials 
Many of the materials in this study were used in multiple different 
experiments. Tris buffered saline (TBS) was used as a buffer for dilutions in 
many experiments, it consisted of 50 mM Tris-base (Sigma-Aldrich, Dorset, 
UK) 150 mM NaCl (Fisher Scientific, Loughborough, UK), pH 7.4. Human 
thrombin (Merck Millipore, Watford, UK) was diluted in distilled water 
(ddH2O) to a stock concentration of 250 NIHU/ml (NIHU - National Institute 
of Health standard Unit). 1 NIHU/ml = 9.16 nM of active units of thrombin 
(Ariens et al., 2000). Thrombin was aliquoted on ice and immediately stored 
at -80ºC to prevent activity loss. Thrombin was defrosted and diluted in TBS 
to the required concentration and kept on ice for a maximum of 30mins for 
each experiment. Experiments were also performed using Reptilase 
(Diagnostica Stago; Theale, UK), a snake venom enzyme which only 
cleaves FpA, but not FpB, from fibrinogen. This was reconstituted in ddH2O 
to 20 BU/ml and kept on ice and used within 8 hours. Many experiments 
required the use of purified human fibrinogen. Commercially available 
human plasma fibrinogen that had been plasminogen-depleted (Merck 
Millipore, Watford, UK) was used for this. This fibrinogen is purified from 
frozen plasma and lyophilised. It was reconstituted in TBS and diluted to a 
stock concentration of 2 mg/ml and then aliquoted and stored at -80ºC. 
Fibrinogen concentration was quantified with a Nanodrop 
Spectrophotometer (Labtech International, UK) at 280 nm using an 
extinction coefficient of 1.51 (Mihalyi, 1968). tPA, (Pathway Diagnostics, 
Dorking, UK) and Glu-plasminogen (Enzyme Research Laboratories, 
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Swansea, UK) were diluted in TBS to 1 mg/ml and 990 μg/ml, respectively 
and stored at -80 ºC. Human FXIII-A2B2 was isolated from Fibrogammin P 
(Zedira) by Sepharose-6B gel filtration to remove contaminating albumin and 
glucose as described previously (Standeven et al., 2007), diluted to 110 
g/ml, aliquoted and stored at -80 ºC. Alexa Fluor 488 or Alexa Fluor 594 
fluorescently labelled fibrinogen (Invitrogen, Paisley, UK) used for confocal 
microscopy imaging was prepared by dissolution in ddH2O to a 
concentration of 2.5 mg/ml, aliquoted and stored at -80 ºC. Fibrinogen-
deficient plasma (Merck Millipore, Watford, UK) was thawed by heating to 37 
ºC in a water bath for 5 minutes before use. 
2.1.2 Whole blood and plasma collection 
Collection of whole blood and plasma samples from patients in the Leeds 
Aneurysm Development Study (LEADS), a large case-control cohort study, 
were used to provide whole blood and plasma samples for some of the 
experiments within this thesis. The inclusion and exclusion criteria, as well 
as the study protocol, consent form and patient information sheet can be 
found in Appendices 1-3. Patients were recruited and their samples collected 
by a senior research nurse, Mrs Anne Johnson. 
Free flowing venous blood was collected from the antecubital vein of 
patients. Ten millilitres of blood was collected into 10 % sodium citrate (9 
parts of blood to 1 part of citrate) or into a K2EDTA coated blood collection 
tubes for DNA extraction. Blood taken into K2EDTA tubes was stored at -20 
°C. Citrated whole blood was used within 4 hours of the blood draw. For 
platelet poor plasma (PPP) whole blood was centrifuged at 2,400 g for 20 
minutes. The plasma supernatant was divided into 0.5 ml aliquots, flash 
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frozen in liquid nitrogen and stored at -80°C until analysis. For platelet rich 
plasma (PRP) whole blood was centrifuged at 200 g for 10 minutes. PRP 
was used within 4 hours of the blood draw 
Whole blood and plasma samples were also collected as per above protocol 
from healthy volunteers for other experiments within this thesis. Ethical 
approval for blood taking was obtained from the University of Leeds Medical 
School or the University Hospitals of Geneva and Faculty of Medicine review 
board. Written informed consent was received from each patient and 
volunteer prior to inclusion in the study in accordance with the declaration of 
Helsinki. 
2.1.3 Normal pool plasma 
Normal pool plasma (NPP) was used as a control for of a number of assays, 
and also for the establishment of a standard curve in the fibrinogen γ’ 
enzyme-linked immunosorbent assays (ELISAs). This was produced by the 
collection of free-flowing venous blood from the antecubital fossa of 25 
healthy individuals. Collection of the NPP was approved by the Leeds NHS 
Trust Research Ethics Committee (HSLTM/12/045 and HSLT/09/020). Blood 
was collected onto 10 % sodium citrate (9 parts blood to 1 part citrate), 
centrifuged for 20 minutes at 2,400 g to separate plasma, which was pooled 
together to create a mixture of all 25 individuals’ plasmas. Aliquots of 0.5-1 
ml were flash frozen using liquid nitrogen, and stored at -80°C until required. 
2.1.4 Fibrinogen levels 
Fibrinogen concentrations were measured in PPP by the Clauss method 
using a Start 4 haemostasis analyser (Diagnostica Stago; Theale, UK) and 
the Fibri-prest automate kit (Diagnostica Stago; Theale, UK) according to the 
- 44 - 
manufacturer’s instructions. In brief, under excess thrombin concentrations, 
the rate limiting step to clotting time is fibrinogen concentration. Therefore 
clotting time can be used to quantify the fibrinogen concentrations in plasma 
samples. Two plasma controls (control N and P), Unicalibrator (plasma with 
known fibrinogen concentration) for use as a standard curve and Fibri-prest 
automate reagent (Human thrombin, ~100 NIH units.ml-1, with heparin 
inhibitor and calcium) provided with the kit were reconstituted with ddH2O. 
The standard curve was prepared by diluting Unicalibrator in the supplied 
buffer (STA-Owren-Koller buffer, pH 7.35 veronal acetate saline buffer) to 
1/7/ 1/10, 1/20 and 1/40. Controls N and P and plasma samples for 
fibrinogen level determination were diluted to 1/20 in STA-Owren-Koller 
buffer. Cuvette strips (Diagnostica Stago; Theale, UK) were pre-warmed to 
37°C, and a steel ball bearing (Diagnostica Stago; Theale, UK) was placed 
in each well. 100 μl of standard/control/plasma sample was added to wells of 
the cuvette strip in duplicate. The cuvette strips were then placed into the 
Start 4 haemostasis analyser which oscillates the steel ball bearings from 
side to side. Fifty microliters of Fibri-prest automate solution was added to 
each well of the cuvette strip to initiate clot formation. The time taken for clot 
formation to impede the movement of the steel ball bearing was recorded. 
The concentration of the plasma sample can be quantified by comparing it to 
the standard curve. 
2.1.5 Purification of fibrinogen γA/γ’ and γA/γA 
γA/γ’ and γA/γA fibrinogen were purified from commercially available plasma 
purified human fibrinogen as previously described (Cooper et al., 2003, 
Domingues et al., 2016, Wolfenstein-Todel and Mosesson, 1980). Plasma 
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purified human fibrinogen was initially purified to remove any FXIII by 
immunoaffinity chromatography (IF-1 mAb, 10 mg; Kamiya Biomedical; 
Seattle, USA) as previously described (Duval et al., 2014). Using the purified 
IF-1 fibrinogen the different fibrinogen variants were separated by anion-
exchange chromatography on a DE-52 column using an AKTAavant 25 (GE 
Healthcare, Little Chalfont, UK). Prior to chromatography, the Enzyme 
Research Laboratory (ERL) fibrinogen was dialyzed into 39 mM Tris, 65 mM 
H3PO4, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM benzamidine 
and 5 mM ε-aminocaproic acid, pH 8.6. Samples were eluted from the 
column using a concave gradient from 0-100 % over 13 column volumes (5 
% increments over the first 6 column volumes and 10 % over the next 7 
column volumes) of 500 mM tris, 650 mM H3PO4, 0.5 mM PMSF, 1 mM 
benzamidine and 5 mM ε-aminocaproic acid, pH 4.2 (Appendices 4). 
Purity of the γA/γA and γA/γ’ preparations was checked by sodium dodecyl 
sulphate–polyacrylamide gel electrophoresis (SDS-PAGE) analysis on a 
NuPAGE unit with 4-12 % Bis-Tris gradient gels (Figure 9). The gel revealed 
a single band at the location of the γ chain for γA/γA fibrinogen, showing that 
only γA fibrinogen was present. For the γA/γ’ fibrinogen two bands of equal 
intensity but different molecular weights were present. This indicated the 
presence of both γA and γ’ chains and therefore γA/γ’ fibrinogen. Aliquots of 
the prepared fibrinogens were stored at -80°C. Fibrinogen concentration was 
determined by absorbency (𝐸1 𝑚𝑔.𝑚𝐿−1
280 𝑛𝑚 = 1.51). 
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Figure 9 γA/γA and γA/γ’ purification. SDS-PAGE analysis of γA/γA and γA/γ’ 
isolated from ERL fibrinogen by anion-exchange chromatography on a DE-52 
column. All lanes were run on the same gel. MW – Molecular weight, Fib – 
fibrinogen.  
 
2.1.6 Measurement of fibrinogen γ’ levels 
An ELISA based on a previously described method was set up to measure 
fibrinogen γ’ levels in plasma samples (Uitte de Willige et al., 2005). Initially, 
a standard curve of NPP was created in order to quantitate the fibrinogen γ’ 
levels within plasma samples. A Nunc MaxiSorp 96 well plate (Thermo 
Scientific, Waltham, MA) was coated with fibrinogen γ’ specific 2.G2.H9 
monoclonal antibody (Santa Cruz Biotech, CA, 200 μg.ml-1) in 50 mM 
sodium carbonate pH 9.5 overnight at 4°C, and then blocked with blocking 
buffer (1 % bovine serum albumin (BSA), 50 mM Triethanolamine, 100 mM 
NaCl, 10 mM Ethylenediaminetetraacetic acid (EDTA), 0.1 % Tween-20, pH 
- 47 - 
7.5) for an hour. Purified γA/γ' was diluted in dilution buffer (50 mM 
triethanolamine, 100 mM NaCl, 10 mM EDTA, 0.1 % Tween-20, 10 mM 
benzamidine, pH 7.5) to a range of concentrations from 0.9 to 0.03 mg.L-1 
and each concentration was added to the plate in six replicates. Normal pool 
plasma was diluted in a range from 1/400 to 1/12800 and each dilution was 
also added to the plate in six repeats, and the plate was then incubated for 1 
hour at room temperature. A horseradish peroxidase (HRP) conjugated goat 
polyclonal antibody against human fibrinogen (1/20000) (Abcam, 
Cambridge, MA) was added to each well and incubated for 1 hour at room 
temperature. 100 μL 3,3’,5,5’-Tetramethylbenzidine (TMB) substrate buffer 
was added and the reaction was stopped after 10 minutes with 50 μL 1 M 
H2SO4. The plate was read at 450 nm at 37°C in a Thermo Fisher Multiscan 
Go Microplate reader (Thermo Fisher Scientific, Waltham, MA). After 
blocking and between each incubation step, the plate was washed three 
times with washing buffer. The fibrinogen γ’ level of the six NPP repeats 
were calculated at each dilution, using the quadratic equation in comparison 
with a standard curve produced with purified γA/γ’ (Figure 10, Table 2). From 
these values the fibrinogen γ’ level in the NPP was calculated as 304.48 
mg.L-1, and this NPP was then used as a standard curve for all future 
ELISAs. 
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Figure 10 Average absorbance of pool plasma compared to purified γA/γ'. 
Average absorbance of six NPP curves at a range of dilutions (1/400-12800) 
compared to purified γA/γ' in increasing concentrations (0.9-0.03), measured at 450 
nm. 
 
Table 2 Creating a plasma standard curve. 
 
To measure fibrinogen γ’ levels in plasma samples, PPP was prepared as 
described above. Nunc MaxiSorp 96 well plates were coated with the 
2.G2.H9 monoclonal antibody (200 μg.ml-1) in 50 mM sodium carbonate pH 
9.5 overnight at 4°C. Plates were then blocked for 1 hour at room 
temperature with blocking buffer (1 % BSA, 50 mM Triethanolamine, 100 
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mM NaCl, 10 mM EDTA, 0.1 % Tween-20, pH 7.5). A standard curve of NPP 
from 1/400 to 1/12800 was added to the plate in duplicate. Plasma samples 
were diluted to 1/1600 and 1/3200 in dilution buffer and added to the plate in 
duplicate and incubated for 1 hour at room temperature. The HRP 
conjugated goat polyclonal antibody against human fibrinogen (1/20.000 in 
dilution buffer) was added to the plate and incubated for 1 hour at room 
temperature to detect bound fibrinogen γ’. One hundred microliters of TMB 
substrate was added and the reaction was stopped after 10 minutes with 50 
μL 1M H2SO4. The plate was read at 450 nm at 37°C in the Microplate 
reader. After blocking and between each incubation step, the plate was 
washed three times with washing buffer. 
Fibrinogen γ’ ratio (%) was calculated by dividing the fibrinogen γ’ level by 
the total fibrinogen level (measured as described in chapter 2.1.4). 
2.1.7 Confocal microscopy 
To assess fibrin clot structure laser scanning confocal microscopy (LSCM) 
was carried out on purified fibrinogen or plasma clots.  
For purified samples, fibrinogen (0.5 mg.ml-1) with or without FXIII (3.7 μg.ml-
1), was spiked with 25 μg.ml-1 of Alexa fluor-488 fluorescein isothiocyanate 
(FITC) -labelled fibrinogen. Plasma samples were diluted by half and spiked 
with 25 μg.ml-1 of the Alexa fluor-488 FITC-labelled fibrinogen. Clotting was 
initiated with the addition of 5 mM CaCl2 and 0.5 U.ml-1 of human thrombin. 
Immediately after the initiation of clotting, 30 μl of the solution was 
transferred to a channel of an uncoated Ibidi slide (Thistle Scientific, UK). 
Once prepared the samples were stored in a dark humidity chamber for at 
least 4 hours to ensure full clot formation. Slides were then imaged using an 
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inverted Zeiss LSM880 microscope (Carl Zeiss; Welwyn Garden City, UK) 
with a 40× oil immersion objective lens. Fibrin clots were prepared in 
duplicate and six images were taken for each clot, Z-stacks (20 μm, 30 
slices) were combined to form 3D images (ZEN 2.1 black, Carl Zeiss, 
Cambridge, UK). Fibre density was calculated using an in-house macro I 
designed as part of this thesis (Appendices 5), which calculates the number 
of fibres crossing 10 horizontal and 10 vertical lines drawn on top of a 
confocal image of the clots. From this the average number of fibres/100 μm 
can be calculated. 
2.1.8 Turbidity and lysis assay 
Clot formation and breakdown were analysed by the turbidity and lysis assay 
as previously described (Scott et al., 2011). To analyse clot formation in a 
purified system, fibrinogen was made up to 0.5 mg.ml-1 with or without FXIII 
(3.7 μg.ml-1). Plasma samples were diluted 1/6 with TBS. They were then 
added to the well of a 96-well Greiner bio-one microtiter plate (Greiner Bio 
One International GmbH) and an activation mix (thrombin – 0.5 U.ml-1, CaCl2 
– 10 mM) was added to initiate clotting. To analyse clot breakdown, the 
assays were set up as above but with the addition of plasminogen (25 μg.ml-
1) and tPA (85 ng.ml-1) for purified clots, or just tPA (85 ng.ml-1) for plasma 
clots. Changes in absorbance at 340 nm was measured every 12 seconds 
for 3 hours at 37°C in a ThermoFisher Multiscan Go Microplate reader 
(ThermoFisher Scientific, Waltham, MA). Investigated parameters were lag 
time, Max OD, time to Max OD, average clotting rate and time between 25 
and 75 %, time to 50 % lysis (time from Max OD to 50 % lysis) and average 
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lysis rate and time between 25 and 75 % lysis (Figure 11). Duplicates were 
measured for each sample and averaged. 
 
Figure 11 Turbidity and lysis curve. An example trace of a turbidity and lysis 
curve with the different measured parameters indicated on the curve. 
 
2.1.9 Rotational thromboelastometry 
Rotational thromboelastometry was carried out on samples of whole blood 
that were collected as previously described (chapter 2.1.2). The experiments 
were carried out using The ROTEM®-delta system (ROTEM, Tem 
International GmBH) combined with the Cup and Pin pro measurement cells 
(ROTEM, Tem International GmBH). Clotting was initiated with the addition 
of 20 μl of star-tem® reagent (re-calcification agent) and either 20 μl ex-
tem® reagent (Rabbit brain thromboplastin) or in-tem® reagent (contact 
activator ellagic acid) to each cup. For fib-tem® analysis, 20 μl of ex-tem® 
reagent followed by 20 μl of fib-tem® reagent (platelet inhibitor cytochalasin 
D) was used. This was followed by the addition of 300 μl of whole blood to 
each cup, and immediate analysis was started and followed for 2 hours 
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using the ROTEM-delta system. A typical trace generated from a ROTEM 
assay can be seen in Figure 12. Each sample was analysed in duplicate. 
Parameters measured in this study included: Lag time, which is the time 
from the start of the measurement until the initiation of clotting, and 
maximum clot firmness (MCF), which reflects the absolute strength of the 
fibrin and platelet clot. 
 
 
Figure 12 ROTEM trace. Typical curve generated by a ROTEM® (adapted from 
Rotem.de). 
 
2.1.10 Clot permeation 
Clots for permeation measurements were generated by mixing 10 µL of 
activation mixture (human thrombin (0.5 U.mL-1) and CaCl2 (10 mM)) with 
100 µL of plasma. Immediately after mixing, 100 µL of the clotting mixture 
was carefully transferred to a 4.5 cm plastic tip with a roughened interior 
surface, which was cut off from a 1 ml Costar pipette tip. The clot was left to 
consolidate in a humidified chamber at room temperature for 2 hours. The 
plastic tip was connected through a silicon tube to a syringe containing TBS 
with a 4 cm pressure drop. Upon connection, TBS was left to permeate 
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through the fibrin clot network for 1.5 hours to wash away other plasma 
proteins (Figure 13). Measurements were performed in duplicate by 
collecting drops passing through the clot in a pre-weighed Eppendorf tube 
and weighing the total volume of liquid in the tube every 30 minutes for two 
hours. Clot permeability was determined by calculating Darcy’s constant 
(Ks), which is a measure of the average pore size of the fibrin network 
(Woodhead et al., 1996). 
 
 
Figure 13 Permeation set-up. Diagrammatic representation of the permeation set-
up. 
 
2.2 The role of fibrinogen γ’ in clot structure  
Given the previous evidence of the role of fibrinogen γ’ in clot structure in 
purified protein systems, a series of experiments were designed to establish 
if fibrinogen γ’ played a role in clot structure at physiological levels and in 
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patient plasma samples. The role of fibrinogen γ’ was also investigated in 
whole blood samples and under flow conditions. 
2.2.1 Measurement of fibrinogen γ’ levels in patients by ELISA 
Fibrinogen γ’ concentrations were measured in 1168 patient plasma 
samples by ELISA as previously described in chapter 2.1.6. From the 1168 
patients measured, all patients who possessed a low (1-7 % (~3 %), n = 41), 
normal (9-11 % (~10 %), n = 45) and high (22-40 % (~30 %), n = 33) 
fibrinogen γ’ levels, with fibrinogen levels between 2.3-4.0 mg.ml-1 were 
selected for further analysis on the effects of fibrinogen γ’ on clot structure. 
2.2.2 Fluorescent labelling of fibrinogen γA/γA and γA/γ’ 
To analyse the effects of fibrinogen γ’ on clot structure by LSCM fibrinogen 
γA/γA and γA/γ’ were fluorescently labelled. Purified fibrinogen γA/γA and 
γA/γ’ were fluorescently labelled with Alexa Fluor-488 using the Alexa Fluor 
protein labelling kit (Thermo Fisher Scientific, UK). In brief, fibrinogen γA/γA 
and γA/γ’ were dialysed into 0.01 M phosphate buffered saline, pH 7.4 (PBS, 
5 PBS tablets dissolved in 1 litre of ddH2O, Sigma-Aldrich, UK). The 
fibrinogens were diluted down to 1 mg.ml-1 and 9 μl of 1 M sodium 
bicarbonate was added to 90 μl (to raise the pH of the reaction mixture). This 
was then added to the appropriate fluorescent dye and incubated for 1 hour 
at room temperature. The fibrinogen γA/γA and γA/γ’ was then purified to 
remove unbound dye from the solutions using a resin purification spin 
column provided in the kit. The degree of labelling and fibrinogen 
concentration was determined by spectrophotometry using a Nanodrop (ND-
1000 Spectrophotometer, LabTech International) to check the fibrinogens 
had been labelled sufficiently.  
- 55 - 
2.2.3 Fibrinogen γ’ clot structure by confocal microscopy 
Previous research has shown that fibrinogen γ’ contributes to changes in clot 
structure (Macrae et al., 2016). To assess if changes to fibrinogen γA/γA and 
γA/γ’ concentrations at physiological levels and ratios played a role in clot 
structure, LSCM was carried out on purified fibrinogens, repleted plasma 
and plasma clots as previously described in chapter 2.1.7, but with some 
differences. 
For purified samples, purified fibrinogen γA/γA and γA/γ’ were combined at 
3, 10 and 30 %, with or without FXIII (3.7 μg.ml-1), and spiked with 
fluorescently labelled γA/γA and γA/γ’ at 2.5 % of the respective fibrinogen 
concentration, with a final total fibrinogen concentration of 0.5 mg.ml-1. For 
repleted plasma samples, fibrinogen deficient plasma (ERL, UK) diluted by 
half was repleted with purified fibrinogen γA/γA and γA/γ’ at above ratios and 
spiked with 25 μg.ml-1 of the fluorescently labelled γA/γA and γA/γ, with a 
final total fibrinogen concentration of 1 mg.ml-1. Patient plasma samples 
were carried out as described previously. 
2.2.4 Role of fibrinogen γ’ in clot formation and breakdown using 
the turbidity and lysis assay 
Previous research has shown that fibrinogen γ’ plays a role in clot formation 
and breakdown (Macrae et al., 2016). In order to establish if physiological 
levels of fibrinogen γ’ played a role in clot formation and breakdown, turbidity 
and lysis experiments were performed as previously described (chapter 
2.1.8) using purified fibrinogen, repleted plasma and patient plasma with 
some changes. 
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For purified samples, purified fibrinogen γA/γA and γA/γ’ were combined at 
3, 10 and 30 %, with or without FXIII (3.7 μg.ml-1) with a final total fibrinogen 
concentration of 0.5 mg.ml-1. For repleted plasma samples, fibrinogen 
deficient plasma (Merck Millipore, Darmstadt, Germany) diluted by half was 
repleted with purified fibrinogen γA/γA and γA/γ’ at above ratios, with a final 
total fibrinogen concentration of 0.5 mg.ml-1. Patient plasma samples were 
carried out as described previously. 
2.2.5 Roles of fibrinogen γ’ in clot viscoelasticity by whole blood 
ROTEM 
The effects of fibrinogen γ' on clot viscoelasticity in whole blood was 
examined using ROTEM as previously described in chapter 2.1.9. It was 
performed on the whole blood of a sub population of 78 patients who were 
the most recent recruits to the pool of 1168 patients that had both fibrinogen 
and fibrinogen γ' levels measured. These most recent patients had ROTEM 
analysis carried out on their blood samples after the acquisition of a ROTEM 
machine, allowing for whole blood analysis. 
2.2.6 Effects of fibrinogen γ' under flow 
The effects of fibrinogen γ' under flow were investigated, in collaboration with 
Prof. Johan Heemskerk, Dr Frauke Swieringa and Dr Constance Baaten at 
the University of Maastricht. Whole blood was obtained after medical ethical 
approval from healthy volunteers after full informed consent, according to the 
declaration of Helsinki. Blood donors were free from antithrombotic 
medication for at least 2 weeks. Free flowing blood was taken by 
venepuncture of the median cubital vein into 1/10 volume of 3.2 % trisodium 
citrate and 40 μg.ml-1 corn trypsin inhibitor (CTI). 
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Glass coverslips were cleaned with 1 M hydrochloric acid (HCL) in 50 % 
ethanol and then coated with two consecutive 2 μl microspots of Horm type I 
collagen (50 μg.ml-1) at least 0.7 cm apart and left in a humidity chamber for 
1 hour (Van Kruchten et al., 2012). After rinsing with saline and drying under 
nitrogen gas, 2 µL of 500 pM TF (Innovin, Siemens, Marburg, Germany) or 
saline solution were applied on each microspot and incubated for 1 hour in a 
humidity chamber. The Collagen/TF-coated coverslips were blocked for 1 
hour with 1 % BSA in HEPES buffer pH 7.45 (136 mM NaCl, 10 mM HEPES, 
2.7 mM KCl, 2 mM MgCl2, 1 mg.ml-1 glucose). Assuming homogeneous TF 
distribution, a coating with 2.0 μL of 500 pM (microspots of 6.75 mm2) gave 
a calculated applied TF density of 89 × 106 molecules TF per mm2. Collagen 
was coated at a density of 14.8 ng.mm-2. 
To investigate thrombus formation in fibrinogen γA/γA and γA/γ’ under flow, 
a two-step model was used. Anticoagulated whole blood, with 3.6 mM MgCl2 
but no re-calcification, was perfused through a parallel-plate flow chamber 
with collagen/TF microspots at a wall shear rate of 1,000 s−1 for 5 minutes. 
Platelet thrombi were formed on the microspots, after which the channel was 
rinsed with saline solution.  
Fibrinogen deficient plasma was repleted with 0.5 mg.ml-1 purified fibrinogen 
γA/γA or γA/γ’ and spiked with 5 μg.ml-1 of the appropriate Alexa fluor-488 
labelled fibrinogen variant. The plasma was then recalcified and immediately 
perfused over the preformed thrombi at 150 s-1 or 500 s-1. Fibrin formation 
was assessed by time series confocal fluorescence imaging with a camera-
containing line-scanning Live-7 microscopic system (Carl Zeiss, 
Oberkochen, Germany) and a 63 × /1.4 numerical aperture oil immersion 
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objective every second. The assay was stopped when fibrin accumulation 
stopped or the channel was occluded. A number of endpoint Z-stack images 
(0.5 μm per slice) were then taken in random locations across the microspot 
to assess differences in endpoint clot formation 
For time series analysis, accumulation of fluorescence was measured from 
the images every 5 seconds and a number of parameters were compared 
including: Lag time, Maximum fluorescence and rate of accumulation. 
Endpoint Z-stacks were depth coded, with cross sections and views from 
above analysed. Maximum heights and volumes were compared. 
2.3 Formation of the fibrin film 
A number of experiments were designed to explore the exterior face of blood 
clots found at the blood air-interface to examine the structures present and 
to explore the fibrin fibre network at this border. 
2.3.1 Mutant fibrinogen expression 
Recombinant human fibrinogen expression and purification was carried out 
by Dr Cedric Duval and Helen McPherson as previously described 
(Standeven et al., 2007, Duval et al., 2014). Briefly, truncations at fibrinogen 
αSer220 and αAsp390, and γ-chain mutations Q398N/Q399N/K406R 
referred to as γ3x, were established through the use of QuikChange II Site-
Directed Mutagenesis Kit (Agilent Technologies; Stockport, UK). The 
expression vector pMLP encoded the entire cDNA for either the α- or γ-
chain. Primers were designed to change residues at desired locations (γ398, 
399, 406) or to create a stop codon at α221 and α391. Mutations and 
truncations were confirmed by sequencing (MRC PPU DNA Sequencing and 
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Services; University of Dundee, Scotland). Plasmids were transfected into 
Chinese hamster ovarian (CHO) cells containing the remaining fibrinogen 
chains. A second plasmid was transfected for selection (pMSV-his). 
Recombinant fibrinogen wildtype (WT), γ3x and α-truncations were produced 
in roller bottles containing microcarrier beads. DMEM/F12 medium (Thermo 
Fisher Scientific; Paisley, UK) was supplemented with aprotinin, 5 μg.ml-1 
insulin, 5 μg.ml-1 transferrin and 5 ng.ml-1 sodium selenite (Roche; Welwyn 
Garden City, UK). Medium was collected and replaced every 48 hours and 
stored at -40 °C with the addition of 150 μM phenylmethylsulfonyl fluoride 
(PMSF), and harvested for 8 weeks. The fibrinogen was precipitated 
overnight with 40 % saturated ammonium sulphate (VWR International, 
Leicestershire, UK) and a mixture of protein inhibitors (MES hydrate 20 mM 
pH 5.6, 6-Aminihexanoic acid 5 mM, benzamidine 5 mM, PMSF 100 μM, 
pepstatin 1 μM, leupeptin 1 μM). The precipitated medium was centrifuged at 
14,500 g for 45 minutes without brakes at 4°C in an Avanti J-265 XPI 
(Beckman Coulter, High Wycombe, UK). The pellet was re-suspended in a 
protein cocktail (NaCl 333 mM, Tris 222 mM, PMSF 111 μM, pepstatin 5 μM, 
leupeptin 5 μM, EDTA 1 mM, trypsin inhibitor 11 U.mL-1, benzamidine 5 mM, 
6-Aminihexanoic acid 5 mM), incubated for 30 min at 4 °C and centrifuged at 
43,000 g for 30 minutes. Supernatant was collected and kept at -80 °C. 
Samples were purified by immunoaffinity chromatography (IF-1 mAb, 10 mg; 
Kamiya Biomedical; Seattle, USA) as previously described (Duval et al., 
2014). Fractions containing fibrinogen were pooled and stored at –80°C. 
Fibrinogen was concentrated and dialysed in 50 mM Tris-HCl and 100 mM 
NaCl pH 7.4. Protein integrity was assessed by SDS-PAGE. 
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2.3.2 Scanning electron microscopy – whole blood, plasma, 
purified, thrombin/tissue factor 
Clots for scanning electron microscopy (SEM) were prepared by adding 10 
μl of activation mixture (Whole blood/plasma – human thrombin 0.5 U.ml-1 or 
tissue factor 5 pM (Diagnostica Stago; Theale, UK), CaCl2 5 mM, Purified 
fibrinogen – human thrombin 0.5 U.ml-1, CaCl2 5 mM final concentrations, in 
TBS) to 100 μl of whole blood, plasma or purified fibrinogens ± FXIII (final 
concentrations: Fibrinogen – 1 mg.ml-1, FXIII – 3.7 μg.ml-1). The clotting 
mixture was immediately transferred to pierced Eppendorf lids (for 
subsequent perfusion). Clots were left to form in a humidified chamber at 
room temperature for 2 hours. Clots were washed with saline solution to 
remove excess salt and prepared for microscopy by fixation in 2 % 
glutaraldehyde solution for at least 120 minutes. Clots were further washed 
with sodium cacodylate buffer (67 mM C2H6AsNaO2, pH 7.4) and dehydrated 
in a series of increasing acetone concentrations (30–100 %). Clots were 
critical-point dried with carbon dioxide (CO2), mounted onto stubs and 
sputter-coated with platinum using a Cressington 208 HR (Cressington 
Scientific Instruments, Watford, UK). Each clot was formed in duplicate and 
imaged in five areas, at different magnifications (2500, 5000, 10000, 20000, 
25000 and 50000 x) using a Hitachi SU8230 high performance cold field 
emission (CFE) SEM (Chiyoda, Tokyo, Japan). 
2.3.3 Laser scanning confocal microscopy – whole blood, plasma 
and purified 
Whole blood or plasma samples were prepared for laser scanning confocal 
microscopy by diluting 1/2 with saline or TBS respectively, and spiked with 
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25 μg.ml-1 AlexaFluor-594 or -488 fibrinogen respectively and 5 mM CaCl2. 
0.5 U.ml-1 of human thrombin or 5 pM tissue factor was added to initiate 
clotting. Purified fibrinogen (1 mg.ml-1) was spiked with 25 μg.ml-1 
AlexaFluor-488 fibrinogen, with or without FXIII (3.7 μg.ml-1) and 5 mM 
CaCl2. 0.5 U.ml-1 of human thrombin was added to initiate clotting. 
Immediately after the initiation of clotting a 30 μl drop of the mixture was 
transferred to the centre of the well of an uncoated 8-well Ibidi slide (Ibidi 
GmbH, Munich, Germany) and the slide was transferred to a dark humidity 
chamber for 4 hours at room temperature. Imaging was performed using an 
inverted Zeiss LSM880 microscope (Carl Zeiss; Welwyn Garden City, UK) 
with a 40×/1.4 numerical aperture oil immersion objective lens. Fibrin clots 
were prepared in duplicate and four images were taken at the air-liquid 
interface for each clot, Z-stacks (20 μm, 30 slices) were combined to form 
3D images (ZEN 2.1 black, Carl Zeiss, Cambridge, UK). 
2.3.4 Conditions - thrombin, calcium, fibrinogen concentration, 
reptilase, temperature, platelets, fibrinogen variants. 
LSCM and SEM were carried out as above, but with some differences 
between the conditions. Experiments were carried out where clotting was 
initiated with different thrombin concentrations (final concentrations: 0.1, 0.5, 
1, 10 U.ml-1), CaCl2 concentrations (0, 5, 10, 20 mM) and fibrinogen 
concentrations (0.05, 0.5, 1, 2.5 mg.ml-1) in a purified system. In some 
experiments clotting was initiated with reptilase (2.4 U.ml-1; Diagnostica 
Stago; Theale, UK) to investigate the effects of only cleaving FpA when 
compared to thrombin (0.5 U.ml-1). The effects of temperature were 
investigated by incubating the reaction mix at different temperatures (room 
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temperature - 21 °C, skin temperature - 31.5 °C, core body temperature - 37 
°C) before and throughout clotting. Average skin temperature was 
determined as 31.5 °C using a contact thermometer on the fore-arm and 
hand. Immediately after clotting initiation, a 30 μl drop of the reaction mixture 
was transferred into the centre of the well of an uncoated 8 well Ibidi slide 
(Ibidi GmbH, Martinsried, Germany) and the slide was transferred to a dark 
humidity chamber in an incubator at the appropriate temperature for 4 hours. 
The effects of platelets on film formation were studied by comparing film 
formation between platelet poor plasma and platelet rich plasma from 6 
healthy volunteers. Reaction mixtures were prepared by diluting PPP or PRP 
by half with saline, and spiked with 25 μg.ml-1 AlexaFluor-594 fibrinogen and 
5 mM CaCl2. 5 pM TF was added to initiate clotting. The effects of fibrinogen 
variants were investigated with purified γA/γA or γA/γ’, γ3x mutant, α220 or 
α390 mutants (each at 2.94 μM). 
2.3.5 Fibrin(ogen)-binding Affimers for imaging the film in dys- 
and afibrinogeneamia 
Free-flowing blood was taken from the antecubital vein of 2 
dysfibrinogenemia patients (FGA c.112A>G - p.R38G, FGG c.901C>T - 
p.R301C) and 3 afibrinogenemia patients (FGA c.635T>G - p.L212X, FGA 
c.635T>G - p.L212X, FGA c.635T>G - p.L212X) and spun down to PPP and 
stored as described above (chapter 2.1.2). Dysfibrinogenemia and 
afibrinogenemia patient plasma samples were provided by Dr Alessandro 
Casini (Geneva University). To image the plasma samples a fibrin(ogen) 
specific Affimer, was isolated from an Affimer phage display library by 
Katherine Kearney using a previously described screening process (Tiede et 
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al., 2017). This Affimer was fluorescently labelled using an Alexa Fluor-488 
protein labelling kit (Invitrogen, Carlsbad, California, United States) 
according to manufacturer’s instructions. Fluorescently labelled Affimer was 
then added to normal pool plasma or patient plasma at 17.6 μM and 
incubated for 30 mins. Clotting was initiated with 5 mM CaCl2 and 0.5 U.ml-1 
of human thrombin and a 30 μl drop of the mixture was immediately 
transferred to the centre of the well of an uncoated 8-well Ibidi slide (Ibidi 
GmbH, Munich, Germany). Clots were incubated for 4 hours in a humidity 
chamber and were then imaged by LSCM as previously described. 
2.3.6 Confocal time series formation/lysis 
To investigate film formation by LSCM, the reaction mixture was produced 
as described in chapter 2.3.3 for both plasma and purified protein reactions. 
A 27 μl drop of this mixture was placed into the centre of a well of an 
uncoated 8-well Ibidi slide and 2 μl of thrombin (0.5 U.ml-1) or tissue factor (5 
pM) was added to the drop, and film formation was immediately followed 
over time by LSCM using a 40x oil immersion objective lens with 29 x 0.7 μm 
Z-stacks every 60 seconds. The effects of preventing polymerization on film 
formation were investigated by pre-incubating fibrinogen (1 mg.ml-1) or 
plasma with Gly-Pro-Arg-Pro (GPRP, 5 mM) for 20 minutes. Three 
microliters of thrombin (0.5 U.ml-1) was then added to the drop, which was 
immediately observed by LSCM as above. 
To investigate fibrinolysis, clots were formed as described above. After film 
formation (1 hour), 5 μl of tPA (85 ng.ml-1) was added to plasma clots, and 5 
μl of plasminogen (25 μg.ml-1) and tPA (85 ng.ml-1) was added to purified 
clots. Film breakdown was immediately observed by LSCM using the same 
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set up as described for film formation. 3D videos were created from the Z-
stacks using ZEN 2.1 black. 
2.3.7 Preventing film formation – oil, tween-20, petroleum jelly 
Reaction mixtures for plasma were produced as described above (chapter 
2.3.3). For oil experiments, a 27 μl drop of this mixture was placed into the 
centre of a well of an uncoated 8-well Ibidi slide. Mineral oil was then 
carefully placed around the drop to fill the well before clotting, to eliminate 
the air-liquid interface. For petroleum jelly experiments, 27 μl of reaction 
mixture was injected into the centre of a small ball of petroleum jelly that had 
been placed in the middle of the well of a slide. For reactions with tween-20, 
the reaction mix was incubated with 0.1 % tween-20 before being placed in 
the bottom of a well of a slide. Two microliters of thrombin (0.5 U.ml-1) was 
added to the reaction mixture to initiate clotting. The slide was then 
transferred to a humidity chamber for 4 hours at room temperature. Imaging 
was performed as described above (chapter 2.3.3). Each fibrin clot was 
prepared in duplicate and four images were taken of each sample, Z-stacks 
were combined to form 3D images. 
2.3.8 Film thickness 
The thickness of the film was calculated using confocal images. The width of 
the film was measured at 60 points per image along the film perpendicular to 
the air liquid interface using Image J (v2.0, NIH), and the average thickness 
for each image was used to compare between conditions. 
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2.3.9 Fluorescence measurements 
To quantify film fluorescence, an outline was drawn around the film on each 
focal plane. Area, integrated density and three adjacent background 
readings were made using ImageJ (v2.0, NIH). Fluorescence was calculated 
using the equation below: 
𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑
𝑓𝑖𝑙𝑚 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒
 = 𝑖𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 −   (
𝑟𝑒𝑔𝑖𝑜𝑛      
𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡       
×  
 𝑚𝑒𝑎𝑛
 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑) 
This was calculated for each focal plane and then the mean of corrected film 
fluorescence from each focal plane was calculated and was divided by 
10,000 arbitrarily to simplify. This was called Mean Sheet Fluorescence 
(MSF). To validate this method, measurements of average film thickness 
was taken from 72 confocal images of separate samples. Average thickness 
for each image was correlated with MSF taken from the same image (Figure 
14). 
 
 
Figure 14 Mean sheet fluorescence v sheet thickness. Mean sheet fluorescence 
was validated by plotting MSF against sheet thickness, Pearson correlation, n = 72 
experiments. MSF – Mean Sheet Fluorescence.  
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2.3.10 Film peel 
Clots were generated by spreading 100 μl of plasma ± 1,3,4,5-Tetramethyl-
2-[(2-oxopropyl)thio]imidazolium chloride (T101, transglutaminase inhibitor, 1 
mM; Zedira; Darmstadt, Germany) or purified fibrinogen (1 mg.ml-1) ± FXIII 
(3.7 μg.ml-1) into an approximately 2x2 cm square on a coverslip. Ten 
microliters of activation mixture (human thrombin, 0.5 U.ml-1 and CaCl2 5 
mM) was added to initiate clotting. After 4 hours a hypodermic needle was 
used to peel the film away from the surface of the clot (Figure 15). The film 
was either, reduced and run on SDS-PAGE, or it was stretched over a 
coverslip exposing either the interior surface or exterior surface of the film 
and was prepped for SEM. 
 
 
Figure 15 Film peel. The film was peeled from clots using a needle. 
 
2.3.11 SDS-PAGE and western blot 
All SDS-page and western blot experiments in Chapter 4 were carried out by 
Katherine Kearney. Clots were made using plasma by the addition of 
thrombin (0.5 U.ml-1) and CaCl2 (5 mM), with and without FXIII inhibitor T101 
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(1 mM). The fibrin film was removed from each clot and reduced by the 
addition of NuPAGE sample reducing agent (100 mM Dithiothreitol (DTT)) 
and heating at 95 °C for 15 minutes. A fibrin sample was prepared by 
forming a clot with IF-1 fibrinogen (1 mg.ml-1), thrombin (0.5 U.ml-1) and 
CaCl2 (5 mM), and then reducing it as described above. Samples of FXIII, 
BSA and IF-1 purified fibrinogen were reduced in a similar way, and run 
alongside the films to help identify bands in the gel, and as controls for the 
blots. Protein concentrations were determined using Nanodrop, to load 2 μg 
of each protein sample on two identical 4-12 % NuPAGE bis-tris gels. After 
running, one gel was stained using GelCode Blue Safe Protein Stain 
(Thermo Scientific, Paisley, UK) and one was transferred to a Polyvinylidene 
fluoride (PVDF) membrane (Thermo Scientific). The membrane was blocked 
overnight using 4 % skimmed milk in 50 mM Tris, 150 mM NaCl, 0.1 % 
tween-20. A polyclonal rabbit anti-human fibrinogen antibody (A0080; Dako, 
Ely, UK) was added to the blot in blocking buffer, and detected using a goat 
anti-rabbit-HRP secondary antibody (P0448; Dako). Signal was detected 
using Supersignal West Pico Chemiluminescent Substrate (Thermo 
Scientific). 
2.3.12 Atomic Force Microscopy sample preparation 
All atomic force microscopy (AFM) experiments were carried out by Dr 
Stephen Baker. Samples for AFM mechanical measurements and imaging 
were prepared from normal pool plasma with a one in two final dilution. 
Plasma was mixed with an activation mix of CaCl2 (5 mM) and thrombin (0.5 
U.ml-1) and placed onto 34 mm diameter tissue culture dish (TPP, 
Trasadingen, Switzerland) with the plasma mixture covering a 10x10 mm 
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square. For samples with T101, a final concentration of 1 mM was added to 
the mixture. Samples were then placed into a humidity chamber and allowed 
to clot for 1 hour. Samples were hydrated with 3-5 ml of 50 mM Tris, 100 mM 
NaCl and placed on the AFM sample stage. Imaging and force 
measurements were performed on a JPK NanoWizard 4 and a Zeiss 
AxioObserver D1 in qi mode with 10 nm radius AFM probes (CB3, qp-
BioAC, Nanosensors, Neuchâtel, Switzerland). All measurements were done 
in triplicate over a 15 x 15 μm square. Young’s modulus was calculated for 
plasma samples with and without transglutaminase inhibitor T101 by fitting a 
Sneddon model for conical tips to all force curves found over the entire area 
that was imaged. The equation for the Sneddon model used was as follows: 
𝐹 = 
2
𝜋
𝐸
(1 − 𝑣2)
 𝑡𝑎𝑛(𝛼)𝛿2 
Where F is the force from the force curve, E is Young’s modulus, ν is 
Poisson’s ratio (0.5), α is the half angle for the indenter (15 degrees for our 
tips), and δ is the indentation. Note that this equation is only accurate with a 
half angle of 15 degrees for the first 200nm of indentation. 
2.3.13 Langmuir-Blodgett trough 
Surface tension measurements were used to determine fibrinogen and fibrin 
adsorption at the air-liquid interface. Measurements were performed with an 
extra small KSV NIMA (Biolin Scientific, Manchester, UK ) double barrier 
Langmuir-Blodgett trough (203 x 50 x 1.2 mm) with surface pressure sensor, 
based on the Wilhelmy method, with a Whatman CHR1 chromatography 
paper plate (perimeter 20.6 mm; accuracy in surface pressure - 0.01 μN.m-1; 
KSV NIMA, Biolin Scientific, Manchester, UK). Because adsorption 
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measurements are sensitive to the presence of impurities, extreme care was 
taken to ensure that all materials and instruments used in this study were 
clean. The trough and barriers were cleaned with methanol and rinsed with 
deionized water before each run. A new Wilhelmy plate was used for each 
run. Due to the duration of the experiment, the trough was maintained in a 
dust and draught exclusion cabinet throughout the measurements to 
minimise the presence of impurities from the atmosphere. A humid 
atmosphere was maintained by putting a trough of water in the enclosing 
box. The sub-phase was composed of 30 ml of 0.2 μm filtered TBS pH 7.4 at 
room temperature. The surface was checked prior to each measurement to 
ensure that it was clean by moving the barriers to the centre and confirm that 
the surface pressure was below 0.3 mN.m-1. The system was set to record 
surface pressure every second for 18 hours. The desired final protein 
concentrations (fibrinogen – 1, 5, 20, 30, 100, 5312 x1013 molecules (final 
concentrations - 0.00018 – 1 mg.ml-1); fibrin 1, 5, 20, 30, 100 x1013 
molecules (final concentrations - 0.00018 - 0.019 mg.ml-1)) were achieved by 
pre diluting fibrinogen or fibrin into TBS, and then injecting this into the 30 ml 
sub-phase of the trough in one 50 μl injection with a Hamilton gastight 
syringe (Thermo Scientific). The accumulation of protein at the surface and 
was then followed for 18 hours. Fibrin monomers were formed by pre-
incubating fibrinogen with GPRP (5mM) overnight at 4 °C, followed by 
incubation with thrombin (0.5 U.ml-1) for 2 hours prior to each experiment. As 
a control a 50 μl mixture of thrombin (0.5 U.ml-1) and GPRP (5 mM) was run 
on the trough to show that the thrombin and GPRP did not cover enough of 
the surface to register an increase in surface pressure.  
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2.4 Roles of the fibrin film 
After demonstrating a hitherto undisclosed structure of fibrin that forms a film 
at the air-liquid interface, experiments were designed to elucidate its 
physiological role at the clot surface. 
2.4.1 Bacteria migration assay 
To investigate bacteria migration, an assay was set up using a Boyden 
chamber (VWR, Lutterworth, UK) shown in Figure 16. Three types of 
bacteria, Escherichia coli (ATCC #13706), Staphylococcus epidermidis 
(ATCC #12228) and Staphylococcus aureus (ATCC #29247), commonly 
found in the natural skin flora were transformed with pSELECT-Zeo plasmid 
(Invivogen, Toulouse, France) to provide resistance to antibiotic Zeocin. A 
single colony was picked for each bacterium and was grown up overnight 
(3.6-8.5 x108 cells.ml-1) in nutrient broth containing Zeocin (25 μg.ml-1, 
Sigma-Aldrich). Three clots for each strain of bacteria were formed in a 
Boyden chamber (0.8 μm pores, Millipore, Billerica, MA), two normal 
(Fibrinogen – 1 mg.ml-1, CaCl2 – 5 mM, Thrombin – 0.5 U.ml-1) and one in 
the presence of tween-20 (0.1 %) and left overnight in a humidity chamber at 
room temperature. The next day the film on one of the normal clots for each 
bacterium was perforated by running a hypodermic needle across the 
surface of the clot. Each bacterium was fluorescently labelled with BacLight 
green following manufacturer’s instructions (ThermoFischer Scientific, Ulm, 
Germany). The bacteria were then spun down and re-suspended in 50 % 
nutrient broth to remove any unused label, and were checked for 
fluorescence levels. Zeocin (25 μg.ml-1) was added to super optimal broth 
with catabolite repression (SOC) media (Thermo Fisher), and 1 ml was 
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added to each well of the plate. Each clot was placed in the well and 300 μl 
of labelled bacteria was added in the chamber on top of each clot. Fifty 
microliters of SOC media was taken from each well and replaced with fresh 
SOC media every 2 hours for 48 hours and measured for fluorescence using 
a Bio-Tek Synergy H1 hybrid plate reader. The time to the first bacteria 
breaking through the clots into the second, lower chamber was defined as 
when fluorescence became greater than 2 % of the fluorescent bacteria 
added to the top chamber. 
 
Figure 16 Method for assessing the role of the film in bacterial migration. 
Diagrammatic representation of the bacteria clot migration assay in the Boyden 
chamber. Bacteria moved from the 50 % nutrient broth through the fibrin film (if 
present), into the fibrin clot and then into the super-optimal broth with 20 mM 
glucose (SOC) medium. Quantity of bacteria moving through the clot over time was 
analysed by fluorescence in the SOC media. 
 
2.4.2 Ex vivo wildtype and fibrinogen deficient mouse clots  
C57BL/6 and fibrinogen-deficient mice (C57BL/6 background; in house) 
(Suh et al., 1995), aged nine- to fourteen-week old and weighing 19-30 g 
were used for all experiments (n = 4). Male and female mice were used in 
equal numbers. The mice were anaesthetized with isoflurane and bled 
through the inferior vena cava (IVC) on 0.109 M sodium citrate before being 
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euthanized (in vivo work was carried out by Dr Cedric Duval and Dr Nadira 
Yuldasheva). Whole blood clots from WT and fibrinogen-deficient mice were 
prepared for and imaged by SEM as described in chapter 2.3.260, but 
clotting was initiated with mouse thrombin (0.5 U.ml-1). 
2.4.3 In vivo mouse dermal punctures 
C57BL/6 (in house) or BALB/cJRj (Janvier Labs; Le Genest-Saint-Isle, 
France), aged nine- to fourteen-week old and weighing 19-30 g were used 
for all experiments. Male and female mice were used in equal numbers. The 
mice were anaesthetized with isoflurane, the abdomen was shaved and 
waxed. Six puncture wounds were created using a 2 mm biopsy punch 
(World Precision Instruments Ltd, Hitchin, UK), and were filled with blood 
from a tail vein. The injury was either left clear or immediately covered with a 
thin layer of oil to remove the air-liquid interface. After 60 minutes the 
animals were euthanized by cervical dislocation, the area around the wound 
together with the clot for each condition was surgically removed and fixed in 
4 % paraformaldehyde, for histology or immunohistochemistry (IHC) (n = 4) 
or 2 % glutaraldehyde, for SEM (n = 4) (in vivo work was carried out by Dr 
Cedric Duval and Dr Nadira Yuldasheva). 
The fixed tissues for histology or IHC were dehydrated and embedded in 
paraffin. Consecutive 5 μm sections were cut and mounted. Sections were 
then stained with Martius, Scarlet and Blue (MSB) to observe the sectioned 
wound, collagen appears in blue, erythrocytes in yellow and fibrin in pink. 
Slides were observed under an Olympus BX40 Dual View microscope, and 
photographs were taken using Image Pro-Plus 8.0 software (Histology work 
was carried out by Dr Nadira Yuldasheva). For IHC an EXPOSE rabbit 
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specific HRP/DAB detection IHC kit (ab80437, Abcam, Cambridge, UK) was 
used following manufacturer’s instructions. Slides were stained with mouse 
anti-fibrin antibody (59D8, 1:1000, antibody provided by Charles Esmon, 
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA), 
which detects mouse fibrin (Hui et al., 1983) for 1 hour at room temperature 
in a humidity controlled chamber. The sections were washed and incubated 
with HRP-conjugated anti-mouse secondary antibody. Negative controls 
were stained simultaneously in the absence of primary antibody. 
Alternatively after fixing, samples were prepared for and imaged by SEM as 
described in chapter 2.3.2. 
2.4.4 Red blood cell retention assay 
Red blood cell retention was measured by analysing the quantity of 
haemoglobin released from different types of whole blood clots. Whole blood 
clots were formed in a well of an uncoated 8-well Ibidi slide in the presence 
of CaCl2 (5 mM), with the addition of 1 pM tissue factor and incubated in a 
humidity chamber for 2 hours at room temperature. Clots were either formed 
with no intervention, in the presence of tween-20 (0.1 %) or with the film 
being perforated after 1 hour. After 2 hours saline solution was added to the 
clot surface and the clots were placed on an orbital shaker (400 rpm) for 30 
minutes. A sample of the solution above the clot surface was carefully taken 
and was diluted by 50 % in distilled water and left for 30 minutes for 
haemolysis to occur. The samples were then analysed for haemoglobin 
levels using the Harboe method and a spectrophotometer (Cookson et al., 
2004). The Harboe method measures the optical density of oxyhaemoglobin 
in a sample at 415 nm, and corrects for background by incorporating optical 
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densities of non-specific plasma components that interfered at 380 nm and 
bilirubin/albumin complexes at 450 nm (Harboe, 1959, Malinauskas, 1997). 
Conversion of absorbance values to haemoglobin (Hb) concentrations was 
made using the following equation: 
𝐻𝑏 (𝑔. 𝐿−1) =   
(𝑘[167.2  × 𝐴415− 83.6 × 𝐴380− 83.6 × 𝐴450])
1000
 
Where the calibration coefficient (k) was 1. 
2.4.5 Wound infection model 
Wound infection models were carried out by Dr Cedric Duval and Dr 
Praveen Papareddy. Bioluminescent Pseudomonas aeruginosa (strain Xen 
41, derived from the parental pleural isolate PAO1; PerkinElmer, Waltham, 
MA), possessing a copy of the luxCDABE operon of Pseudomonas 
luminescens, integrated at a single site on the chromosome, were 
aerobically grown in Todd Hewitt (TH) broth at 37 °C to logarithmic phase 
(OD620∼0.5). Bacteria were harvested, washed in phosphate buffered saline 
(PBS), and diluted in the same buffer to 2 x108 colony forming units CFU ml-
1. BALB/cJRj mice (8 weeks of age; Janvier Labs; Le Genest-Saint-Isle, 
France) were maintained under specific-pathogen-free conditions and had 
free access to commercial chow and water. Male and female mice were 
used in equal numbers. For the experimental procedures, animals were 
anaesthetised with isoflurane, and one puncture wound was created using a 
2 mm biopsy punch (World Precision Instruments Ltd, Hitchin, UK) on the 
back of each mouse. The puncture wound was filled with blood, from a 
BALB/cJRj donor mouse, and the wound was either left to clot while 
exposed to the air for 30 minutes (experimental group 1, n = 8), or 
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immediately covered with mineral oil and left to clot for 30 minutes, before 
the oil was washed off the clot with saline (experimental group 2, n = 8). As a 
control to investigate the effect of oil on bacterial proliferation, blood was not 
added to the puncture wounds on some mice, and these were either left 
untreated (control group 1, n = 4) or covered with mineral oil (control group 
2, n = 4). All animals were subsequently infected with 2 μl of bioluminescent 
Pseudomonas aeruginosa suspension carefully deposited on top of the 
clots. Mice were then anaesthetized and imaged to check that the same 
amount of bacteria was added to each mouse and then anaesthetized again 
at 4, 8, 12 hours after bacterial infection to allow for data acquisition using a 
three-dimensional IVIS Spectrum In vivo Imaging System (PerkinElmer), and 
analysis using the Living Image® software (PerkinElmer). Differences in 
appearance between mice +film and –film in Figure 56 are due to the oil 
used to prevent film formation being transferred to the fur of the mice.  
2.4.6 Determination of bacterial colony forming units  
Bacterial growth and dissemination experiments were carried out by Dr 
Cedric Duval and Dr Praveen Papareddy. In order to study bacterial growth 
and dissemination, the skin around the wound was harvested from sacrificed 
animals at the end of the experiment (12 hours). The tissues were 
mechanically homogenized using 1.4 mm ceramic beads (Qiagen; 
Sollentuna, Sweden) and a MagNA Lyser (Roche; Bromma, Sweden), and 
serial dilutions were subsequently plated on TH agar plates overnight at 37 
°C in order to enumerate the bacterial CFU present in the samples. The 
quantity of bacteria on the plates was also measured by bioluminescence 
and the three-dimensional IVIS Spectrum In vivo Imaging System.  
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2.5 Clotting in AAA 
Fibrin clot structure plays a role in the development and progression of AAA. 
Patients with AAA produce fibrin clots that are denser and more resistant to 
proteolytic degradation. This contributes to the development of an ILT that is 
more stable and therefore increases the proteolytic and hypoxic burden in 
the AAA. In view of the central role of FXIII and fibrinogen in thrombus 
formation and the complications of ILT in AAA, a series of experiments were 
designed to investigate 1) links between genetic sequence variants of FXIII 
and fibrinogen and AAA, to identify high risk genotypes and potential 
disease mechanisms and 2) the relationship between fibrinogen and 
fibrinogen γ' levels with AAA. 
2.5.1 Blood sampling and DNA extraction for genotyping 
Whole blood was collected by Mrs Anne Johnson from five hundred and 
twenty (n = 520) AAA patients and four hundred and ninety nine (n = 499) 
age-matched control subjects that were enrolled as part of the LEADS as 
previously described (chapter 2.1.2). DNA was extracted from whole blood 
taken into K2EDTA tubes using a QIAamp DNA Blood Maxi Kit (QIAGEN, 
Manchester, UK) following manufacturer’s instructions. A full protocol can be 
found in Appendices 6. The DNA samples were diluted to 10 ng.ml-1 using 
DNA- and RNA- free Tris Buffered Saline, and stored at 4°C until 
genotyping. DNA concentration was measured using the 260/280 nm optical 
density ratio using a Nanodrop ND-1000 spectrophotometer (LabTech 
International, Uckfield, UK). 
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2.5.2 Real Time Polymerase Chain Reaction 
TaqMan single nucleotide polymorphism (SNP) Genotyping Assays (Life 
Technologies, Paisley, UK) were used to identify each of the genetic 
sequence variants (FXIII A Val34Leu (rs5985), FXIII B His95Arg (rs6003), 
Splice Variant (intron K nt29576C-G) (rs12134960), Fib-b Arg448Lys 
(rs4220), Fib-a Thr312Ala (rs6050), Fib-γ 10034C>T (rs2066865). Real-time 
polymerase chain reaction (PCR) was set up in 384 well PCR plates with 2.2 
μl of 10 ng/ml DNA in each well, 2.50 μl of Master Mix and 0.25 μl of probe. 
The TaqMan universal PCR master mix is a premix of all the components, 
except primers and probe, necessary to perform a 5’ nuclease assay. Two 
no template controls (containing only MasterProbe) were included on each 
plate. A Roche LightCycler480 (Roche Diagnostics, Burgess Hill, UK) was 
used for programming the real time polymerase chain reaction, with final 
PCR conditions being: 95°C for ten minutes, 95°C for 15 seconds, and 60°C 
for one minute 30 seconds for 50 cycles. End-point genotyping was used to 
determine genotype frequencies. Genotyping was called with an accuracy of 
96–100 %; samples which were not called successfully were repeated. In 
addition to the no template controls, random samples were repeated on 
each plate to ensure reproducibility of the results. Only samples that had all 
six genotypes successfully determined were included in the analysis. 
2.5.3 Fibrinogen γ’ and total fibrinogen levels 
Fibrinogen γ’ (chapter 2.1.6) and fibrinogen levels (chapter 2.1.4) were 
measured in plasma collected as previously described (chapter 2.1.2) from 
608 AAA patients and 560 age and sex matched controls (same total patient 
population as the 1168 patients in chapter 2.1.6). 
- 78 - 
2.6 Clotting in PNH and the effects of eculizumab 
To assess the clotting characteristics of patients with PNH and to determine 
the role of eculizumab in thrombosis reduction, 104 patients selected from 
the PNH National Service Clinic at St James University Hospital, Leeds were 
enrolled into the study. Participation in the study was voluntary with patients 
recruited by routine clinic appointments. 22 patients were removed from the 
analysis due to them being on anticoagulant therapy or having missing data. 
2.6.1 Blood samples 
Blood was taken and stored by members of the PNH Clinic led by Dr Anita 
Hill as previously described (chapter 2.1.2) when patients attended routine 
clinical appointments. 
2.6.2 PNH Diagnosis, granulocyte clone size and LDH levels 
Diagnosis of PNH was determined by GPI deficiency. GPI deficient cells 
were identified using flow cytometry carried out by members of the PNH 
Clinic. Detection of PNH granulocytes and/or monocytes in peripheral blood 
was carried out as follows. 100 μL of whole blood was labelled with 45 μL of 
a combination of fluorochrome conjugated monoclonal antibodies and 
probes in a single six colour test. These included fluorescent aerolysin 
(FLAER) reagent alexa 488 (Protox biotech, Pinewood Scientific Services 
Inc, Victoria BC, Canada), CD24 PE (Becton Dickinson Pharmingen, Oxford, 
UK), CD16 PerCP:Cy5.5 (Becton Dickinson Biosciences, Oxford, UK 
(BDB)), CD33 PE:Cy7 (BDB), CD15 APC (Becton Dickinson Pharmingen, 
Oxford UK) and CD14 APC:Cy7 (BDB). The whole blood was left to stain for 
20 minutes and then the RBCs were removed by adding 2 mL of 
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FACSLysing solution (BDB). After two washes to remove excess unbound 
antibody and cellular debris, samples were analysed on a FACSCanto II flow 
cytometer (BDB) using FACSDiVa software (BDB). Granulocytes were 
identified by CD15 expression and light scatter characteristics as described 
previously (Richards and Barnett, 2007) and monocytes were identified by 
bright CD33 expression and low/ intermediate light scatter. Granulocyte PNH 
clones were identified by the lack of GPI-anchored antigens CD16 and CD24 
and, in a small (less than 5 %) populations, by deficiency of FLAER (a pan-
GPI-anchor marker). The percentage of granulocyte PNH clones was 
calculated and used as a scale of disease severity. 
Serum lactate dehydrogenase (LDH) levels were measured as a marker of 
cell damage and lysis, using a Bayer Advia 1650 or 2400 (Siemens 
Healthcare, Surrey, UK). The adult reference range is 160–430 IU.L-1 for 
serum or plasma. LDH levels in patients in this study ranged from 279-6568 
IU.L-1. 
2.6.3 PNH Clot permeability 
Permeability of clots formed from plasma of PNH patients were measured as 
previously described (chapter 2.1.10). 
2.6.4 PNH confocal microscopy 
Confocal microscopy was carried out on clots formed from patient plasma as 
previously described in chapter 2.1.7. 
2.6.5 PNH turbidity and lysis 
Clot formation and breakdown in patients with PNH was analysed using the 
previously described turbidity and lysis assay (chapter 2.1.8). 
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2.6.6 PNH fibrinogen levels 
Fibrinogen levels in patients with PNH were measured as previously 
described in chapter 2.1.4. 
2.6.7 PNH thrombin generation 
Thrombin generation was measured in patients with PNH using the 
Calibrated Automated Thrombogram (CAT) method (Thrombinoscope BV, 
The Netherlands). Measurements were taken following the manufacturer’s 
instructions. In brief, for each patient 80 μl of plasma was added to 6 wells of 
an “Immulon 2HB transparent U-bottom 96-well plate”. To the first 3 wells 20 
μl of thrombin calibrator (citrate buffered saline, bovine proteins and 
saccharides) was added to the patient plasma. The thrombin calibrator is a 
thrombin-like enzyme at a known activity that is not inhibited by plasmatic 
inhibitors and does not react with any substrates in plasma. This allows for 
quantification of thrombin concentration in the plasma. To the second 3 
wells, 20 μl of PPP-Reagent (phospholipids 4 μM and tissue factor 5 pM) 
was added to the patient plasma. The plate was immediately placed in a 
Fluoroskan™ Microplate Fluorometer (Thermo Fisher Scientific, 
Massachusetts USA), where 20 μl of FluCa solution (20 μM of HEPES, 60 
mg.ml-1 BSA and CaCl2) was added at time zero that initiates clotting due to 
the addition of calcium. Fluorescence using a 390/460 nm filter pair was 
measured every 20 seconds for 120 minutes at 37⁰C. The data was 
collected using the thrombinoscope software (Thrombinoscope BV, The 
Netherlands) and curves were automatically calculated by the analysis 
software correcting for inner filter effect, substrate consumption and α2-
macroglobulin-thrombin activity. 
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2.6.8 PNH ROTEM 
ROTEM in patients with PNH was carried out as previously described in 
chapter 2.1.9. It was performed on the whole blood of a sub population of a 
selection of 15 patients who were the most recent recruits from the study 
population of 82 patients. These most recent patients had ROTEM carried 
on their blood samples after the acquisition of a ROTEM machine allowing 
for whole blood analysis. 
2.7 Data analysis 
All raw data was initially collected into Microsoft Excel. GraphPad Prism v7 
(La Jolla, CA, USA) was used to represent the data graphically. Statistical 
tests were performed using GraphPad Prism v7 or IBM SPSS Statistics v20 
(SPSS Inc. Chicago, Illinois, USA). Statistically significant results were taken 
as p < 0.05. Distribution of data was tested using the D’Agostino and 
Pearson normality test. Continuous parametric data was presented as mean 
± standard deviation and continuous non-parametric data was presented as 
median and interquartile range. For patient demographics, continuous data 
is presented as mean ± standard deviation (parametric) or median and inter-
quartile range (non-parametric) and categorical data as number of subjects 
(% of total), with differences between the groups initially analysed using 2 
tailed t-tests or Mann-Whitney U test for continuous data and Pearson’s Chi-
Squared for categorical data, before carrying out binary logistic regression 
analysis. 2-tailed unpaired t-tests for comparison of two groups, Paired t-
tests for paired groups, one-way ANOVA followed by Tukey’s multiple 
comparisons test or two-way ANOVA followed by a Sidak’s multiple 
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comparisons test for comparison of multiple groups were used for parametric 
data. Mann-Whitney U test for the comparison of two groups, Wilcoxon 
matched pairs singed-rank test for paired groups and Kruskal-Wallis test 
followed by Dunn’s multiple comparisons test for the comparison of multiple 
groups was used for non-parametric data. 
For genetic sequence variants data, genotype distributions were tested for 
concordance with the Hardy-Weinberg equilibrium. The difference in the 
distribution of genotypes between groups was analysed using Pearson’s 
Chi-Squared testing. 
2.8 Study approvals 
Ethical approval for blood taking was obtained from the Leeds East National 
Research Ethics Committee (approval number 03/142), Maastricht medical 
ethics committee (METC 10-3-023) or the University Hospitals of Geneva 
and Faculty of Medicine review board. Written informed consent was 
received from all patients and volunteers prior to inclusion in a study in 
accordance with the Declaration of Helsinki. All mouse experiments were 
conducted according to institutional guidelines and were authorized by either 
the University of Leeds Ethics Committee, in accordance with Home Office 
UK Animals (Scientific Procedures) Act 1986 (PPL 70/8115), or the Malmö- 
Lund Animal Care Ethics Committee, Sweden (entry no. M89-16). 
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Chapter 3  - Fibrinogen γ’ and its role in clot structure 
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Fibrinogen γ’ is one of the most common mutations in fibrinogen. It results in 
a bulky negatively charged extension being formed at the c-terminus of the 
γ-chain of about 10-12 % of all fibrinogen molecules, although this can vary 
quite drastically. This variant has been shown to modulate thrombin via 
binding to exosite II and influence clot architecture, forming clots with 
increased branching, smaller pores and thinner fibres. It has also been 
shown to play a role in fibrin clot breakdown, making clots more resistant to 
lysis. Increases in fibrinogen γ’ have been associated with arterial 
thrombosis and decreases with venous thrombosis suggesting that 
fibrinogen γ’ induced changes in clot structure may play a role in the 
pathophysiology of thrombosis. So far this variant has been found in all 
human individuals, with many studies investigating its role in 
pathophysiology. The majority of previous studies have investigated the 
roles of fibrinogen γ’ using purified proteins, comparing 100 % γ’ to 100 % of 
the WT fibrinogen (γA) in static conditions. In this chapter the role of γ’ in clot 
formation and breakdown is investigated at physiological levels, in plasma 
and whole blood. This will help to demonstrate if previously described effects 
of γ’ on fibrin clot formation and breakdown play a role when both variants of 
fibrinogen are present at physiological concentrations. Furthermore, very 
little research has been carried out on fibrinogen γ’ under flow conditions. 
Therefore, initial experiments into the role of fibrinogen γ’ under flow are also 
discussed in this chapter. These will help to uncover how fibrinogen γ’ 
modulates clot structure at different flow rates. 
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3.1 Fibrinogen γ’ and fibrinogen γ’ percentage 
A splice variant of the fibrinogen γ-chain leads to a negatively charged 
extension at the C-terminus, known as fibrinogen γ’ (Macrae et al., 2016). 
This variant has been shown to influence clot architecture. The majority of 
clot structure studies have been performed using purified proteins, 
comparing 100 % γA/γ’ to 100 % γA/γA. In view of this we went on to 
investigate the effects of physiological levels of fibrinogen γ’ on clot 
formation and breakdown, and if these effects were similar to those seen in 
previous studies. 
3.1.1 The effects of physiological plasma fibrinogen γ’ levels 
Fibrinogen γ’ levels were measured in 1164 plasma samples, provided by 
patients recruited into LEADS (chapter 2.1.2), using the γ’ ELISA described 
in chapter 2.1.6 (Figure 17A). The demographic and clinical characteristics 
of this group can be seen in Table 3. Fibrinogen levels were also measured 
in the same patients (Figure 17B) and from this fibrinogen γ’ % was 
calculated (Figure 17C). Levels of γ’ in the whole group covered a large 
range from 0.8-39.5 %. 
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Figure 17 Fibrinogen γ’ and total fibrinogen levels. Fibrinogen γ’, total fibrinogen 
levels and fibrinogen γ’ % were measured in 1164 patients plasma samples. A, 
Fibrinogen γ’ levels measured in patient plasma by ELISA. B, Fibrinogen levels 
measured by Clauss method. C, Fibrinogen γ’ % calculated from total fibrinogen 
and fibrinogen γ’ levels. n = 1164.Data presented as median and IQR. 
 
Table 3 Demographic and clinical characteristics of all patients with γ’ levels 
measured.
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From this large cohort of patients three groups of patients that represented a 
low level, a normal or average level and a high level of γ’ were selected: all 
patients who possessed low (1-7 % (~3 %), n = 41), normal (9-11 % (~10 
%), n = 45) and high (22-40 % (~30 %), n = 33) fibrinogen γ’ levels, all with 
fibrinogen levels between 2.3-4.0 g.L-1  were chosen (Table 4, Figure 18A-
C). These samples were then analysed by confocal microscopy and turbidity 
and lysis assays. 
 Table 4 Fibrinogen γ’ level groups. 
  
 
Figure 18 Selection of fibrinogen γ’ level groups. Three groups of patient 
samples were selected with low, normal and high fibrinogen γ’ levels. A, Fibrinogen 
γ’ levels. B, Total fibrinogen levels. C, Fibrinogen γ’ %. n = 1164. ▪ represents 
difference from 1st column, * represents difference between other columns. **** or 
▪▪▪▪ p < 0.0001. Data presented as mean ± SD. 
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The demographic and clinical characteristics of the three groups are 
represented in Table 5. No statistically significant differences were found in 
any of the basic demographical or clinical characteristics between the three 
groups. 
Table 5 Demographic and clinical characteristics of the low, normal and high 
fibrinogen γ’ level groups. 
 
  
- 89 - 
The clot structure of the three patient groups were then compared to the clot 
structure of clots produced with purified fibrinogens with and without FXIII, 
and a repleted plasma system with the same fibrinogen γ’ ratios. Differences 
in clot structure were analysed by confocal microscopy. Clots were produced 
in the presence of fluorescently labelled fibrinogen and the density of clots 
was calculated. No differences in clot structure or density were found 
between different fibrinogen γ’ % in a purified system in the absence of FXIII 
(Figure 19A-B). However, when FXIII was added there was a significant 
increase in clot density as γ’ % increased (Low – 5.86 ± 0.51, Normal – 9.69 
± 0.71, High – 12.01 ± 0.98 fibres/100 μm). This pattern was also seen in the 
repleted plasma (Low – 39.00 ± 2.45, Normal – 41.53 ± 1.76, High – 44.20 ± 
2.10 fibres/100 μm, p = 0.0027) and the patient plasma (Low –33.48 ± 4.57, 
Normal – 35.41 ± 4.11, High –38.21 ± 3.22 fibres/100 μm, p < 0.0001) 
(Figure 19A-B). These data show that the ratio of γA/γ’ to γA/γA fibrinogen 
plays an important role in clot structure, and that an increase in γA/γ’ % in 
patient plasma may lead to the formation of a denser clot in the presence of 
FXIII. These findings agree with previous studies that showed that clots 
produced with 100 % fibrinogen γA/γ’ were denser than those made with 100 
% γA/γA (Cooper et al., 2003, Siebenlist et al., 2005), even though these 
earlier studies were performed in the absence of FXIII. The findings were 
backed up by permeation assays performed on the patient plasma, showing 
a similar trend, with permeability decreasing as the percentage of fibrinogen 
γ’ increased (p = 0.0022, Figure 19C). 
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Figure 19 Changes in clot structure with increasing fibrinogen γ’ %. A, Clots 
were formed with 3, 10 and 30 % fibrinogen γ’ in a purified system with (n = 3) or 
without FXIII (n = 3), in repleted plasma (n = 9) or in patient samples (Low n = 41, 
Normal n = 45, High n = 33) with these fibrinogen γ’ percentages. Clots were spiked 
with fluorescently labelled γA/γA and γA/γ’ and viewed by LSCM. Scale bar - 25μm. 
B, Clot density was quantified by calculating the number of fibres per 100μm. C, 
Permeation assays were carried out to calculate porosity of clots (Ks cm2 x10-9). * p 
< 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Data presented as mean ± SD. 
One way ANOVA. 
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The effects of fibrinogen γ’ percentage on clot formation were further 
explored using turbidity assays. Clots were produced in wells of a 96-well 
plate with 3, 10 or 30 % fibrinogen γ’ in a purified system with or without 
FXIII, in repleted plasma or in patient plasmas. Clot formation was initiated 
with 0.5 U.ml-1 thrombin, and clot formation was followed by measuring the 
absorbance of the clot at 340 nm wavelength (Figure 20A-D).  
 
 
Figure 20 Clot formation curves with increasing fibrinogen γ’ %. Clot formation 
was followed over time in clots formed with 3, 10 and 30 % fibrinogen γ’ in a purified 
system with or without FXIII, in repleted plasma or in patient samples with these 
fibrinogen γ’ percentages using the turbidity assay. The effects of γ’ % on clot 
formation was followed in A, a purified system, n = 3, B, a purified system in the 
presence of FXIII, n = 3, C, repleted plasma, n = 9 D, patient plasma, Low n = 41, 
Normal n = 45, High n = 33. Abs – absorbance.  
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From these curves a number of clot formation parameters were calculated. 
In a purified system Max OD was found to decrease with increasing 
fibrinogen γ’ percentage both with and without FXIII. This was also seen in 
repleted plasma and in the patient samples (Figure 21A, Table 6). These 
data suggest that an increase in fibrinogen γ’ percentage leads to clots with 
thinner fibres, which is in agreement with previous studies that have shown 
clots made with 100 % fibrinogen γA/γ’ have thinner fibres than clots formed 
from 100 % γA/γA (Cooper et al., 2003, Siebenlist et al., 2005). No 
differences in time to Max OD were seen in the purified, repleted plasma or 
patient plasma experiments (Figure 21B, Table 6). Time to Max OD was 
much shorter with experiments in purified fibrinogen without FXIII and the 
repleted plasma experiments. In the graphs in Figure 20A and Figure 20C 
the curves can be seen to rapidly increase up to a maximum but then begin 
to gradually decrease relatively early in comparison to the curves in Figure 
20B and Figure 20D. This could be due to the lack of FXIII in the purified 
experiments, and lower FXIII levels in the fibrinogen depleted plasma as 
some FXIII will have been lost bound to fibrinogen in the depletion process. 
This decrease or lack of FXIII would lead to a less stable clot being formed. 
A decrease in the maximum rate of clotting (turbidity Vmax) with an increase 
in fibrinogen γ’ percentage was found in purified experiments with and 
without FXIII. This was not the case in repleted plasma and patient samples 
where no difference in maximum clotting rate was seen as the fibrinogen γ’ 
percentage increased (Figure 21C, Table 6). This may be due to other 
factors in the plasma playing a role in clot formation, negating the effect of 
the increase in fibrinogen γ’ percentage. There was a decrease in average 
rate of clotting as fibrinogen γ’ percentage increased in the purified 
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experiments with and without FXIII. However, this was not seen in repleted 
plasma or patient sample experiments, again further suggesting that other 
components of plasma negate the effects of fibrinogen γ’ on clotting rate 
(Figure 21D, Table 6). Together, these results show that increases in 
fibrinogen γ’ percentage effect clot structure, forming clots with thinner 
fibres, but in plasma there is no effect on the rate of clot formation. 
 
Figure 21 The effects of fibrinogen γ’ % on clot formation. The effects of 
fibrinogen γ’ % on clot formation parameters in purified system with (n = 3) and 
without (n = 3) FXIII, in repleted plasma (n = 9) and patient plasma samples (Low n 
= 41, Normal n = 45, High n = 33) using the turbidity assay. A, Max OD, B, time to 
Max OD, C, Turbidity Vmax, D, Average rate of clotting between 25-75 % of clot 
formation. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Data presented as 
mean ± SD. One way ANOVA. Abs – absorbance.  
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Table 6 The effects of fibrinogen γ’ % on clot formation.
 
 
The effects of fibrinogen γ’ percentage on clot breakdown were also 
explored using the turbidity assay. Clots were produced in the same way as 
described for clot formation assays. In the purified experiments, both tPA (85 
ng.ml-1) and plasminogen (25μg.ml-1) were added to the clotting mixture, 
while in repleted plasma or patient plasma experiments just tPA (85 ng.ml-1) 
was added at the beginning of the experiments to induce lysis. Clot 
formation was initiated with 0.5 U.ml-1 thrombin, and clot formation and 
breakdown was followed by measuring the absorbance of the clot at 340 nm 
(Figure 22A-D). 
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Figure 22 Clot breakdown curves with increasing fibrinogen γ’ %. Clot 
breakdown was followed over time in clots formed with 3, 10 and 30 % fibrinogen γ’ 
in a purified system with or without FXIII, in repleted plasma or in patient samples 
with these fibrinogen γ’ percentages using the turbidity assay. The effects of γ’ % 
on clot breakdown was followed in A, a purified system, n = 3, B, a purified system 
in the presence of FXIII, n = 3, C, repleted plasma, n = 9 D, patient plasma, Low n = 
41, Normal n = 45, High n = 33. Abs – absorbance. 
 
A number of clot breakdown parameters were calculated from the lysis 
curves. Both time to 50 % lysis and 75 % lysis were found to increase with 
increasing γ’ percentage in a purified system with and without FXIII and 
repleted plasma experiments. In the patient samples as γ’ percentage 
increased there appeared to be no difference in time to 50 % lysis, while 
time to 75 % lysis was increased (Figure 23A, Table 7). These data suggest 
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that an increase in fibrinogen γ’ percentage leads to an increase in lysis 
time, in agreement with previous studies that show fibrinogen γA/γ’ has 
longer lysis times than γA/γA, and that an increase in fibrinogen γA/γ’ levels 
caused a delay in clot lysis (Siebenlist et al., 2005, Kim et al., 2014, Falls 
and Farrell, 1997, Pieters et al., 2013). No significant differences in 
maximum lysis rate or average lysis rate were seen in purified experiments 
without FXIII, reflecting the lack of change in clot structure in the absence of 
FXIII. A significant decrease in maximum lysis rate and average lysis rate 
were seen in purified experiments with FXIII and repleted plasma. However, 
only maximum lysis rate was effected in patient samples as γ’ percentage 
increased (Figure 23C-D, Table 7). These data suggest that other factors 
(thrombin concentration, FXIII levels etc.) within the plasma may negate or 
lessen some of the effects of increasing γ’ levels. 
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Figure 23 The effects of fibrinogen γ’ % on clot breakdown. The effects of 
fibrinogen γ’ % on clot breakdown parameters in purified system with (n = 3) and 
without (n = 3) FXIII, in repleted plasma (n = 9) and patient plasma samples (Low n 
= 41, Normal n = 45, High n = 33) using the turbidity and lysis assay. A, Time to 50 
% lysis, B, time to 75 % lysis, C, Lysis Vmax, D, Average rate of lysis between 25-
75 % of clot formation. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Data 
presented as mean ± SD. One way ANOVA. 
 
Table 7 The effects of fibrinogen γ’ % on clot breakdown. 
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3.1.2 The effects of γ’ in whole blood clot viscoelasticity 
From the 1164 patients that had γ’ levels measured, a subset of 78 patients 
had ROTEM analysis carried out on their whole blood and the relationship 
between γ’ levels and ROTEM outputs were investigated. The demographic 
for this group of patients can be seen below in Table 8. 
Table 8 Demographic of ROTEM analysed patients. 
 
 
Three hundred microliters of whole blood from each patient was combined 
with 20 μl of either ex-tem or in-tem reagent (tissue factor) and 20 μl of star-
tem reagent (calcium) and the viscoelastic properties of clot formation were 
followed over time using the ROTEM delta. Parameters from these 
measurements were correlated with fibrinogen level, fibrinogen γ’ level and 
fibrinogen γ’ % (Table 9).  
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Table 9 Correlation of ROTEM parameters with γ’ levels and γ’ %. 
 
 
Fibrinogen levels correlated with MCF when clotting was initiated with ex-
tem (r = 0.2772, p = 0.014) or in-tem (r = 0.2314, p = 0.0473). This was 
expected as previous studies have shown that an increase in fibrinogen 
levels leads to an increase in clot strength (Harr et al., 2013, Rourke et al., 
2012). When clotting was initiated with the ex-tem reagent fibrinogen γ’ 
levels and γ’ % were both found to negatively correlate with lag time (Figure 
24A-B) and positively correlate with the clotting rate between end of lag time 
and 25 % clotting (Figure 24C-D), but not with the clotting rate between 25 
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and 50 % clotting (Figure 24E-F). This indicates that in whole blood higher 
levels of γ’ fibrinogen may lead to a faster onset of clotting and more rapid 
clot formation in the early stages, but this increase in rate does not 
propagate through to later points of clot formation as there was no change in 
the time to MCF as γ’ levels increased (Table 9). Fibrinogen γ’ levels and γ’ 
% were also found to positively correlate with the maximum clotting rates 
(Figure 25A-B) and negatively with the time taken to reach the maximum 
clotting rate (Figure 25C-D), but not with the average rate of clotting (Figure 
25E-F). This further suggests that γ’ is playing a role in the early stages of 
clotting, with increasing levels of γ’ leading to higher maximum clotting rates 
and these maximum rates being reached more quickly. However, this 
increase in clotting rate does not continue as there was no relationship 
between average clotting rates and γ’ levels. 
When clotting was initiated with the in-tem reagent no correlations were 
seen apart from with MCF with fibrinogen levels. This suggests that in whole 
blood fibrinogen γ’ is only having an effect on the extrinsic pathway and not 
on the intrinsic pathway. 
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Figure 24 Ex-tem ROTEM analysis of the effects of fibrinogen γ’ levels and γ’ 
% on early clotting. The effects of fibrinogen γ’ level and γ’ % on the initial stages 
of clotting were assessed when clotting was initiated with EXTEM using ROTEM (n 
= 78). A,C,E Fibrinogen γ’ levels correlated with A, lag time, C, Clotting rate 
between end of lag time and 25 % clotting E, Clotting rate between 25 and 50 % 
clotting. B, D, F Fibrinogen γ’ % correlated with B, lag time, D, Clotting rate 
between end of lag time and 25 % clotting F, Clotting rate between 25 and 50 % 
clotting. Spearman’s rank correlation. 
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Figure 25 Ex-tem ROTEM analysis of the effects of fibrinogen γ’ levels and γ’ 
% on clotting rates. The effects of fibrinogen γ’ level and γ’ % on clotting rates 
were assessed when clotting was initiated with EXTEM using ROTEM. (n = 78). 
A,C,E Fibrinogen γ’ levels correlated with A, Maximum clotting rate, C, Time to 
maximum clotting rate E, Average clotting rate. B, D, F Fibrinogen γ’ % correlated 
with B, Maximum clotting rate, D, Time to maximum clotting rate F, Average clotting 
rate. Spearman’s rank correlation. 
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3.2 Fibrinogen γ’ under flow 
The majority of research into the effects of fibrinogen γ’ on clot structure 
have been done in static conditions, with only a couple of papers 
investigating the role of γ’ and its thrombin binding abilities under flow 
conditions (Muthard et al., 2015, Zhu et al., 2018). Due to previous links of 
fibrinogen γ’ levels with both venous and arterial thrombosis, its effects on 
clot structure under flow conditions could help to explain this link and provide 
a mechanism for its role in thrombosis. 
3.2.1 Fibrinogen γ’ under venous and arterial flow rates 
The effects of venous and arterial flow rates on clot formation with γA/γA and 
γA/γ’ fibrinogen was investigated using a two-step model in a microfluidic 
chamber in collaboration with Prof. Johan Heemskerk, Dr Frauke Swieringa 
and Dr Constance Baaten at the University of Maastricht. Initially, 
anticoagulated whole blood was perfused through a flow chamber that 
contained microspots of collagen and tissue factor at a shear rate of 1000 s-
1. This led to the formation of platelet thrombi on the microspots. Fibrinogen 
deficient plasma was repleted with purified and fluorescent γA/γA or γA/γ’, 
re-calcified, and then immediately perfused over the preformed thrombi at 
either 150 s-1 or 500 s-1. Fibrin formation around the platelet thrombi was 
followed by time series confocal fluorescent imaging and quantified by 
fluorescence accumulation (Figure 26). 
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Figure 26 The effects of γA/γA and γA/γ’ on fibrin accumulation under venous 
and arterial flow. γA/γA or γA/γ’ fibrinogen repleted plasma was perfused over 
platelet thrombi at 150 s-1 500 s-1, and fibrin accumulation was quantified by 
fluorescence over time. 
 
The time to the first fibrin deposition, or lag time, of fibrinogen γA/γ’ at a flow 
rate of 150 s-1 was found to be significantly shorter than γA/γA at 150 s-1 and 
500 s-1 and γA/γ’ at 500 s-1. Fibrin deposition was seen after just 42 s ±14 
with γA/γ’ at 150 s-1, but not until 118 s ± 10 and 101 s ± 16 with γA/γA at 
150 s-1 and 500 s-1 respectively, and 100 s ± 8 with γA/γ’ at 500 s-1 (p = 
0.0013) (Figure 27A). The average rate of fibrin deposition was significantly 
slower at 500 s-1 than 150 s-1, but no difference in the average rate of fibrin 
deposition was seen between γA/γA and γA/γ’ at either flow rate (Figure 
27B). Maximum fibrin deposition, or maximum fluorescence, was 
significantly higher at 500 s-1 than at 150 s-1, and at both 150 s-1 and 500 s-1, 
maximum fibrin deposition was found to be significantly higher with γA/γ’ 
(150 s-1 - 11.5 ± 1.1 x106, 500 s-1 - 28.8 ± 1.4 x106) than γA/γA (150 s-1 - 9.2 
± 0.8 x106, 500 s-1 - 22.8 ± 0.7 x106, p < 0.0001)(Figure 27C). At 150 s-1, 
γA/γ’ reached maximum fluorescence more quickly than γA/γA fibrinogen 
(γA/γ’ – 4.62 ± 0.82 mins, γA/γA – 6.68 ± 0.66 mins, p = 0.0274), but no 
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difference in the time taken to reach maximum fibrin deposition was seen at 
500 s-1 (Figure 27D). These data suggest that at venous flow rates γA/γ’ 
fibrinogen may lead to faster deposition of fibrin, and at both venous and 
arterial flow rates γA/γ’ fibrinogen leads to a greater deposition of fibrin 
around platelet thrombi. 
 
 
Figure 27 Differences in fibrin deposition between γA/γA and γA/γ’ fibrinogen 
at arterial and venous flow rates. From the accumulation of fluorescence data a 
number of parameters were compared between γA/γA and γA/γ’ fibrinogen. A, lag 
time, B, Average rate of fibrin deposition, C, Maximum fluorescence, D, Time to 
maximum fluorescence. * p < 0.05, ** p < 0.01. Data presented as mean ± SD. 
One-way ANOVA. Fluor – fluorescence.  
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At the end of each experiment, a number of endpoint Z-stacks were taken at 
random points around each microspot to assess differences in endpoint clot 
formation. Volume and height of the clots were measured and images were 
depth coded for visual representation. 
When the clots were visualised by depth coding clear differences were 
observed between γA/γ’ and γA/γA clots. The γA/γ’ clots were much taller 
(Figure 28A) and appeared to have a greater volume at 150 s-1 than clots 
formed from γA/γA fibrinogen, with γA/γA clots appearing more fibrous 
(Figure 29A). Similar differences were seen at 500 s-1, but with both forms of 
fibrinogen producing clots with less height and volume (Figure 28B and 
Figure 29B). 
  
- 107 - 
 
Figure 28 End-point cross-sectional view of depth coded clots formed from 
γA/γA or γA/γ’ at venous and arterial flow rates. Cross sections of depth coded 
endpoint Z-stacks of clots formed from γA/γA or γA/γ’ fibrinogen repleted plasma 
perfused over platelet thrombi at A, 150 s-1 and B, 500 s-1. Images 90 x 213 μm. 
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Figure 29 End-point depth coded clots formed from γA/γA or γA/γ’ at venous 
and arterial flow rates from above. Depth coded endpoint Z-stacks of clots 
formed from γA/γA or γA/γ’ fibrinogen repleted plasma perfused over platelet 
thrombi viewed from above at A, 150 s-1 and B, 500 s-1. Images 213 x 213 μm. 
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Quantitative analysis of these images confirmed the differences between 
γA/γA and γA/γ’ fibrinogen. The volume of the fibrin clots formed with γA/γ’ 
fibrinogen were found to be greater than clots formed with γA/γA at both 150 
s-1 (70.21 ± 23.19 μm3 vs 28.51 ± 10.89 μm3, p < 0.0001) and at 500 s-1 
(26.64 ± 2.30 vs 17.69 ± 5.07 μm3, p < 0.0001) (Figure 30A). The maximum 
height of clots formed from γA/γ’ were also found to be significantly higher 
than clots formed with γA/γA at 150 s-1 (52.91 ± 14.09 μm3 vs 26.77 ± 8.96 
μm3) and at 500 s-1 (20.95 ± 2.31 vs 11.55 ± 2.43 μm3, p < 0.0001)(Figure 
30B). When the volume of fibrin in each slice of the Z-stacks was plotted 
against the distance of the slice from the slide, the differences between the 
distribution of fibrin and the heights of the clots can clearly be seen (Figure 
30C). Clots formed at 150 s-1 are tall and the largest area per slice of fibrin is 
away from the surface, with a small area of contact with the platelets and the 
surface. However, clots formed at 500 s-1 are more compact with the largest 
area per slice of fibrin on, or close to the surface, with a larger area of fibrin 
in contact with the slide. This helps to explain why there is an increase in 
maximum fluorescence at 500 s-1 compared to 150 s-1 in time series 
experiments (Figure 27C), when endpoint images appear to show much 
greater volumes of fibrin at 150 s-1. Time series experiments were imaged 
close to the surface, and so analysis of time series experiments were picking 
up the increased deposition of fibrin on the slide surface at 500 s-1. At 150 s-1 
γA/γ’ appears to increase the height and the distance of the largest area per 
slice of fibrin from the slide when compared to γA/γA, but at 500 s-1 γA/γ’ 
only appears to effect the height of the clots. 
  
- 110 - 
 
Figure 30 The effects of γA/γ’ on clot height and volume at venous and 
arterial flow rates. Height and total volume of fibrin was calculated from endpoint 
Z-stacks of clots formed from γA/γA or γA/γ’ fibrinogen repleted plasma perfused 
over platelet thrombi at 150 s-1 and 500 s-1. A, Total volume of fibrin, B, Maximum 
height of fibrin clot, C, Area of fibrin per slice vs distance from the clotting surface. 
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3.3 Discussion 
There is a plethora of studies investigating the role of fibrinogen γ’ in clot 
structure, but the majority of these have used purified proteins, comparing 
100 % γA/γ’ to 100 % of the wildtype fibrinogen (γA/γA) in static conditions. 
In this chapter the effects of physiological levels of fibrinogen γ’ in plasma 
and whole blood on clot structure were examined, and how fibrinogen γ’ 
impacts clot structure under flow. Fibrinogen γ’ influenced clotting and clot 
structure in plasma even at physiological levels, with clot density increasing 
as the level of γ’ increased, but only in the presence of FXIII. Clot formation 
rates appeared to decrease as γ’ levels increased, but this was not seen in 
clots made with plasma samples from patients with cardiovascular diseases. 
Fibrinolysis was also effected by γ’, with increased levels prolonging lysis 
times and slowing fibrinolysis rates. In whole blood analysis increasing γ’ 
levels led to shorter clotting times and an increased rate of clotting in the 
early stages of clot formation, but this did not propagate to the later stages of 
clot formation, with no change in average rate of clotting or time to MCF. 
Fibrinogen γ’ also influenced clot formation under flow conditions, shortening 
the lag times at slower flow rates, and increasing amounts of fibrinogen 
being deposited around the platelet aggregates at both low and high flow 
rates. Analysis of end-point clots showed that clots formed with 100 % γA/γ’ 
lead to clots with greater height and volume. Than clots formed from 100 % 
γA/γA. 
Changes seen in clot structure at physiological levels of γ’ fibrinogen mostly 
agreed with previous studies. An increase in clot density was seen as the 
percentage of γ’ increased in a purified system, repleted fibrinogen deficient 
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plasma and in patient plasma samples. This was in agreement with previous 
studies showing that fibrinogen γ’ forms denser clots (Cooper et al., 2003, 
Siebenlist et al., 2005). In addition, using a combination of purified and 
plasma based systems, this study now indicates that the changes in clot 
structure appeared to be FXIII dependent. The same trend was seen in 
permeation assays, with increases in γ’ leading to decreases in clot 
permeability, but in the absence of FXIII porosity was not affected. In this 
study IF-1 fibrinogen purification was used to eliminate all FXIII from 
fibrinogen preparations, before fibrinogen variants γA/γ’ and γA/γA were 
produced using anion-exchange chromatography. Previous studies that 
have shown changes in clot structure due to fibrinogen γ’ did not do this 
(Cooper et al., 2003, Siebenlist et al., 2005, Allan et al., 2012), and so they 
were potentially all carried out in the presence of some FXIII as it has been 
found to copurifiy with fibrinogen γ’ on anion-exchange chromatography 
(Mosesson and Finlayson, 1963). Therefore, further studies using FXIII 
inhibitors should be carried out to confirm the FXIII dependent clot changes 
caused by fibrinogen γ’. 
There were similarities and differences in clot formation and breakdown data 
to previous studies. As fibrinogen γ’ levels increased, there was a decrease 
in Max OD, indicative of the formation of thinner fibres, and a decrease in 
clotting rates, both in agreement with previous data (Cooper et al., 2003, 
Siebenlist et al., 2005). Interestingly, the effects of fibrinogen γ’ on clotting 
rates were not seen in the repleted plasma or patient plasma samples, 
suggesting that other factors within the plasma may negate or lessen the 
effects of the changes in fibrinogen γ’ levels. Changes in clot breakdown 
followed a similar trend, with increasing fibrinogen γ’ levels leading to 
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prolonged lysis times and decreased lysis rates, mirroring previous findings 
(Falls and Farrell, 1997, Siebenlist et al., 2005, Kim et al., 2014, Pieters et 
al., 2013), but in patient samples lysis was only found to be prolonged at 75 
% lysis and no change in average lysis rates were found. This suggests that 
although fibrinogen γ’ levels influence fibrinolysis, the effects are reduced in 
patient plasma samples, and this may be due to other contributing factors in 
the plasma (FXIII levels, α2AP levels). 
In a novel approach, the effects of fibrinogen γ’ levels on the mechanical 
properties of whole blood clots were investigated by ROTEM (n = 78). As 
fibrinogen γ’ levels increased there was a decrease in lag time and an 
increase in the rate of early clot formation and maximum rate of clot 
formation. However, this increase in rate did not propagate to the later 
stages of clot formation, with no changes seen in average rate of clot 
formation or time to MCF. Finally, no differences were seen in MCF as 
fibrinogen γ’ levels increased. These data suggest that in whole blood, 
increases in fibrinogen γ’ may in fact lead to an increase in early clotting 
rates, which is in agreement with Allan et al., who reported earlier gelling of 
fibrinogen γ’ clots (Allan et al., 2012). No effect of increasing fibrinogen γ’ 
was seen on the stiffness of whole blood clots. This was unexpected as 
differences in stiffness between γA/γ’ and γA/γA have previously been 
reported in purified and plasma systems, with γA/γ’ being significantly more 
viscous (Allan et al., 2012, Domingues et al., 2016). This might be explained 
by two possible reasons, either the effect of fibrinogen γ’ on clot stiffness is 
annulled in whole blood by the presence of other blood cells, or another 
possibility is that the ROTEM is not sensitive enough to pick up the small 
differences in clot stiffness induced by fibrinogen γ’ in whole blood. To 
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further investigate this, a more sensitive system may be required like the 
magnetic tweezers used in the paper of Allan et al. This could be modified to 
investigate clot stiffness in whole blood clots using fluorescently labelled 
magnetic beads (Allan et al., 2012). The increase in the early rates of 
clotting and maximum rates of clotting with increasing fibrinogen γ’ levels in 
whole blood clots differs from many studies that have demonstrated a 
reduction in clotting rates with fibrinogen γA/γ’ (Cooper et al., 2003, 
Siebenlist et al., 2005, Lovely et al., 2007, Allan et al., 2012). This suggests 
that the effects of fibrinogen γ’ in whole blood may be reduced with average 
clot formation rates normalised, and at the same time its effects on faster 
clot gelation and increased early clotting rates dominating. Further studies 
are needed to confirm this, using other whole blood clotting techniques. 
In ROTEM experiments changes in fibrinogen γ’ only appeared to induce 
effects on clot formation when clotting was triggered via the extrinsic 
pathway. When clotting was initiated with the in-tem reagent no differences 
were seen as fibrinogen γ’ levels increased. This suggests the effects of 
fibrinogen γ’ in whole blood are produced via the extrinsic pathway. This was 
somewhat unexpected as previous studies have linked fibrinogen γ’ to the 
intrinsic pathway, showing that the fibrinogen γ’ C-terminal peptide (410-427) 
inhibits the intrinsic pathway via FVIII (Lovely et al., 2007). These studies 
were carried out at very high concentrations of peptide, and so physiological 
levels of fibrinogen γ’ may have little to no effect on the intrinsic system. This 
may suggest that in whole blood fibrinogen γ’ may impart its effects through 
the extrinsic pathway or the thrombin feedback loop. Whole blood thrombin 
generation in patients with a range of fibrinogen concentrations could be 
used to further study this (Ninivaggi et al., 2012). 
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In collaboration with Prof Johan Heemskerk’s lab at the University of 
Maastricht the effects of venous and arterial flow rates on clot formation with 
γA/γA and γA/γ’ fibrinogen was investigated using a two-step model in a 
microfluidic chamber. Fibrinogen deficient plasma repleted with fluorescent 
γA/γA or γA/γ’ fibrinogen was perfused over preformed platelet thrombi, and 
the accumulation of fluorescent fibrin around the platelet thrombi was 
quantified. Fibrin deposition occurred much more rapidly with γA/γ’ 
fibrinogen at venous flow rates than γA/γA fibrinogen, but this effect was 
abolished at arterial flow rates. This fits with the decrease in lag time and 
increase in initial clotting rates with increasing γ’ levels seen in ROTEM 
analysis, and with previous findings that demonstrate faster gelling of γ’ 
fibrinogen clots (Allan et al., 2012). Clots in the ROTEM analysis and in 
previous studies were all formed in static conditions, so combining this with 
the flow data puts forward the idea that in static or reduced flow rate 
conditions γ’ fibrinogen leads to an increase in early clot formation, but at 
higher flow rates this effect is nullified. At both flow rates more fibrin was 
deposited around the platelet thrombi with γA/γ’ than γA/γA fibrinogen at the 
end of the experiment, and this supports the idea of γ’ fibrinogen being more 
prothrombotic and a cardiovascular risk factor (Pieters et al., 2013). At 
arterial flow rates more fibrin was laid down around the platelet thrombi, and 
at a faster rate, with both fibrinogen variants. γA/γ’ fibrinogen appeared to 
reach maximum fluorescence more quickly than γA/γA at venous flow rates, 
but this may be reflective of the shorter lag times. 
When end-point clot images were analysed, there were clear differences in 
clot morphology between the flow rates and fibrinogen variants. Clots formed 
at arterial flow rates were much shorter and smaller than clots formed at 
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venous flow rates. This was expected as the pressure is much higher at 
arterial flow rates and this would prevent growth of the clots away from the 
surface. γA/γ’ fibrinogen led to significantly taller and more voluminous clots 
at both venous and arterial flow rates. This mirrored the results from the 
kinetic experiments, with γA/γ’ fibrinogen leading to a greater maximum 
fluorescence, indicating more fibrin being deposited around the platelet 
thrombi. When the volume of each slice was plotted against the distance 
from the slide the distribution of fibrin in these clots was remarkably different 
between the different flow rates and the two fibrinogen splice variants. At 
venous flow rates, the majority of the fibrin clot forms away from the slide 
surface and the platelet thrombi, with only a small area of contact, and this 
was exaggerated greatly in the γA/γ’ clots with more height and volume. At 
higher flow rates clots were much lower in height and the largest area of 
fibrin was on the surface around the platelet thrombi. This was reflected in 
the results from the kinetic experiments, which showed significantly more 
fibrin deposited around platelet thrombi with both fibrinogen variants at 
higher flow rates. γA/γ’ fibrinogen had less of an effect on the volume of the 
clot at higher flow rates, but still resulted in significantly taller clots. These 
data clearly indicate γA/γ’ fibrinogen leads to the formation of much larger 
clots at both venous and arterial flow rates, much more so at venous flow 
rates. Interestingly, even though γA/γ’ led to the formation of much larger 
clots at venous flow rates, most previous studies have linked venous 
thrombosis with a decrease in γ’ fibrinogen levels (Uitte de Willige et al., 
2005, Mosesson et al., 2007, Nowak-Gottl et al., 2009). This raises 
questions about the properties of these larger γA/γ’ clots at venous flow 
rates. These clots appeared to be made up of voluminous clouds of fibrin 
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when compared to the more familiar fibrous clots formed with γA/γA 
fibrinogen, with very small points of contact with the platelet thrombi. This 
could result in these clots being much weaker than the more fibrous γA/γA 
clots, leading to clots that embolize more easily or clots that are more easily 
broken down. This could help to explain the association of decreasing levels 
of fibrinogen γ’ with venous thrombosis, as lower levels of fibrinogen γ’ in 
clots formed at venous flow rates may lead to clots that are more difficult to 
breakdown forming a more stable clot, and this may create conditions where 
venous thrombosis is more likely. At higher flow rates the clots formed with 
both fibrinogen splice variants were much shorter, with a wider base. This 
would suggest that these clots would be much more stable. γA/γ’ clots, in 
these more stable conditions, were still significantly larger than clots formed 
from γA/γA, and this could be important in conditions involving obstructive 
clots. Previous studies have already associated increased γ’ levels with 
ischemic stroke (Cheung et al., 2008, van den Herik et al., 2011) and 
myocardial infarction (Mannila et al., 2007), and this may be due to the 
increased clot size with increasing levels of fibrinogen γ’ that are more likely 
to obstruct blood flow. Further studies will be required to see if the size of 
clots under flow are effected at physiological fibrinogen γ’ levels, and if 
increases in these levels lead to increases in volume. Another area of 
interest is how these clots break down under flow, and if fibrinogen γ’ plays a 
role in fibrinolysis under flow. 
All together the data from this chapter indicate that γ’ fibrinogen may play an 
important role in thrombosis. At physiological concentrations it increases clot 
density and prolongs lysis, and in whole blood and under flow it appears to 
speed up the initial stages of clot formation. Under flow γ’ fibrinogen also 
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resulted in the formation of much larger clots. All of these changes in clot 
structure suggest γ’ fibrinogen may play a significant role in thrombosis, and 
highlight the need for more work to be carried out to understand the 
mechanisms involved. 
3.4 Future work 
This chapter has highlighted that γ’ fibrinogen may play an important role in 
the pathogenesis of thrombosis and that more work is required to uncover 
the significance of this clinically, and if the mechanisms underlying this role 
in thrombosis can be targeted. Due to the apparent role of FXIII in fibrinogen 
γ’ induced changes in clot structure, more research is required to confirm 
this and uncover its mechanisms. By Inhibiting FXIII in plasma with T101 or 
another FXIII inhibitor, it would be possible to see if the effects of γ’ on clot 
structure could be reversed. This would add to the evidence that the 
changes are indeed FXIII dependent. More flow experiments need to be 
carried out, with more repeats of the clot formation experiments under 
venous and arterial flow needed. Following on from these experiments with 
different ratios of γA/γ’ to γA/γA fibrinogen are required to examine how 
physiological levels of γ’ fibrinogen influence clot formation and structure at 
venous and arterial flow rates. The relationship between fibrinogen binding 
receptors on platelets and γ’ fibrinogen could be assessed under flow by 
introducing different receptor inhibitors. The role of γ’ in fibrinolysis needs to 
be investigated in more detail. Whole blood ROTEM fibrinolysis and lysis 
under flow could be explored to elucidate if γ’ prolongs lysis in whole blood 
and under flow conditions. Experiments of lysis under flow have already 
begun, but more repeats are required. One step flow experiments using 
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patient whole blood samples with measured γ’ levels could also be carried 
out. This would be more physiologically relevant as clot formation would 
proceed in one step, as opposed to platelet thrombi formation first followed 
by fibrin deposition, and it would also eliminate the need to use fibrinogen 
deficient plasma. 
Together these studies would take this investigation forward taking a more 
in-depth look at the role of γ’ in thrombosis, uncovering the significance of its 
impact and potentially creating a new therapeutic target in the treatment of 
thrombosis. 
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Chapter 4 - Clot structure at the air-blood interface 
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Haemostasis is a pivotal mechanism to prevent life-threatening blood loss 
from sites of injury and involves close interplay between coagulation and 
platelets. The resulting blood clot contains activated platelets, RBCs, and 
fibrin polymer, which holds the clot together. Fibrin is formed by limited 
proteolysis of fibrinogen by thrombin. Thrombin cleaves small peptidic 
sequences from the N-termini of the Aα- and Bβ-polypeptides, exposing 
interaction sites for binding pockets in the C-terminal domains of the β- and 
γ-chains, respectively (Weisel, 2005). Fibrin then polymerizes into 
protofibrils, which aggregate laterally into fibres. The fibres branch and 
produce a 3D network with remarkable elastic properties (Liu et al., 2006). 
The structure of the fibrin network is determined by fibre diameter, protofibril 
packing, and pore size, the latter of which is sufficient for the incorporation of 
cells. Dense networks with thin fibres and increased rigidity are associated 
with increased risk of thrombosis, while loose clot networks with thick fibres 
and reduced rigidity are associated with bleeding (Weisel, 2005, Undas and 
Ariens, 2011, Wolberg, 2010). 
A major conundrum after decades of fibrin polymer research is that fibrin 
fibres in blood clots appear endless, with little or no evidence of fibre ends 
(Figure 31). Thus, the mechanisms and structures that determine the 
external boundary of an extravascular (haemostatic) blood clot are unknown. 
What happens to the fibrin network and fibres when they reach the 
peripheral, exposed surface of the clot? Do the fibres just stop, flatten, or 
bend, or is the surface lined by platelets, RBCs, or other cells? The 
architecture of this interface is important because it forms a distinction 
between host and the environment. To explore this, the structural 
characteristics of the exterior face of the blood clot were investigated.  
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Figure 31 Fibrin clot network. SEM image of a three-dimensional fibrin fibre 
network from the inside of a clot. Fibrin fibres in this image appear limitless and 
without fibre ends. Scale bar -2 μm. Image from Macrae et al. (2018). 
 
4.1 Film forms at air-liquid interface 
Scanning electron microscopy and laser scanning confocal microscopy were 
used to investigate the liquid-air interface of clots (Figure 32 and Figure 33). 
In dehydrated conditions used in SEM, a thin film was found to form at the 
liquid-air interface of clots formed from whole blood or PPP, when clotting 
was initiated with either thrombin (0.5 U.ml-1, Figure 32A-B) or tissue factor 
(5 pM, Figure 32C-D). This film was also seen in clots formed in fully 
hydrated conditions using LSCM, in both whole blood (thrombin - 0.5 U.ml-1, 
TF – 5 pM, Figure 33A-B) and PPP (thrombin - 0.5 U.ml-1, tissue factor – 5 
pM, Figure 33C-D). The film was found to be continuous, covering the entire 
air-liquid interface, when single slices of clots were examined in the Z-plane 
using LSCM (Figure 33E). 
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Figure 32 Film forms on clot surface at the air-liquid interface. SEM of film 
formed at the air-liquid interface in whole blood and plasma clots. A, B, clotting was 
initiated with thrombin. C, D, clotting was initiated with tissue factor. At places 
where the film is torn (due to SEM sample processing procedures), red blood cells 
(asterisk), platelets (thick arrow) and fibrin (thin arrow) are observed in whole blood 
clots, and fibrin in plasma clots. Red blood cells are also seen shining through the 
film in whole blood clots. Images represent findings reproduced in at least n = 3 
experiments. Scale bars: A, B – 10 μm, C, D – 20 μm. Data from Macrae et al. 
(2018). 
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Figure 33 Film is present in hydrated conditions. LSCM of film formed at the air-
liquid interface in whole blood and plasma clots. A, C, clotting was initiated with 
thrombin. B, D, clotting was initiated with tissue factor. Fibrinogen was fluorescently 
labelled with Alexa Fluor-488 (green) or -594 (red). Under fully hydrated conditions 
of LSCM, tears in the film were not observed. E, LSCM of a single Z-plane slice of a 
plasma clot showing continuous film around the clot. The central gap in the clot 
image is where the pipette was introduced into the plasma drop to inject thrombin. 
Images represent findings reproduced in at least n = 3 experiments. Scale bars: A-
D – 50 μm, E – 1 mm. Data from Macrae et al. (2018).  
 
4.2 Film is composed of fibrin 
Fluorescence encountered within the film in LSCM images indicated 
fibrinogen or fibrin was present (Figure 33). To elucidate the components of 
the film, it was peeled away from the surface of plasma clots (Figure 34A) 
formed with or without T101 (transglutaminase inhibitor). The films were 
reduced and subjected to SDS-PAGE (Figure 34B). The film was found to 
mainly contain fibrin and this was confirmed by western blotting with a 
polyclonal antibody against fibrinogen (Figure 34C). 
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Figure 34 Film contains fibrin. 
 A, The film was peeled from clots using a needle. B, Films removed from clots 
produced ± T101 were run alongside FXIII, BSA, purified fibrin and purified 
fibrinogen (Fgn), on reducing SDS-PAGE. MW – molecular weight marker. C, films 
removed from clots formed with or without T101, and run alongside FXIII, BSA, a 
reduced purified fibrin clot and purified fibrinogen on reducing SDS-PAGE and 
analysed by western blotting with a polyclonal antibody against fibrinogen. Fgn – 
purified fibrinogen, BSA – bovine serum albumin, MW –molecular weight marker. 
Representative gel and blot of n = 3 experiments. Data from Macrae et al. (2018). 
 
To ascertain whether the film could be formed from fibrin alone, clots were 
produced using purified fibrinogen (1 mg.ml-1) and thrombin (0.5 U.ml-1) and 
were examined using SEM and LSCM. Films that mimicked those formed on 
whole blood and plasma clots were observed (Figure 35A-B). Films were 
also found to transition from film to fibres in places (Figure 35C), and 
connected to the fibrin network through tethering fibres (Figure 35D). These 
observations show that fibrin(ogen) alone is capable of producing a film at 
the clot surface.  
Plasma film
F
X
III
B
S
A
MW, 
kDa
F
g
n
F
ib
rin-T101     +T101
250
150
100
75
50
37
25
20
Fgn α-chain
Fgn β-chain
Fgn γ-chain
FXIII
D-dimer
A
B C
- 126 - 
 
Figure 35 Only fibrin is required for film formation. A, SEM of the film in a clot 
produced from purified fibrinogen. A tear in the film exposes the underlying clot as 
often observed in SEM. Scale bar – 10 μm. B, LSCM of the film at the air-liquid 
interface of a clot produced from purified fibrinogen, without breaks in fully hydrated 
conditions. Fibrinogen fluorescently labelled with Alexa Fluor-488. Scale bar – 50 
μm. C, SEM image of areas of film transitioning into fibres. Scale bar – 1 μm. D, 
LSCM of tethering fibres connected to the film. Scale bar – 50 μm. Images A-D 
representative of n = 3 experiments. Data from Macrae et al. (2018). 
 
To investigate if plasma components influenced film formation different 
clotting conditions were used and their influence on film density and 
thickness was assessed. Purified fibrinogen was spiked with Alexa Fluor-488 
fibrinogen (25 μg.ml-1) and different clotting conditions were tested. Film 
MSF, as a measure of fibrinogen density, and film thickness were measured 
to quantify changes (Table 10).  
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Table 10 Mean sheet fluorescence and film thickness of fibrin films in 
different conditions. Table from Macrae et al. (2018). 
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Figure 36 Thrombin and calcium effect on film formation. A, Mean sheet 
fluorescence (MSF) measurements of the film at different thrombin concentrations, 
n = 4, B, Film thickness at different thrombin concentrations, n = 4. C, 
Representative images (n = 4) of 3D Z-stack images obtained with LSCM of clots 
produced with purified fibrinogen initiated with different thrombin concentrations, D, 
MSF of the film at different CaCl2 concentrations, n = 4, E, Film thickness at 
different CaCl2 concentrations, n = 4, F, Representative images (n = 4) of 3D Z-
stack images obtained with LSCM of clots produced with different CaCl2 
concentrations. * represents difference from 1st column, ▪ represents difference 
between other columns. * p < 0.05, ** or ▪▪ p < 0.01, *** or ▪▪▪ p < 0.001, **** or ▪▪▪▪ 
p < 0.0001. Mean ± SD. One-way ANOVA (multiple groups). Scale bars -50 μm. 
Data from Macrae et al. (2018).  
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The role of thrombin concentration on film formation was studied first. The 
film was found to form at all thrombin concentrations tested (0.1, 0.5, 1, 10 
U.ml-1, Figure 36A-C). However, film thickness and density decreased in a 
stepwise matter as the thrombin concentration increased, indicating a 
reduction in the quantity of fibrin present in the film. Thrombin generation 
triggered by tissue factor in plasma starts slowly after a short lag-phase, and 
then its concentration rapidly increases to a maximum of several hundred 
nM (tens of U.ml-1) (Hemker and Beguin, 1995, Hemker et al., 2003). 
However, fibrin formation occurs at just 2-3 nM thrombin (0.2-0.3 U.ml-1), 
before the vast majority of thrombin has been generated (Brummel et al., 
2002). Film formation appeared to be optimal at lower thrombin 
concentrations, when clotting times are longer, allowing more fibrin to 
accumulate at the surface before the underlying network has formed. 
Previous data from our lab has shown that lower thrombin concentrations 
are optimal for maximum protofibril packing in fibrin fibres (Domingues et al., 
2016). 
Changes in CaCl2 concentration (5, 10, 20 mM) had no effect on film density 
or thickness (Figure 36D-F), but the absence of CaCl2 resulted in at least a 
1.9x decrease in MSF and 1.5x decrease in film thickness. This indicates 
that film formation is not influenced by fluctuations in CaCl2 concentration, 
but the absence of CaCl2 dramatically reduces its formation. 
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Figure 37 Influence of fibrinogen concentration on film formation. A, Mean 
sheet fluorescence (MSF) measurements of the film at different fibrinogen 
concentrations, n = 6, B, Film thickness at different fibrinogen concentrations, n=6. 
C, Representative images (n = 6) of 3D Z-stack images obtained with LSCM of clots 
produced with purified fibrinogen initiated with different thrombin concentrations, D, 
single Z-plane slices of plasma clots with different fibrinogen concentrations 
showing a continuous film around the whole clot even when there is insufficient 
fibrinogen to fill the whole droplet. * represents difference from 1st column, ▪ 
represents difference between other columns. * p < 0.05, ** or ▪▪ p < 0.01, *** or ▪▪▪ 
p < 0.001, **** or ▪▪▪▪ p < 0.0001. Mean ± SD, One-way ANOVA (multiple groups). 
Scale bars -50 μm. Data from Macrae et al. (2018). 
 
Film formation occurred at all fibrinogen concentrations tested (0.05, 0.5, 1, 
2.5 mg.ml-1, Figure 37A-D), even when the fibrinogen levels were not 
sufficient to form a clot that filled the whole volume of the liquid (Figure 37D). 
Surprisingly, as fibrinogen levels increased up to 1 mg.ml-1 the MSF and film 
thickness decreased in a stepwise manner signifying a reduction in film 
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formation. Increases in fibrinogen concentration have been shown to lead to 
shorter lag times and faster clotting rates (Weisel and Nagaswami, 1992). 
So in a similar fashion to thrombin concentrations, shorter lag times led to 
less fibrin accumulating at the air-liquid interface leading to thinner films. 
Film formation was assessed in patients with dysfibrinogenemia and 
afibrinogenemia (patient plasma provided by Dr Alessandro Casini). To 
prevent changes in the clot or film structure with the addition of normal 
fluorescently labelled fibrinogen, a non-antibody binding protein (Affimer) 
(Tiede et al., 2017) specific to fibrinogen was fluorescently labelled with 
Alexa fluor 488. This was added to the patient plasma before a clot was 
formed, where it bound to any fibrinogen within the plasma. Clotting was 
then initiated, and once a clot had formed it was imaged using LSCM. 
Patients with dysfibrinogenemia formed a film that had a slightly higher MSF 
and thickness than clots formed from normal pool plasma. As expected 
patients with afibrinogenemia did not form a fibrin clot or film (Figure 38A-C). 
No difference in MSF of film thickness was found in clots produced with 
reptilase (2.4 U.ml-1), which only cleaves FpA (and not FpB) from fibrinogen, 
and thrombin (0.5 U.ml-1, Figure 38D-F). This demonstrates that film 
formation only requires fibrinogen to fibrin conversion, regardless of the 
activating protease and independent of FpB release. 
The effects of temperature on film formation was investigated (21°C – room 
temperature, 31.5°C – skin temperature, 37°C – core body temperature). 
Films were found to form at all three temperatures, but film formation 
increased at least 20-30 % at 31.5°C compared to room temperature or core 
body temperature (Figure 38G-I). Enhanced film formation at skin 
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temperature supports a physiological role for fibrin films in cutaneous 
wounds and dermal injuries. 
 
Figure 38 The role of other factors in film formation. A, MSF in normal pool 
plasma (NP) v Dysfibrinogenemia (Dysfib)/Afibrinogenemia (Afib) plasma, B, Film 
thickness in NP v Dysfib/Afib plasma, C, Representative LSCM images of 3D Z-
stack images of clots produced from NP v Dysfib/Afib plasma. D, MSF with 
thrombin v reptilase, n = 4, E, Film thickness with thrombin v reptilase, n = 4, F, 
Representative LSCM images (n = 4) of 3D Z-stack images of clots produced with 
thrombin v reptilase, n = 4, G, MSF with different temperatures, n=4, H, Film 
thickness with different temperatures, n = 4, I, Representative LSCM images (n = 4) 
of 3D Z-stack images of clots produced at different temperatures, n = 4. * 
represents difference from 1st column, ▪ represents difference between other 
columns. * p < 0.05, ** or ▪▪ p < 0.01, *** or ▪▪▪ p < 0.001, **** or ▪▪▪▪ p < 0.0001. 
Mean ± SD, Unpaired student’s t-test for pairwise comparisons (two groups); One-
way ANOVA (multiple groups). Scale bars - 50 μm. Data from Macrae et al. (2018). 
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There were no differences in film MSF or thickness with or without FXIII (3.7 
g.ml-1; Figure 39A-C), showing that the presence of FXIII is not a necessity 
for film formation. 
The role of platelets in film formation was investigated by comparing film 
formation in PPP and PRP. No difference in MSF and film thickness 
between PPP and PRP indicated that platelets did not influence film 
formation (Figure 39D-F).  
 
 
Figure 39 Role of FXIII and platelets in film formation. A, MSF with and without 
Factor XIII (FXIII), n = 4, B, Film thickness with and without FXIII, n = 4, C, 
Representative LSCM images of 3D Z-stack images of clots produced with and 
without FXIII, n = 4, D, MSF in platelet poor plasma (PPP) v platelet rich plasma 
(PRP), n = 6, E, Film thickness in PPP v PRP, n = 6, F, Representative LSCM 
images (n = 6) of 3D Z-stack images of clots produced with in PPP v PRP, n = 6. 
Mean ± SD, Unpaired student’s t-test for pairwise comparisons (two groups), Scale 
bars -50 μm. Data from Macrae et al. (2018). 
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The impact of fibrinogen structural elements on film formation was explored, 
by assessing natural and recombinant fibrinogen variants: γA/γA, the 
common fibrinogen isoform; γA/γ’, a heterodimeric splice variant which adds 
negative charge to the C-terminus of the γ-chain (Macrae et al., 2016); γ3x, 
a triple γ-chain mutant that eliminates all γ-chain crosslinking (Standeven et 
al., 2007), which was produced by Dr Cedric Duval; α220, in which the α-
chain is truncated after residue Ser220 removing the connector and C-
terminal globular domain of the αC-region; and α390, in which the α-chain is 
truncated after residue Asp 390 removing the C-terminal globular domain, 
which were both produced by Helen McPherson. Clots formed with γA/γA or 
γ A/γ’ both formed films with no differences in MSF or sheet thickness 
(Figure 40A-C). Clots formed with 3xγ, α390 or α220 were all found to form 
films with an increased MSF, with 3xγ and α220 also forming thicker film 
(Figure 40D-I). These differences in MSF are likely attributable to differences 
in polymerization rates of the mutants, which lead to longer lag 
times.(McPherson et al., 2017) These data indicate that neither the C-
terminal domain of the γ-chain, the α-chain C-terminal connector region, nor 
the α-chain C-terminal globular domain are required for film formation, but 
they do play a role in its rate of formation and final thickness. 
Collectively, these findings show that fibrin produces a film that covers the 
blood clot at the air-liquid interface, and although other factors modulate film 
thickness or the amount of fibrin in the film, only fibrin is required. 
  
- 135 - 
 
Figure 40 Effect of fibrinogen structural elements on film formation. A, MSF of 
γA/γA fibrinogen v γA/γ’ fibrinogen, n = 6, B, Film thickness of γA/γA fibrinogen v 
γA/γ’ fibrinogen, n = 6, C, Representative LSCM images of 3D Z-stack images of 
clots produced with γA/γA fibrinogen v γA/γ’ fibrinogen, n = 6, D, MSF of fibrinogen 
triple γ-chain crosslinking mutant v wildtype fibrinogen, n = 6, E, Film thickness of 
fibrinogen triple γ-chain crosslinking mutant v wildtype fibrinogen, n = 6,F, 
Representative LSCM images of 3D Z-stack images of clots produced with 
fibrinogen triple γ-chain crosslinking mutant v wildtype fibrinogen, n = 6, G, MSF of 
fibrinogen α-chain deletion mutants v wildtype fibrinogen, n = 6, H, Film thickness of 
fibrinogen α-chain deletion mutants v wildtype fibrinogen, n = 6, I, Representative 
LSCM images of 3D Z-stack images of clots produced with fibrinogen α-chain 
deletion mutants v wildtype fibrinogen, n = 6, * represents difference from 1st 
column, ▪ represents difference between other columns. * p < 0.05, ** or ▪▪ p < 0.01, 
*** or ▪▪▪ p < 0.001, **** or ▪▪▪▪ p < 0.0001. Mean ± SD. Unpaired student’s t-test for 
pairwise comparisons (two groups); One-way ANOVA (multiple groups). FXIII – 
factor XIII, WT – Wildtype. Scale bars - 50 μm. Data from Macrae et al. (2018). 
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4.3 Mechanism of formation 
The transitioning of film to fibres (Figure 35C) and connections of the film to 
the clot network via tethering fibres (Figure 35D) indicated that a specific 
biophysical mechanism governs fibrin film formation. To identify this 
mechanism, LSCM was used to visualise film formation and breakdown in 
plasma and purified fibrinogen solutions over time. Clot formation was 
initiated with thrombin (0.5 U.ml-1) in plasma (Figure 41A) or purified 
fibrinogen (Figure 41B), and with TF (5 pM) in plasma (Figure 41C). Fibrin 
accumulated at the surface forming a film before, or at a similar rate as the 
earliest fibrin fibres that constitute the clot network underneath. 
Once the clot was fully formed, clot breakdown was initiated with tPA (85 
ng.ml-1) in plasma clots (Figure 42A), or tPA and plasminogen (25 g.ml-1) in 
purified systems (Figure 42B), and observed over time. In both cases, the 
films lysed at the same rate as the underlying network of fibrin fibres. 
  
- 137 - 
 
Figure 41 Film formation over time. A-C, Stills from movies of fibrin film formation 
over time. A, In plasma when clotting was initiated with thrombin. B, with purified 
fibrinogen when clotting was initiated with thrombin C, in plasma when clotting was 
initiated with tissue factor. n = 3 experiments, Scale bars – 50 μm. Data from 
Macrae et al. (2018). 
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Figure 42 Film lysis over time. A-B, Stills from movies of fibrin film lysis over time. 
A, Film lysis by tPA in plasma clots. B, Film lysis by tPA and plasminogen in 
purified fibrinogen clots. n = 3 experiments, Scale bar – 50 μm. plg – plasminogen. 
Data from Macrae et al. (2018). 
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The behaviour of fibrinogen and fibrin at the air-liquid interface was 
subsequently investigated by following their accumulation at the air-liquid 
interface using a Langmuir-Blodgett trough, which analyses monolayer film 
formation of amphiphilic molecules at the air-liquid interface (Hann, 1990, 
Langmuir, 1917). A small number of previous studies have investigated the 
behaviour of fibrinogen at the air-liquid interface (Hernandez and Franses, 
2003, Razumovsky and Damodaran, 1999, Werb et al., 1992, 
Sankaranarayanan et al., 2010), but none thus far had examined fibrin. 
Purified fibrinogen or fibrin monomers (fibrinogen ± 1 U.ml-1 thrombin and 5 
mM GPRP) were injected into the sub-phase of the trough at increasing 
quantities (1 x1013 – 100 x1013 molecules of fibrinogen/fibrin) and surface 
pressure measurements were recorded over time. As protein accumulated at 
the surface over time, surface pressure increased and then plateaued, 
resulting in a maximum pressure (Figure 43A). At 1 x1013 molecules, neither 
fibrin nor fibrinogen covered the surface so there was no increase in surface 
pressure. At 5 and 20 x1013 molecules of fibrinogen/fibrin there was a delay 
before fibrinogen or fibrin resulted in an increase in surface pressure. 
However, higher quantities (30 and 100 x1013 molecules) of fibrinogen and 
fibrin caused an increase in surface pressure almost instantaneously (Figure 
43B, Table 11). 
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Figure 43 Fibrin(ogen) behaviour at the air-liquid interface. A, Changes in 
surface pressure in the Langmuir-Blodgett trough with different fibrinogen or fibrin 
concentrations over time. Data shown as mean ± SD, n = 3 experiments. B, Early 
time points of surface pressure in the Langmuir-Blodgett trough (0-15 min), n = 3 
experiments, SP – Surface pressure. C, Maximum Langmuir-Blodgett trough 
surface pressure of fibrinogen and fibrin with increasing concentrations, data shown 
as mean ± SD, ** p < 0.01, **** p < 0.0001, n = 3 experiments. Two-way ANOVA, F 
= 293.5, df = 1, p = < 0.0001. Data from Macrae et al. (2018). 
 
Table 11 Effect of fibrinogen or fibrin quantity on time to first increase in 
surface pressure. Table from Macrae et al. (2018). 
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Maximum surface pressure was found to escalate with increasing amounts 
of fibrinogen and fibrin (Figure 43C, Table 12). Fibrin presented with 
significantly lower surface pressures than fibrinogen at 5 and 20 x1013 
molecules, but as the quantity of fibrinogen/fibrin increased, these 
differences were no longer seen. The addition of more than 30 x1013 
molecules of fibrinogen did not lead to a further increase maximum pressure 
(100 x1013 and 5312 x1013 molecules (1 mg.ml-1)), signifying that 30 x1013 
(0.006 mg.ml-1) is the maximum amount of fibrin/fibrinogen that can be 
accommodated at the surface. The concentration of fibrinogen or fibrin in the 
subphase (0,006 mg.ml-1) required for this was much lower than 
physiological circulating fibrinogen levels (2-4 mg.ml-1). 
Table 12 Maximum surface pressure. Table from Macrae et al. (2018). 
 
From this it was possible to calculate that at 30 x 1013 molecules there would 
be ~30-34 nm2 per fibrin/fibrinogen molecule at the air liquid interface. 
Assuming previously described fibrin(ogen) D-region (~6.5-6.7 nm) and E-
region (~5-5.3 nm) diameters, (Wilgus et al., 2013, Hall and Slayter, 1959) 
and implementing the half-staggered fibrin model,(Fowler et al., 1981) it was 
possible to create a model that would allow for ~28-31 nm2 per 
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fibrin/fibrinogen molecule (Figure 44). This was in close agreement with our 
experimental data. These data indicates that fibrin/fibrinogen molecules are 
tightly packed and are positioned perpendicularly to the air-liquid interface. 
 
Figure 44 Fibrin(ogen) molecule packing at the air-liquid interface. 
Calculations carried out to estimate the area/molecule of fibrin(ogen) in the film at 
the smallest and largest described domain sizes. D domains are represented by 
blue circles and E domains by red circles. 
 
In order to investigate the morphology of the film below the surface, the 
interior and the exterior surfaces were compared using SEM. The film was 
peeled away from the exterior of the clot and stretched over a coverslip with 
either the interior or exterior surface exposed (Figure 45). The exterior 
surface was smooth, sometimes with very small pores (~24.8 ± 8.8 nm 
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pores, yellow arrows) or with small nodes (~6.4 ± 0.9 nm domains, yellow 
circles). In contrast, the interior surface was rough with holes, pores and a 
fibrous structure, more closely resembling the clot network. In agreement 
with the Langmuir-Blodgett trough data, these data imply that fibrin films 
have an ordered, dense structure at the surface, but deeper into the film it 
becomes less ordered, where the film transitions into more fibrous 
structures. 
 
Figure 45 Comparing the interior and exterior of the film. SEM images of the 
interior and exterior surfaces of films peeled away from plasma clots. Note 
differences in scale bars – Interior 3 μm, Exterior left 500 nm, right 50 nm. Data 
from Macrae et al. (2018).  
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Figure 46 The effect of fibrin(ogen) polymerization of film formation in a 
purified system. A, Accumulation of fibrinogen, fibrin monomers (fibrinogen + IIa + 
GPRP) or polymerizing fibrinogen at the air-liquid interface in a purified system over 
time, imaged by LSCM. Images representative of n = 3 experiments. B, 
Accumulation of MSF of clots from purified fibrinogen over time, data shown as 
mean ± SD. C, Maximum MSF, n = 3 experiments, F = 330.7, df = 2, p < 0.0001, 
time to maximum MSF, n = 3 experiments, F=0.1875, df = 2, p = 0.8337, maximum 
rate of MSF increase, n = 3 experiments, F = 20.55, df = 2, p = 0.0021 as analysed 
by LSCM, data shown as mean ± SD. * represents difference from fibrinogen (black 
dots), * p < 0.05, ** p < 0.01, **** p < 0.0001. MSF –mean sheet fluorescence, IIa –
thrombin, GPRP -Gly-Pro-Arg-Pro peptide, Fgn –fibrinogen. Scale bars - 50 μm. 
Data from Macrae et al. (2018). 
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With the interior surface looking so similar to a fibrous clot network, it was 
hypothesised that fibrin polymerisation may play a role in film formation. To 
assess this, accumulation of fibrin/fibrinogen below the surface of the air-
liquid interface was followed over time by LSCM and the impact of 
polymerization on film formation was analysed. Time courses of 
polymerizing fibrin, fibrin monomers or fibrinogen alone spiked with Alexa 
Fluor-488 fibrinogen were followed in a purified system (1 mg.ml-1 
fibrinogen/fibrin) (Figure 46A). 
Accumulation was quantified by MSF (Figure 46B). Purified fibrinogen 
accumulated at the air-liquid interface with a maximum rate of 0.26 ± 0.03 
MSF.min-1, reaching maximum fluorescence (5.5 ± 1.3 MSF) after 57.3 ± 2.1 
min. Fibrin monomers had a maximum rate ~3-fold faster than that of 
fibrinogen (0.8 ± 0.8 MSF.min-1), with twice as much protein accumulating at 
the surface (Max MSF – 10.4 ± 0.8) after 58 ± 1.5 min. Polymerizing fibrin 
accumulated at the surface at the greatest rate, with a maximum increase in 
fluorescence of 1.46 ± 0.39 min-1, over 5-fold the rate of fibrinogen. It 
reached a maximum fluorescence (27.1 ± 1.1 MSF) after 59 ± 0.7 min 
(Figure 46C, Table 13). 
Table 13 Mean sheet fluorescence of fibrin(ogen) accumulation at air-liquid 
interface. Table from Macrae et al., 2018. 
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Figure 47 The effect of fibrin(ogen) polymerization of film formation in 
plasma. A, Accumulation of fibrinogen, fibrin monomers (plasma + IIa + GPRP) or 
polymerizing fibrinogen at the air-liquid interface in a plasma system over time, 
imaged by LSCM. Images representative of n = 3 experiments. B, Accumulation of 
MSF of plasma clots over time, data shown as mean ± SD. (n = 3 experiments) C, 
Max MSF, F = 370.2, df = 2, p < 0.0001, time to max MSF, F = 0.6036, df = 2, p = 
0.5770 and maximum rate of MSF increase, F = 38.51, df = 2, p = 0.0004, data 
shown as mean ± SD, n = 3 experiments. * represents difference from fibrinogen 
(black spots), ** p < 0.01, *** p < 0.001. MSF – mean sheet fluorescence, IIa –
thrombin, GPRP - Gly-Pro-Arg-Pro peptide, Plas – Plasma. Scale bars - 50 μm. 
Data from Macrae et al. (2018). 
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A similar pattern was seen in plasma with polymerizing fibrin accumulating at 
the surface quicker than fibrin monomers and fibrinogen (Figure 47A-C, 
Table 13). This indicates that fibrin polymerization contributes to film 
formation by enhancing the accumulation of fibrin at the air-liquid interface. 
This effect is likely due to a combination of stronger interactions between the 
molecules of fibrin versus fibrinogen, and an increase in hydrophobicity of 
fibrin (van Oss, 1990, Weisel, 2005), both of which retain it at the surface. 
The strength of the film was quantified using AFM, carried out by Dr Stephen 
Baker. Young’s Modulus was calculated for plasma samples with and 
without transglutaminase inhibitor T101 by fitting a Sneddon model for 
conical tips to all force curves found over the entire area that was imaged 
(Figure 48A-B). Fibrin fibres were visible under the film surface and these 
areas presented with much stiffer Young’s modulus than places suspended 
between fibres. To find the stiffness of the film alone, Young’s Modulus was 
determined by measuring areas between the underlying fibres of clots 
formed from plasma. The average Young’s Modulus of the film was ~3-fold 
lower than regions supported by fibres (suspended- 7.65 ± 0.24 kPa vs fibre 
- 21.79 ± 2.79 kPa, p = 0.0001). Inhibition of cross-linking with T101 
decreased the modulus of the suspended film further by just over 10-fold to 
0.72 ± 0.14 kPa, which is slightly more than the decrease in fibrin stiffness 
previously reported in whole clots and single fibres (2-8.5x) (Collet et al., 
2005, Koh and DiPietro, 2011, Liu et al., 2010, Shen and Lorand, 1983). 
Areas supported by fibrin fibres decreased just over 4-fold to 5.1 ± 0.75 kPa 
in the absence of cross-linking (Figure 48C). As a consequence, although 
fibrin crosslinking is not required for film formation (Figure 39B), it increases 
film elastic modulus. 
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Figure 48 Investigating the strength of the film. A, Sneddon model used to 
calculate Young’s Modulus, where F is the force from the force curve, E is Young’s 
modulus, ν is Poisson’s ratio (0.5), α is the half angle for the indenter (15 degrees 
for our tips), and δ is the indentation. Note that this equation is only accurate with a 
half angle of 15 degrees for the first 200 nm of indentation. B, Strength of the fibrin 
film in clots produced with plasma and thrombin with or without T101 (FXIII 
inhibitor) investigated using atomic force microscopy (AFM). Fibrin fibres were 
visible under the film surface and these areas presented with stiffer Young’s 
modulus than fibrin film suspended between fibres. Grey lines in the zoomed-in 
images represent Young’s modulus scan area represented in the line force graphs. 
Scale bar -2 μm. C, Young’s Modulus was calculated for the suspended film and 
the film supported by fibres with and without T101 by fitting a Sneddon model to all 
AFM force curves found over the entire area that was imaged. 20 measurements 
were taken for each condition. **** p < 0.0001. Data from Macrae et al. (2018). 
 
Given that fibrin accumulates at the air-liquid interface, it was hypothesised 
that film formation should be preventable by blocking the air interface with 
surfactant molecules. In agreement with this, the addition of tween-20 (0.1 
%) prevented film formation and resulted in a dense, partly collapsed clot, 
probably due to the loss of surface tension (Figure 49A). Furthermore, 
blocking the air-liquid interface using mineral oil or petroleum jelly also 
prevented film formation (Figure 49B-C).  
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Figure 49 Blocking the air-liquid interface prevents film formation. Clots 
produced from plasma with thrombin in the presence of different surfactants and 
imaged by LSCM. A, tween-20 (0.1 %). B, Oil. C, Petroleum jelly. Yellow line 
represents the location of the air-liquid interface. Images representative of n = 3 
experiments. Scale bars – 50 μm. Data from Macrae et al. (2018). 
 
Based on the Langmuir-Blodgett data (Figure 43) and accumulation data 
(Figure 46 and Figure 47) a model of film formation is proposed (Figure 50A) 
where, upon injury and exposure to air, fibrinogen molecules in the blood are 
rapidly adsorbed to the air exposed surface, forming an organized 
monolayer at the air-liquid interface. Simultaneously, tissue factor stimulates 
fibrinogen cleavage via thrombin, leading to fibrin formation. Fibrin(ogen) 
continues to rise and accumulate at the air-liquid interface, packing in more 
molecules. At the same time fibrin begins to fit together in a half-staggered 
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formation, allowing for the build-up of multiple layers of fibrin through A:a 
and B:b knob-hole interactions, and the formation of tethering fibres (Figure 
50A-C). This leads to a dense layer of fibrin across the surface of the clot. 
 
 
Figure 50 A model of fibrin film forming at the clot surface. A, Proposed 2D 
model of fibrin(ogen) rising to the air-liquid interface and accumulating into a multi-
layer film with half-staggered fibrin molecules and tethering protofibrils (beginning of 
fibrin fibres). B, A side-on view of a 3D model of the fibrin film with half-staggered 
fibrin molecules. D-regions are represented by 6.7 nm diameter blue spheres, E-
regions are represented by 5.3 nm diameter red spheres and the connecting α-, β- 
and 𝛾-chains are represented by an orange cylinder. The translucent box 
represents the liquid at the air-liquid interface C, Top view of the 3D fibrin film 
model. Data from Macrae et al. (2018). 
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4.3 Discussion 
This chapter demonstrates that fibrin produces a continuous film at the 
interface between the clotting blood and the air that encapsulates the clot. 
The structural characteristics of this fibrin film are completely different from 
those of the fibrin fibre network. Rather than forming a porous network of 
fibres, these films are made up of tightly packed molecules arranged 
perpendicular to the liquid-air interface. The film only requires fibrin to form, 
producing a continuous layer of fibrin that is connected to the fibrous fibrin 
network through tethering fibres. Film formation is initiated by the exposure 
of blood to the air interface and accumulates due to the conversion of 
fibrinogen to fibrin, and the resultant increase in hydrophobicity of the fibrin 
molecule (Weisel, 2005, van Oss, 1990). The unique fibrin polymerization 
mechanisms, which involve knob-hole interactions, lead to fibrin being able 
to produce both films and fibres (O'Brien et al., 2008), and this culminates in 
a remarkable integrated clot structure that includes a fibrin film covering a 
network of fibres. The thickness of the film was modulated by multiple 
conditions, such as thrombin concentration, [Ca2+], fibrinogen concentration, 
fibrinogen variants and temperature, and it was shown to be digested by 
plasmin, which typically is responsible for fibrinolysis of fibrin clots. The 
internal and external surfaces of the film have been characterized using 
SEM, showing a very smooth external face and a more porous and fibrous 
internal face. Mechanisms of film formation were elucidated with the use of a 
Langmuir-Blodgett trough, using changes in surface pressure to quantify the 
maximum amount of protein that could fit at the air-liquid interface. This was 
followed by calculations of molecular dimensions of the film and the 
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orientation of molecules. Formation of the film was followed as a function of 
time using confocal microscopy, showing that fibrin accumulates at a much 
faster rate than fibrinogen. Strength of the film was tested using atomic force 
microscopy in the presence and absence of FXIIIa activity. FXIII was found 
to stabilize the film highlighting the contribution of crosslinked fibrin in the 
structural integrity of films. The formation of the film was shown to be 
prevented by blocking or disrupting the blood-air interface with surfactants or 
oils, indicating the importance of the alignment of fibrin at the air-liquid 
interface in film formation. This finding transforms our understanding of 
blood clots at injury sites and sheds new light on a major enigma — how the 
clot ends at the air-blood interface — that has troubled the field for a long 
time. 
This study was originally motivated by observations from SEM revealing thin 
film-like structures on the surface of blood clots. This film has previously 
been observed in our laboratory and those of others in SEM images of 
blood, plasma, or fibrin clots for more than two decades. However, until now, 
it has been overlooked, as it was alleged to be an artefact of sample 
preparation. The close association of fibrin clot structure with thrombosis risk 
(Undas and Ariens, 2011, Ariens, 2016, Bridge et al., 2014) has led 
researchers to focus on areas of the clot not covered by the fibrin film, i.e., 
away from the clot-air interface, or in areas where the film may have 
ruptured during sample processing. Previous studies have also shown that 
fibrin is able to produce sheet-like structures, across gaps in a striated 
substrate, for example (O'Brien et al., 2008), or in blood clots (Pretorius et 
al., 2012). However, researchers have failed to highlight the physiological 
relevance of these structures and the mechanism of formation were not 
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explored. In addition to the previous sightings of these film-like structures, 
Langmuir film formation has been recognized for over 100 years as a 
common phenomenon with most or all protein solutions forming monolayers 
at air-liquid interfaces (Langmuir, 1917). However, fibrin film formation 
appears to expand on this mechanism, resulting in the accumulation of 
multiple layers of protein at the surface, due to the conversion of fibrinogen 
to fibrin and its subsequent polymerisation. 
So far only a model of film formation can be proposed. The model puts 
forward the idea that upon cutaneous injury fibrinogen molecules in the 
blood are rapidly adsorped to the air liquid interface, forming an organized 
monolayer through a biophysical mechanism similar to Langmuir film 
formation (Zasadzinski et al., 1994). Simultaneously, haemostatic pathways 
are activated and thrombin cleaves fibrinogen to fibrin. More fibrin continues 
to move to and pack together at the surface, forcing the molecules 
perpendicular to the air-liquid interface, forming a dense and tightly packed 
sheet. At the same time fibrin molecules begin to fit together in a half-
staggered formation, allowing for the build-up of multiple layers through 
knob-hole interactions. These interactions also allow for the film to connect 
to the underlying network through tethering fibres. More information is 
required on the precise structure of these films. The orientation of the 
molecules at the air liquid interface was deduced from Langmuir-Blodgett 
trough data. Attempts to take high definition images of the surface of the film 
were attempted using AFM, hoping to demonstrate the presence of fibrin D 
domains which would fit with our model. Unfortunately problems were 
encountered due to the stickiness of the films, preventing high definition 
imaging with the AFM tip. Other structural data that should be obtained 
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would include more precise thicknesses of the films, possibly obtained using 
transmission electron microscopy, AFM imaging with functionalised (E- or D-
region, GPRP) tips, information on the contribution of other proteins to the 
films arrangement and finally the contribution of the film to clot contraction. 
Naming of these structures as fibrin biofilms may result in some potential 
confusion. The term “fibrin films” in the past has been used to describe fibrin 
clots that have been compressed and have been used as a sealant for 
wound healing and other surgical procedures (Matras, 1985). On top of this 
the term “biofilms” in the past has been used to refer to colonies of bacteria 
that form a thick layer on many surfaces and provide protection to the 
bacteria. Therefore the name fibrin biofilm is perhaps not ideal, but it was 
chosen to be used until a better proposal is made. 
The findings in this chapter raise many questions about what this film is for 
and if it plays a role in haemostasis, and this will be discussed in the next 
chapter. 
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Chapter 5 - The physiological roles of the fibrin film 
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The obvious questions that arose after finding the fibrin film (described in 
Chapter 4) that covers the external surfaces of haemostatic clots is, what is 
its physiological function? Many characteristics of the film described in the 
previous chapter lend themselves towards having some form of 
physiological role. Its rapid formation, before the underlying network, and 
changes in film thickness instigated by changes in clotting conditions all 
point to it playing a part in the early stages of clotting. Furthermore, the 
organised nature of the fibrin molecules, the density of protein at the surface, 
and the smoothness of the film with very small pores also suggest that the 
film may contribute to cell and fluid containment or as a protective covering. 
In this chapter the reasons for film formation are explored highlighting how it 
provides a natural limit to clot growth, prevents blood cell loss, and protects 
from bacterial infection. 
5.1 Film protects against microbes 
In view of the rapid formation of the fibrin film after exposure of blood to an 
air-liquid interface, it was theorised that the film may play an important 
physiological role, forming an immediate barrier across an injury to protect 
the vascular breach against microbial invasion, until white blood cells are 
recruited to the wound site (Velnar et al., 2009). To investigate this 
hypothesis, a bacterial migration assay in a Boyden chamber was used to 
study migration of three types of bacteria commonly found in the natural skin 
flora (Escherichia coli, Staphylococcus epidermidis and Staphylococcus 
aureus) through clots (chapter 2.4.1 and Figure 16). Bacteria were grown to 
3.6-8.5 x108 cells.ml-1, fluorescently-labelled with BacLight green, and 
applied to the external surface of three types of clots: 1) clots formed with 
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0.1 % tween-20 to prevent film formation, 2) clots where the surface was 
perforated with a needle to make holes in the film and 3) normal clots with 
intact film. 
Fluorescent bacteria that moved through the clots were quantified over 48 
hours (Figure 51A). The time taken for the first bacteria to break through the 
clots was defined as when fluorescence became greater than 2 % of the 
total added fluorescent bacteria. No fluorescent bacteria migrated through 
the clots within the first 8 hours. E.coli migrated through the perforated (11.3 
± 1.2 hours, p = 0.0005) and tween-20 treated clots (25.3 ± 1.2 hours, p = 
0.0193) significantly faster than the normal clots (38.0 ± 7.2 hours) (Figure 
51B). A similar trend was seen with S. epidermidis (perforated - p = 0.0022, 
tween-20 - p = 0.0075) and S. aureus (perforated - p = 0.0076, tween-20 - p 
= 0.0401, Figure 51B), with bacteria moving through perforated and tween-
20 treated clots much quicker than in clots with an intact film. After the initial 
breakthrough, the rate of bacteria migration was comparable between clot 
types. This suggests that the film plays a role in preventing bacterial 
infiltration into the site of injury for at least 12-27 hours, allowing time for 
white blood cell recruitment and the underlying clot to fully form. 
  
- 158 - 
 
Figure 51 Film slows bacterial migration. A, Movement of fluorescently labelled 
E. coli, S. epidermidis and S.aureus bacteria through three types of clot, (displayed 
as quantity of fluorescent bacteria breaking through the clot as a percentage of 
fluorescent bacteria added) with three different film conditions; normal, perforated 
or removal with tween-20. B, Time taken for the first fluorescently labelled E. coli, S. 
epidermidis or S. aureus bacteria to break through the clot. * represents difference 
from normal clot. * p < 0.05, *** p < 0.001, n = 3 experiments, one-way ANOVA. 
Bac – Bacteria. Data from Macrae et al. (2018). 
 
5.2 Fibrin film formation and its role in blood cell retention 
To investigate the function of the film in vivo, a novel murine dermal injury 
model was established. Initially, the formation of the fibrin film ex vivo in 
mouse blood was investigated. Clots were formed with whole blood from WT 
or fibrinogen-deficient mice and were prepared for SEM. Blood from WT 
mice formed a fibrin film at the air-liquid interface, whereas blood from 
fibrinogen-deficient mice did not (Figure 52).  
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Figure 52 Ex vivo film formation in wildtype and fibrinogen deficient mice. 
Clots formed using whole blood and murine thrombin from wildtype and fibrinogen-
deficient mice were imaged by SEM. Images representative of n = 4 mice. Scale 
bars – 20 μm. FD – fibrinogen deficient mice. Data from Macrae et al. (2018). 
 
A murine dermal injury model was established next, in which a 2 mm 
puncture was created in the skin on the back or abdomen of anaesthetised 
mice. The in vivo work was carried out by Dr Cedric Duval. The injury was 
either left clear to clot exposed to the air or immediately covered with a thin 
layer of oil to remove the air-liquid interface, which was washed off with 
saline once the clot had formed. After 60 minutes, clots and surrounding skin 
were surgically removed, processed, and imaged by SEM (Figure 53A). In 
the untreated control sections, clots possessed a film on the exterior surface. 
Consistent with the in vitro experiments, oil treatment prevented film 
formation, leaving the underlying fibrous fibrin network exposed and clearly 
visible. Some of these clots were embedded in paraffin, sectioned, and were 
either stained using MSB or probed with a fibrin specific antibody (59D8). In 
the untreated control sections stained with MSB the film can be seen along 
the surface of the clot, as a thin pink layer (Figure 53B), or as a thin brown 
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layer with 59D8 staining, confirming that fibrin makes up the film in vivo 
(Figure 53C). In clots treated with oil, the film is not present. This showed 
that the oil prevented film formation in vivo and could be used to assess 
bacterial migration and proliferation in clots without a film. 
During the establishment of the in vivo model, regions of loose cells that 
were not retained within the clot were found in histology sections of clots 
formed in the presence of oil, and therefore lacking the film (Figure 54A). In 
micrographs of the control clots we found erythrocytes pushed against the 
inside of the film (Figure 54B). These findings suggested the fibrin film helps 
to prevent leakage of blood cells from dermal lesions. To investigate this, 
clots from whole blood were formed either with no intervention, in the 
presence of tween-20 (0.1 %) or with the film being perforated after 1 hour. 
After two hours, the quantity of RBCs released from the clot was assessed 
by measuring haemoglobin levels. The quantity of haemoglobin released 
was more than 12-fold higher in the tween-20 (4.37 ± 0.38 g.L-1) and 
perforated clots (4.14 ± 0.85 g.L-1), with almost no haemoglobin being 
released from the normal clot (0.32 ± 0.18 g.L-1, p = 0.0002, Figure 35C). 
This data shows that the film plays a role in the retention of RBCs within the 
clot. 
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Figure 53 Fibrin film forms in vivo. A, Clots were formed in a ventral or dermal 
puncture injury model in mice and left clear or covered with a thin layer of mineral 
oil, fixed, dehydrated and imaged by SEM. The white box represents the area of 
magnification for the image to the right. Images are representative of n = 4 mice. 
Scale bars – left 1 mm, right 2 μm. B,C, Clots left clear or with a layer of oil covering 
the surface from the dermal puncture model were surgically removed, and cross-
sections were stained with: B, Martius, Scarlet and Blue (MSB; erythrocytes in 
yellow, and fibrin in pink). Fibrin film shows as continuous pink layer, clot appears 
yellow interspersed with pink. Or C, stained with mouse anti-fibrin antibody (59D8). 
In the absence of oil, a brown layer can be seen along the surface of the clot, 
showing fibrin is present in the film. This layer was absent in clots formed with oil. * 
highlights air liquid interface. Images representative of n = 4 mice. Data from 
Macrae et al. (2018).  
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Figure 54 Fibrin film helps retain blood cells within the clot. A, Clots from the 
murine dermal puncture model covered with oil showed extrusion of red blood cells 
from the clot in the absence of a fibrin film. * highlights extrusion of red blood cells 
from the clot. Images representative of n = 4 mice. B, Clots produced with human 
whole blood and thrombin, and imaged by SEM demonstrated containment red 
blood cells by the fibrin film. Images representative of n = 3 individuals. Scale bar – 
40 μm. C, Haemoglobin retention assay in normal, perforated and tween-20 treated 
clots. * represents difference from normal clot. *** p < 0.001, n = 3 individuals, one-
way ANOVA, F = 52.14, df = 2, p = 0.0002. Hb – haemoglobin. Data from Macrae 
et al. (2018). 
 
5.3 Protective role of fibrin film in a murine dermal injury 
model 
The role of the fibrin film in protection against bacterial proliferation and 
dissemination in vivo was investigated next. This work was carried out by Dr 
Cedric Duval and Dr Praveen Papareddy at the University of Lund. After the 
clots were formed as described above (with or without a layer of oil), 2 μl of 
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bioluminescent Pseudomonas aeruginosa (4 x105 CFU), a Gram-negative 
flagellated bacterium associated with severe hospital-acquired infections and 
significant resistance to antibiotics, were carefully deposited on the surface 
of the clots covering the dermal punctures. Mice were imaged every 4 hours 
using a three-dimensional IVIS spectrum in vivo imaging system to assess 
bacterial proliferation. Control experiments were run in parallel where 
wounds with no clots were subjected to a layer of oil or were left clear to 
demonstrate oil had no effect on bacterial proliferation. In the absence of a 
clot, the oil had no effect on the levels of bacteria present in the wound over 
12 hours (Figure 55A-B).
 
Figure 55 In the absence of a blood clot oil has no effect on bacteria number. 
A, Measurement of bioluminescent bacteria proliferation with no clot present with or 
without oil in a murine dermal injury model over time. Images representative of n = 
4 mice. B, Quantification of bioluminescent bacteria in this model, n = 4 mice.  
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Once it was established that the oil had no effect on bacteria proliferation, 
experiments on mice with blood clots in their wounds were carried out. In the 
mice with an intact fibrin film, the bioluminescence did not increase over 12 
hours, showing that the bacteria did not proliferate over this period in these 
mice. This also suggests the bacteria did not disseminate into the clot 
because, in mice without a fibrin film the bioluminescence was significantly 
higher after 4 hours and increased over time up to 1.03 x105 p.sec-1.cm-2.sr-1 
(IQR – 0.470, 0.359), compared to 0.15 x105 p.sec-1.cm-2.sr-1 (IQR - 0.107, 
0.371, p = 0.0005) in the mice with films (Figure 56A-B, Table 14). These 
data show that the bacteria had moved into the clot and were proliferating 
within the wound in the absence of the film. To confirm the difference in 
bacteria numbers, the clots and surrounding skin were harvested from 
sacrificed animals after 12 hours and mechanically homogenised. Serial 
dilutions of the homogenates were plated on agar to analyse 
bioluminescence and bacterial CFUs (Figure 56C-D). In agreement with the 
bioluminescence data, the mice that had no film on their clot showed a much 
greater number of bacteria (2.53 ± 0.298 x106 CFU.ml-1) within the wound 
and skin than the mice that had an intact clot film (0.064 ± 0.014 x106 
CFU.ml-1). These data demonstrate that the film has a protective role, 
slowing or preventing the proliferation of bacteria and reducing the 
movement of bacteria into wounds and skin for at least 12 hours after injury. 
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Figure 56 Fibrin film slows bacteria proliferation and dissemination in vivo. A, 
Measurement of bioluminescent bacteria proliferation with or without film in a 
murine dermal injury model over time. Images representative of n = 8 mice B, 
Quantification of bioluminescent bacteria in this model. * p < 0.05, *** p < 0.001, n = 
8 mice, Kruskal-Wallis test, Kruskal-Wallis statistic = 36.55, 6 groups, p < 0.0001. 
C, Measurement of bioluminescent bacteria from wound and surrounding skin with 
and without film after 12h spread on agar plates. Images representative of n = 3 
mice D, CFU/ml of bacteria from wound and surrounding skin with or without film 
after 12h. ** p < 0.01, n = 3 mice, Unpaired student’s t-test for pairwise 
comparisons, t = 8.26, df = 4, p = 0.0012. CFU – colony forming unit. Data from 
Macrae et al. (2018). 
 
Table 14 Bacterial proliferation measured by bioluminescence. Table from 
Macrae et al. (2018). 
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5.4 Discussion 
This chapter shows that fibrin films form in vivo and play an unexpected role 
in haemostasis, producing a film that not only encapsulates the clot and 
thereby retains cells, but also functions as a protective layer at the interface 
between the clotting blood and the air, preventing microbial infection. 
There have been many previous links between haemostasis and innate 
immunity due to their common evolutionary ancestry as a rapid response 
system in the event of a physical injury (Krem and Di Cera, 2002). Extensive 
crosstalk between the coagulation cascade and the complement cascade 
allows for an arrangement where the host responses can be amplified or 
dampened in both systems, coordinating blood coagulation with infection 
control (Esmon, 2004, Foley and Conway, 2016). The outcome of this 
relationship between the two cascades has been termed 
“immunothrombosis”; and this involves the formation of the fibrin clot and 
activation of white blood cells and platelets, which all come together to 
recognize, compartmentalize and trap pathogens (Engelmann and 
Massberg, 2013). The importance of the fibrin clot in this process was 
highlighted in previous studies with mice lacking fibrinogen, and mice that 
possessed a mutant fibrinogen that could not polymerize to form fibrin clots. 
These mice had decreased survival due to impaired bacterial clearance 
(Prasad et al., 2015, Degen et al., 2007). The fibrin network appears to act 
through two mechanisms: 1) as a physical barrier to bacterial invasion; and 
2) fibrin(ogen) can activate a number of immune and inflammatory cells, 
such as neutrophils at a site of injury (Foley and Conway, 2016). In 
opposition to this, some bacteria have developed the ability to specifically 
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bind fibrin to evade innate immune surveillance and form resistant bacterial 
biofilms (Degen et al., 2007). 
The previously overlooked fibrin film structures in this thesis present another 
mechanism for antimicrobial protection and suggests a novel mechanism of 
collaboration between the haemostatic and immune systems. In response to 
external injury, the fibrin film forms an almost instant barrier that provides an 
initial line of defence against microbial invasion, allowing the formation of an 
underlying clot and activation of immune system. This is supported by the 
formation of thicker films at lower thrombin concentrations which are present 
in the early stages of haemostasis. To show these films function as 
bioprotective barriers, a bacterial migration assay was set up using Boyden 
chambers and different types of bacteria commonly found in skin flora 
(Escherichia coli, Staphylococcus epidermidis, and Staphylococcus aureus). 
Intact fibrin films prevented bacterial infiltration for the first 36 hours, but 
when film formation was disrupted with surfactants, or the film was 
damaged, bacterial invasion occurred much sooner (12-24 hours). 
Disruption of the fibrin film also resulted in the leakage of RBCs, highlighting 
the role of the film in cell retention. Cell retention could also play a role in 
infection control via two mechanisms: 1) retention of white cells within the 
clot would help fight infection, and 2) a clot with a higher RBC content would 
be less porous, slowing the movement of bacteria through the clot. 
Importantly this antimicrobial protection was also confirmed in a murine 
model of dermal infection with P. aeruginosa. This model indicated that the 
films not only prevented infiltration of bacteria, but that they may also play a 
role in preventing bacterial proliferation. Bacteria in mice that possessed an 
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intact film appeared not to proliferate over time suggesting that the film may 
play an active role in preventing bacterial growth. 
The finding of this film and its physiological roles in host defence begins to 
raise important questions about its potential clinical implications. The role of 
the films in controlling infections is supported by the prevalence of dermal 
infections in some afibrinogenemia patients (Figure 57). However, many 
immune mechanisms already exist that help limit microbial invasion, and the 
importance of the films in this are currently unknown. Does this structure 
play an important pathophysiological process? There is no current research 
into the effects of current wound treatments and their effects on the film, and 
if this would increase infection and related morbidity. One area of required 
research would be to address the question of whether the application of 
petroleum jelly to help stem bleeds from injuries in contact sports or to a 
wound after minor surgery wound actually increase the risk of infection. 
 
Figure 57 Dermal infection in a patient with afibrinogenemia.  
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Another research question to be addressed is the possibility of these films 
occurring in intravascular clots or thrombi, or on other surfaces such as 
stents or medical devices. There is some previous evidence that this may be 
the case, with film like structures found on the outer faces of thrombi (Autar 
et al., 2018, van Es et al., 2017). These films could play a role as a site for 
the initiation of intravascular fibrin fibre formation in thrombotic conditions. 
They could also play a part in the clot stability of old and new thrombi, and 
may influence perfusion through clots, which in turn may alter the rate of 
fibrinolysis or thrombolysis. 
The findings of the extraordinary formation of a protective fibrin film on the 
blood clot exterior reveal a mechanism in haemostasis that helps retain 
blood cells and control microbial infection. More research is required to 
reveal the structure of these biofilms and their pathophysiological roles. Clot 
film formation appears an important physiological process that should be 
exploited in the future to improve recovery and healing from minor and major 
injuries. 
5.5 Future work 
Chapter 4 and Chapter 5 have discussed the discovery of novel, previously 
unexplored fibrin biofilms and how they have physiological roles, retaining 
cells within the clot and preventing the proliferation and dissemination of 
bacteria into a site of injury. However, there are still many questions to be 
answered relating to the biofilm structure and its pathophysiological roles.  
We currently do not accurately know how the fibrin molecules interact within 
the biofilms. Langmuir trough data indicate that fibrin monomers aligned at 
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the air-liquid interface occupy roughly the same area as the diameter of a 
single fibrin monomer positioned perpendicularly to the air-liquid interface. 
Future atomic force microscopy experiments could be used to create more 
detailed images of the surface revealing nanometer definition, and also to 
probe the film surface with GPRP peptide and fibrin D-region to test for the 
presence of D- and E-region in the film. By embedding clots with films and 
taking cross-sections of the film, transmission electron microscopy could be 
used to help elucidate the molecular packing arrangement of the films and 
better characterise the transition from films to fibres. Together, these 
approaches should elucidate how the fibrin units are packed in the biofilm 
and a more detailed understanding of the molecular arrangements in the 
films could help to engineer ways to alter the film to improve its ability to 
resist bacterial invasion. 
Another direction for further research in this field is alternative locations of 
film formation. Previous studies have presented extracted thrombi from 
patients that possess similar structures to the fibrin biofilms and also the 
formation of films on other surfaces such as stents (Autar et al., 2018, van 
Es et al., 2017). We also already have persuasive pilot evidence for the 
formation of intravascular biofilm structures in thrombi. Biofilms are 
consistently observed in thrombi extracted from patients with abdominal 
aortic aneurysms. We also observe films in clots from mice after FeCl3 
induced thrombosis, also after in vivo fixation before retrieval of the thrombi. 
Formation of fibrinogen films on phosphatidylcholine coated surfaces further 
contributes to the possibility of intravascular films (Sankaranarayanan et al., 
2010). These films could play an important role in determining the physical 
limit of thrombi and their stability. Established models of murine femoral vein 
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thrombosis could be used to investigate the make-up of in vivo thrombi and 
assess intravascular fibrin biofilm formation. Further studies into film 
formation on different surfaces could also be carried out using the Langmuir-
Blodgett trough and flow chambers. 
The role of the films in infection control also needs to be investigated further. 
In this chapter, fibrin biofilms have been shown to protect against bacterial 
proliferation and dissemination for at least 12 hours, but for how long do 
these films provide protection? Bacterial proliferation on wounds in the 
presence and absence of films could be followed over longer periods of time 
(24-72 hours), and the dissemination of bacteria to organs (liver, spleen and 
kidneys) could be monitored to assess if these films can deter systemic 
infection and sepsis. On top of this, the effects of infection prevention by the 
film could be analysed by assessing the effects on complement activation, 
inflammation and neutrophil and macrophage recruitment. 
Infection at injury sites is known to impair the wound healing process, and is 
a major contributor in chronic wound formation. With this in mind, the 
protective role of the film against infection in the initial stages of tissue repair 
could benefit wound healing. To investigate this, tissue repair in the 
presence and absence of film formation and bacterial infection could be 
followed, with levels of growth factors being monitored in tissue samples 
over the healing period. The Infiltration of neutrophils, macrophages and 
contractile myofibroblasts into wounds could be monitored and the rates and 
quantity of angiogenesis within the wound could be quantified. The 
replacement of the film with extracellular matrix, epithelial cells or fibroblasts 
could be followed as the wound heals by IHC and SEM. Finally, the 
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proliferation and migration of primary dermal fibroblasts, epithelial and 
endothelial cells on the film could be explored in vitro using cell culture. 
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Chapter 6 - Common FXIII and Fibrinogen Polymorphisms in 
Abdominal Aortic Aneurysms 
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In this chapter the link between fibrinogen and FXIII with AAA is investigated 
by analysing associations between known sequence variants and disease. 
Also discussed in this chapter is the association of fibrinogen and fibrinogen 
γ’ levels with AAAs. About 75 % of all larger aneurysms are characterized by 
the presence of an ILT, which forms over many years, and persists even 
after endovascular repair when it remains present between the stent and the 
aneurysmal wall (Vorp et al., 2001, Harter et al., 1982). The ILT is composed 
of a three dimensional (3D), FXIII crosslinked, fibrin network structure that 
incorporates red and white blood cells, platelets, other blood proteins, and 
cellular debris. Many studies have shown that the ILT accelerates the 
dilatation of an AAA due to hypoxia and biochemical stress. In addition to the 
effects of the ILT, it has been found that patients with AAA demonstrate 
abnormal coagulation and clot structure profiles (Parry et al., 2009). The 
main proteins involved in thrombus formation are coagulation factors 
fibrinogen, thrombin and FXIII, and functional common genetic sequence 
variants have been identified in both FXIII and fibrinogen. Variants FXIII-A 
Val34Leu, Fib-α Thr312Ala, Fib-β Arg448Lys and Fib-γ 10034C>T have all 
previously been linked to alterations in clot structure. The sequence variant 
FXIII-A 34Leu occurs in the activation peptide of FXIII and has been shown 
to accelerate FXIII activation. Clotting in the presence of this variant occurs 
more quickly resulting in clots with thinner fibres and smaller pores (Ariens et 
al., 2000). This variant has also been suggested to have a protective effect 
against venous thromboembolism and MI (Wells et al., 2006, Franco et al., 
2000). The Fib-α 312Ala sequence variant occurs in close proximity to the 
FXIIIa crosslinking site at position Aα 328 (Muszbek et al., 1996)  It has been 
shown to form clots with thicker fibres and increased α-chain cross-
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linking,(Standeven et al., 2003) and has been suggested to result in 
increased embolization (Carter et al., 2000). Clots formed from fibrinogen-β 
448Lys have been shown to be stiffer with thinner fibres and smaller pores 
and have increased resistance to lysis (Ajjan et al., 2008). Fib-γ 10034T has 
indirectly been linked to changes in fibrin clot structure via the alteration of 
fibrinogen γ’ levels (Uitte de Willige et al., 2007) and has been linked to 
venous thrombosis (Grunbacher et al., 2007). In view of the central role of 
FXIII and fibrinogen in thrombus formation and the complications of ILT in 
AAA, the relationship between these genetic sequence variants and AAA 
was explored. 
Both sequence variants FXIII-B His95Arg and FXIII-B splice variant (Intron K 
nt29577C-G) show considerable geographic differentiation, with FXIII-B 
His95Arg being most common in populations of African descent, whereas 
the FXIII-B splice variant is most common in populations of Asian descent 
(Ryan et al., 2009). AAA incidence has been reported to be decreased in 
both these populations (Costa and Robbs, 1986, Li et al., 2013). Therefore, 
the association of these polymorphisms with AAA was explored.   
Finally, fibrinogen γ’ levels have previously been linked to a number of 
arterial and venous thrombotic disorders and may also play a role in the 
pathophysiology of AAAs. To explore this, the levels of fibrinogen and 
fibrinogen γ’ were investigated in AAA patients to determine if the splice 
variant influences AAA development. 
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6.1 Common factor XIII and fibrinogen sequence variants in 
abdominal aortic aneurysms 
In total 969 participants, comprising 520 AAA patients and 449 controls, 
recruited into LEADS provided samples of plasma and whole blood for the 
study. DNA was extracted from the whole blood, and TaqMan genotyping 
assays were used to analyse six sequence variants: FXIII-A Val34Leu, FXIII-
B His95Arg, FXIII-B splice variant (Intron K nt29577C-G), Fib-α Thr312Ala, 
Fib-β Arg448Lys and Fib-γ 10034C>T. Fibrinogen levels were measured in 
plasma using the Fibri-prest automate assay. These methods are described 
in full in chapter 2.5.1, 2.5.2 and 2.5.3. The demographic and clinical 
characteristics of the two groups are represented in Table 15. As expected, 
the AAA group had larger aortic diameters compared with controls. There 
were higher rates of CVD, including angina, CVA/TIA, hypertension and MI 
at recruitment, in agreement with previous studies (Alcorn et al., 1996). 
There was a greater prevalence of current and ever smokers in the AAA 
group, in agreement with previous studies showing that smokers have a 
higher risk of developing an AAA compared with non-smokers (Singh et al., 
2001). A higher proportion of AAA patients were taking statins and aspirin, 
likely a reflection of the increased number of subjects with CVD in this group, 
and there was no major difference in alcohol consumption between the two 
groups. However, fibrinogen levels were found to be higher in patients with 
AAA compared with control subjects (p = 0.0003), in agreement with 
previous findings (Al-Barjas et al., 2006). After binary logistic regression 
analysis, only aortic diameter remained significantly different between the 
two groups (p < 0.0001). 
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Table 15 Demographic and clinical characteristics of the AAA and Control 
groups from the LEADS study. Adapted from Macrae et al. (2014). 
 
 
All genotype distributions for each sequence variant were consistent with the 
Hardy-Weinberg equilibrium (Table 16), and overall allele frequencies for 
each sequence variant were consistent with those reported by SeattleSNPs 
and other previously published studies on these sequence variants in 
different cardiovascular diseases (Nickerson, 2003, Rasmussen-Torvik et 
al., 2007, Ryan et al., 2009, Ruigrok et al., 2010, Suntharalingam et al., 
2008). An example of the output generated using PCR and end-point 
genotyping is shown in Figure 58. 
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Table 16 Genotype distributions for each sequence variant were consistent 
with the Hardy-Weinberg. Adapted from Macrae et al. (2014).
 
 
 
Figure 58 Example output of end-point genotyping assay. Genotyping was 
carried out using TaqMan genotyping assays. The relative amount of the two 
reporter dyes can be used to determine the genotype. This can be plotted on a 
graph as shown above. The example shown is for FXIII His95Arg; blue triangles 
represent His/His homozygotes, red triangles represent His/Arg heterozygotes, and 
green triangles represent Arg/Arg homozygotes. Grey circles represent blanks.  
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6.1.1 Polymorphic allele distribution in AAA vs Controls 
The distribution of the FXIII-B 95Arg allele was significantly different 
between AAA patients and controls, with a significantly higher percentage of 
AAA patients presenting as heterozygous (1.45x higher) and homozygous 
(2.33x higher) for the Arg variant when compared with controls (p = 0.006; p 
= 0.03 after Bonferroni adjustment for multiple testing) (Table 17). When 
combining the heterozygote and homozygote carriers of the rare Arg allele, 
the relative risk of developing an AAA with the FXIII-B 95Arg allele was 
1.240 (CI 1.093–1.407) indicating a small increase in the risk of developing 
an AAA when in possession of an Arg allele. The distribution of the Fib-γ 
10034C>T sequence variant was also significantly different between AAA 
patients and controls, with a significantly higher percentage of AAA patients 
presenting as homozygous for the C allele (CC, 1.14x higher) than controls 
(p = 0.028, Table 17), although this was not significant after Bonferoni 
adjustment. When comparing the homozygote carriers of the C allele to the 
carriers of the sequence variant T allele, the relative risk of developing an 
AAA with at least one T allele was 0.830 (CI 0.725-0.950) suggesting that 
the possession of one T allele may have a small protective effect against 
developing an AAA. There were no associations between the rare alleles of 
FXIII-A Val34Leu, FXIII-B Splice variant, Fib-α Thr312Ala or Fib-β 
Arg448Lys sequence variants and AAA (Table 17). 
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Table 17 Sequence variant distribution in AAA vs Controls. Adapted from 
Macrae et al. (2014). 
 
 
6.1.2 Association of sequence variants with fibrinogen levels 
The effect of the possession of at least one rare allele, for each sequence 
variant, on fibrinogen levels was investigated in the total study population. 
Patients who possessed at least one Fib-β 448Lys allele (3.81 g.L-1) were 
found to have significantly higher fibrinogen levels than patients 
homozygous for the Arg allele (3.55 g.L-1) in the whole study population (p =  
0.001) (Table 18). Fibrinogen levels were found to increase step wise with 
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an increase in the number of Lys alleles, Arg/Arg 3.55 g.L-1 (3.08,4.13), 
Arg/Lys 3.74 g.L-1 (3.22, 4.44) and Lys/Lys 4.18 g.L-1 (3.41, 4.53) (p = 
0.0009). There was no association of fibrinogen levels with FXIII-A 
Val34Leu, FXIII-B His95Arg, FXIII-B Splice variant, Fib-a Thr312Ala and Fib-
γ 10034C>T sequence variants (Table 18, Figure 59A-F). 
 
Table 18 Association of sequence variants with fibrinogen levels in total 
study population. Adapted from Macrae et al. (2014). 
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Figure 59 Association of genotypes with fibrinogen levels. Comparison of 
fibrinogen levels across different genotypes for each sequence variant: A, FXIII-A 
Val34Leu, B, FXIII-B His95Arg, C, FXIII-B splice variant (Intron K nt29577C-G), D, 
Fib-α Thr312Ala, E, Fib-β Arg448Lys and F, Fib-γ 10034C>T. Data shown as 
median and IQR. * represents significant difference from first bar. * p < 0.05, ** p < 
0.01. Kruskal-Wallis test. 
 
6.1.3 Association of alleles 
The association of alleles was investigated to assess for relationships 
between sequence variants (Table 19). In the total study population there 
was evidence of negative linkage disequilibrium between the His95Arg and 
Splice Variant sequence variants (D’ = -0.609, p = 0.011) (Table 20). In the 
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control subjects the sequence variants were found to be close to complete 
negative disequilibrium (D’ = -1.0, p = 0.018). The association of His95Arg 
with AAA was still significant if subjects with the Splice Variant were 
excluded from the analysis (p = 0.016). 
Table 19 The association between sequence variants. 
 
 
Table 20 The association between the FXIII-B His95Arg and Splice Variant 
sequence variants in the total study population. Adapted from Macrae et al., 
2014. 
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6.2 Fibrinogen-γ’ levels in AAA 
After finding a difference in the distribution of the Fib-γ 10034C>T, a 
sequence variant associated with fibrinogen γ’ levels, between AAA patients 
and controls, fibrinogen levels and fibrinogen γ’ levels were next analysed in 
608 AAA patients and 560 control subjects. The basic demographic for these 
groups can be seen in Table 21. As expected, the AAA group had larger 
aortic diameters compared with controls. The two groups were compared for 
compounding risk factors. There were some differences in the incidence of 
cardiovascular disease, in agreement with previous studies (Alcorn et al., 
1996). There were more current and ever smokers in the AAA group, once 
again in agreement with previous studies with smokers having a greater risk 
of developing an AAA (Singh et al., 2001). There was a greater number of 
AAA patients being on medication, reflecting the increased cardiovascular 
disease burden in this group of patients. After binary logistic regression 
analysis, only aortic diameter remained significantly different between the 
two groups (p < 0.0001). 
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Table 21 Demographic and clinical characteristics of the AAA and Control 
groups from the LEADS study. 
 
 
The plasma levels of fibrinogen γ’ in the AAA and control groups were 
measured by an in-house ELISA described in chapter 2.1.6. All samples 
were diluted to two different concentrations and run in duplicate to ensure 
accuracy of results. Intra-assay variability was measured by comparing the 
same sample on each plate (Figure 60A). Any plates containing a control 
sample that fell outside two standard deviations (red dots) were repeated. 
The plasma fibrinogen levels were measured by the Fibri-prest automate 
assay as described in chapter 2.1.4. All samples were run in duplicate, if the 
duplicate variability was greater than 5 % the sample was repeated. To 
ensure repeatability between days, controls (Control N and P) supplied in 
the kit were monitored between days (Figure 60B). On days where controls 
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were outside the suggested range, all samples on that day were repeated 
(red points). 
 
Figure 60 Intra-assay variability. A, Fibrinogen γ’ ELISA variability, each dot 
represents the average fibrinogen γ’ concentration, from four wells on each plate, of 
a control plasma sample. The solid black line represents the mean value and the 
black dotted lines represent 2 standard deviations from the mean. All plates 
containing a control sample outside 2 standard deviations were repeated (red dots). 
Coefficient of variation = 9.68 %. B, Fibrinogen level assay variability, each point 
represents the fibrinogen level of either Control N or Control P each day the assay 
was carried out. The dotted lines represent the range of acceptable fibrinogen 
levels for Control P (green) or Control N (black). On days where either Control P or 
Control N were outside these ranges (red points), all samples on that day were re-
measured. 
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Figure 61 Association between total fibrinogen levels and fibrinogen γ’. The 
association of fibrinogen and fibrinogen γ’ levels were analysed in A, the whole 
study population (solid line, r = 0.080, p = 0.027). B, AAA patients (Black dots, 
dashed line, r = 0.038, p = 0.428). C, Control subjects (Green dots, dash/dot line, r 
= 0.1281, p = 0.008). 
 
The levels of fibrinogen and fibrinogen γ’ were measured in 606 AAA 
patients and 558 control patients. No association was found between 
fibrinogen and fibrinogen γ’ levels in AAA patients (r = 0.038). However, 
there was a very weak but significant positive correlation within the whole 
study population (r = 0.080, p = 0.027) and control patients (r = 0.1281, p = 
0.008) (Figure 61). This is similar to previous studies that have found at most 
a weak correlation between fibrinogen and fibrinogen γ’ levels (Pieters et al., 
2013, Appiah et al., 2016, Appiah et al., 2015, Uitte de Willige et al., 2005). 
AAA patients were found to have significantly increased plasma levels of 
fibrinogen (3.68 (3.19 - 4.32) g.L-1) compared with control subjects (3.50 
(3.09 - 4.08) g.L-1, p = 0.0012) (Figure 62A). This is in line with a much 
smaller previous study that showed increased fibrinogen levels in AAA 
patients (Al-Barjas et al., 2006). There was no difference in fibrinogen γ’ 
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levels between the AAA patients and control subjects (334.5 (212.2 - 508.0) 
μg.ml-1 vs 334.4 (211.3 - 511.0) μg.ml-1 respectively, p = 0.734) (Figure 62B). 
There was no difference in fibrinogen γ’ % in the controls (9.4 (6.0 - 14.9) %) 
compared with the AAA patients (9.3 (5.6 - 13.7) %, p = 0.17) (Figure 62C). 
There was a very large range of gamma prime levels ranging from 1200 
μg.ml-1 down to 35 μg.ml-1 resulting in gamma prime ratios that ranged from 
40 % down to 1 %. 
 
Figure 62 Increased fibrinogen but not fibrinogen γ’ levels in AAA patients. A, 
Total fibrinogen levels were measured in 609 AAA patients and 558 controls using 
the Clauss method. B, Fibrinogen γ’ levels were measured by ELISA in 609 AAA 
and 558 control patients. C, Fibrinogen γ’ % was calculated by dividing the 
fibrinogen γ’ level by the total fibrinogen level. Data shown as median and IQR. ** p 
< 0.01. Mann-Whitney U test for pairwise comparisons. 
 
After finding no differences in fibrinogen γ’ levels between AAA patients and 
control subjects, the association of the Fib-γ 10034C>T sequence variant 
with fibrinogen γ’ levels within this cohort of patients was assessed (Figure 
63). Fib-γ 10034C>T has previously been linked to a reduction in fibrinogen 
γ’ levels in a number of studies (Uitte de Willige et al., 2005), so this was 
assessed in this group of patients to see if they followed a similar trend. No 
differences in fibrinogen, fibrinogen γ’ levels or fibrinogen γ’ % were 
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observed in patients in possession of the Fib-γ 10034C>T allele in the whole 
study group, or within the AAA patients or control subjects (Table 22, Figure 
63).
 
Figure 63 The association of Fib-γ 10034C>T with fibrinogen and fibrinogen γ’ 
levels. A, Total fibrinogen levels, B, Fibrinogen γ’ levels and C, Fibrinogen γ’ % 
were compared between patients with or without the Fib-γ 10034C>T sequence 
variant (± Thr allele). D, Total fibrinogen levels, E, Fibrinogen γ’ levels and F, 
Fibrinogen γ’ % were compared between patients with or without the Fib-γ 
10034C>T sequence variant (± T allele) within AAA patients or control subjects. 
Data shown as median and IQR. * p < 0.05, ** p < 0.01. Mann-Whitney U test for 
pairwise comparisons. 
 
Table 22 Association of Fib-γ 10034C>T with fibrinogen and fibrinogen γ’ 
levels. 
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6.3 Discussion 
In this chapter the links between five previously described sequence variants 
in the FXIII and fibrinogen genes and AAAs were investigated. In addition, 
the levels of fibrinogen and fibrinogen γ’ in AAA patients were assessed. The 
sequence variants investigated were FXIII-A Val34Leu, FXIII-B His95Arg, 
FXIII-B Splice Variant (intron K nt29576C-G), Fib-α Thr312Ala, Fib-β 
Arg448Lys and Fib-γ 10034C>T. An association between the Arg allele at 
position 95 of FXIII-B and the occurrence of AAA was found. There was a 
small association between the possession of a Fib-γ 10034T allele and 
control patients suggesting a small protective effect of the sequence variant 
against the development of an AAA, but this was not significant after 
Bonferoni adjustment. FXIII-B His95Arg and FXIII-B splice variant were 
found to be in negative linkage disequilibrium. Finally, fibrinogen levels, but 
not fibrinogen γ’ levels, were found to be associated with the development of 
an AAA.  
An over-representation of the Arg allele in patients with AAA suggested that 
FXIII-B Arg allele is a potential risk factor for the development or progression 
of an AAA. The FXIII-B His95Arg sequence variant has previously been 
linked to a 50 % increased risk of venous thrombosis and has been shown to 
increase subunit dissociation of the FXIII-A and -B subunits in plasma 
(Komanasin et al., 2005). It has previously been shown that in the N-terminal 
region of FXIII-B, within the peptide YGCASGYK spanning positions 96–103 
in the second sushi domain, there is an interaction site for FXIII-B with FXIII-
A2 (Katona et al., 2014). FXIII-B His95Arg occurs in the amino acid position 
immediately before the start of this interaction site and may play a role in 
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FXIII-A2 and FXIII-B interactions. Substitution of His to Arg at position 95 
could therefore have an effect on FXIII activation which could result in 
altered cross-linking activity, potentially influencing the stability of the ILT. An 
increase in fibrin clot stability likely leads to a more stable, lysis resistant ILT, 
which in turn may enhance the inflammatory and proteolytic insult on the 
underlying aortic wall, resulting in AAA progression. Although the B-subunit 
has no enzymatic activity, it has been suggested that FXIII-B may help to 
stabilize FXIII-A in plasma and also be important in the secretion of the 
FXIII-A subunit from its site of synthesis in the bone marrow (Iwata et al., 
2009). In addition, there may be hitherto unknown functional roles for FXIII-B 
after it has dissociated from FXIII-A. As FXIII-B may bind to fibrinogen (de 
Willige et al., 2009, Byrnes et al., 2016), FXIII-B may also play an important 
role directing FXIII transglutaminase activity towards its main substrate fibrin. 
These findings indicate that further studies are warranted to fully investigate 
the role of FXIII in AAA. Alternatively, the FXIII His95Arg sequence variant 
could be affecting the role of FXIII in tissue repair of the diseased aortic wall. 
The FXIII A-subunit belongs to the transglutaminase family of enzymes, 
which are known to cross-link various matrix proteins and are involved in 
tissue repair (Dardik et al., 2006). Indeed, FXIII may crosslink collagen and 
fibronectin for example, two proteins involved in the extracellular matrix of 
the vascular wall. Due to its effect on increased subunit dissociation, the 
FXIII-B His95Arg sequence variant could increase FXIII activation at the site 
of fibrin deposition and within the ILT, reducing the amount of FXIII available 
for diffusion into the aortic wall. An increase in the stability of the ILT would 
result in a thicker ILT, so that local hypoxia of the underlying wall would be 
more marked, and there would also be a larger distance between the lumen 
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and the wall, so repair proteins would have further to travel. This could 
negatively affect the role of FXIII in repairing the tissue damage that occurs 
in the aortic wall, resulting in an increased level of AAA development. In 
support of a systemic role of FXIII in arterial wall repair, FXIII Val34Leu has 
been previously associated with arachnoid aneurysms (Ladenvall et al., 
2009). 
Genetic association studies on multiple SNPs can result in type I errors, 
when the null hypothesis is rejected due to multiple testing, but there is no 
true association between the sequence variant and the phenotype (Lunetta, 
2008). To correct for this, we used the Bonferroni adjustment for multiple 
testing. After multiplication of the P values by the total number of SNP’s 
tested, the P value for the association of FXIII-B His95Arg and AAA was 
0.03 so should still be considered significant. However, our findings will need 
to be confirmed in other, large studies of FXIII in AAA.  
There is an ongoing debate in previous literature whether Fib-β Arg448Lys is 
associated with a change in fibrinogen levels. Some studies found no effect 
on fibrinogen concentrations (Lim et al., 2003) and some have found that 
Fib-β 448Lys was associated with an increase in fibrinogen concentrations 
(Kain et al., 2002). In this study increased fibrinogen levels were found in 
patients possessing the Fib-β 448Lys allele, and the association appeared to 
be related to the number of Lys alleles which is largely in agreement with the 
observations by Kain et al, 2002 (Kain et al., 2002). Fib-β Arg448Lys has 
been shown to be in linkage disequilibrium with Fib-β -455 G/A 
(Suntharalingam et al., 2008, Kain et al., 2002), and Fib-β -455 G/A has also 
been associated with an increase in fibrinogen levels (van der Bom et al., 
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1998). The inconsistency of the relationship between Fib-β Arg448Lys and 
fibrinogen levels is likely a reflection of complex gene environment 
interactions including several genetic and environmental factors. FXIII-B 
His95Arg was not found to be associated with fibrinogen levels, so it can be 
assumed that the association with AAA is not due to fibrinogen levels. 
A strong negative linkage disequilibrium was found between the His95Arg 
and Splice Variant sequence variants (D’ = -0.609) of FXIII, and in the 
control subjects the sequence variants were found to be closer to complete 
negative disequilibrium (D’ = -1.0). This should be interpreted cautiously, as 
this relationship may be due to low numbers of heterozygotes for both 
sequence variants. These findings indicate that the minor allele at one locus 
is associated with the major allele at the other locus. Both of these sequence 
variants have previously been reported to show considerable geographic 
differentiation, with FXIII-B His95Arg being most common in populations of 
African descent, whereas the FXIII-B splice variant is most common in 
populations of Asian descent (Ryan et al., 2009). This could help to explain 
the low numbers of heterozygotes and homozygotes for the rare allele for 
both sequence variants. Although the two factor XIII polymorphisms were in 
strong negative linkage disequilibrium, the association of His96Arg with AAA 
was not observed with the Splice Variant. The association of His95Arg with 
AAA was still observed when only subjects who did not possess the splice 
variant were included in the analysis. This further corroborates that the FXIII 
His95Arg substitution plays a role in AAA and that its effects do not appear 
to occur through linkage disequilibrium with the FXIII-B splice variant. 
However, linkage disequilibrium with other potentially functional variants 
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cannot be excluded with these data, and future studies, including genome 
wide association studies, are required to confirm these findings. 
A weak positive correlation was found between fibrinogen and fibrinogen γ’ 
levels in control patients, and this is in agreement with previous studies 
(Pieters et al., 2013, Appiah et al., 2016, Uitte de Willige et al., 2005). This 
correlation was not seen in the AAA group. This suggests that although 
levels of fibrinogen γ’ do fluctuate due to changes in fibrinogen level, other 
factors appear to have a greater influence on γ’ levels. Fibrinogen levels 
were found to be increased in AAA patients, as previously described in a 
much smaller study (Al-Barjas et al., 2006). This maybe be due to the 
relationship between fibrinogen expression and IL-6 (Heinrich et al., 1990) 
with elevated IL-6 levels being previously reported in AAA patients (Juvonen 
et al., 1997), and recent meta-analysis of GWAS studies in AAA indicating 
IL-6 receptor as a major risk factor for AAA (Jones et al., 2017). No 
difference in γ’ levels or γ’ percentage was seen, and this was slightly 
different to previous studies that have shown a link between increased γ’ 
levels and arterial thrombosis (Cheung et al., 2009, van den Herik et al., 
2011, Pieters et al., 2013). Nonetheless, these studies supported the idea 
that other factors modulate γ’ levels. Another result that supports this is the 
huge range of γ’ levels found in the study group ranging from 1200 μg.ml-1 
down to 35 μg.ml-1 resulting in gamma prime ratios that ranged from 40 % 
down to 1 %. With only a weak correlation between fibrinogen and fibrinogen 
γ’ levels within this group, other stronger modulators must be causing the 
vast changes in γ’ levels. 
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In conclusion, FXIII-B Arg95 was found to be associated with an increased 
risk of developing AAA. FXIII-B His95Arg was shown to be in negative 
disequilibrium with the FXIII-B Splice Variant. Finally, fibrinogen, but not 
fibrinogen γ’ levels were increased in AAA patients. Further studies are 
warranted to elucidate the role of FXIII and fibrinogen in AAA pathogenesis 
using in vitro and in vivo models to clarify the underlying mechanisms and 
provide potential avenues in the development of new therapeutic agents. 
6.4 Future work 
This chapter has discussed the association of the sequence variant FXIII-B 
His95Arg with AAAs. The next step in this research would be to assess the 
downstream effects of this sequence variant, and if the changes in FXIII 
caused by this sequence variant play a direct role in AAA development or 
progression. This could be initially examined by examining the FXIII A2B2 
95Arg variant more closely, investigating its role in cross-linking fibrin and 
other matrix proteins. A previous study has shown that the Arg variant leads 
to an increase in subunit dissociation (Komanasin et al., 2005), but the study 
failed to look at the downstream effects of this change. Another approach 
would be to develop a FXIII-B 96Arg mouse model, or inject FXIII-B 96Arg 
into a FXIII deficient mouse, and explore its effects on AAA by using the 
CaCl2 or elastase model of AAA formation (Tsui, 2010). 
To investigate the role of fibrinogen in AAA development, models of murine 
AAA could be carried out in fibrinogen deficient mice. By infusing fibrinogen 
into these mice, the role of fibrinogen in the slowing or progression of 
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dilatation could be investigated. The use of recombinant fibrinogen variants 
could also be investigated in this setting. 
These studies would help to identify if the FXIII-B His95Arg sequence variant 
and fibrinogen play a functional role in the development and progression of 
AAA. They will also help to identify new therapeutic targets for the 
prevention and treatment of AAA. 
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Chapter 7 - The relationship between PNH clone size, 
eculizumab treatment and fibrin clot structure 
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PNH is a rare acquired hematologic disorder, the most serious complication 
of which is thrombosis. The increased incidence of thrombosis in PNH is still 
poorly understood, which unlike many other thrombotic disorders, 
predominantly involves complement-mediated mechanisms. This chapter 
explores the link between thrombosis in patients with PNH and changes in 
clot structure, and also the effects of treatment with eculizumab on clot 
formation. These areas of research are of interest because they may help 
uncover new factors that contribute to the increased risk of thrombosis in 
PNH. Many previous studies have demonstrated links between altered clot 
structure and thrombosis (Bridge et al., 2014). In view of this, clot structure 
was examined in patients with PNH to determine if altered clot structure 
contributes to the increased thrombotic risk in PNH. Pathological effects of 
platelet activation, intravascular haemolysis and neutrophil/monocyte 
activation have already been reported to increase thrombotic risk. While 
impaired fibrinolysis has also been observed and may be caused by several 
mechanisms involving interactions between complement activation, 
coagulation and fibrinolysis. In this chapter, in vitro analysis has been carried 
out on plasma and whole blood samples taken from patients with PNH, in an 
attempt to uncover mechanisms that contribute to thrombosis and impaired 
fibrinolysis in PNH. 
7.1 Patient demographics 
Previous studies on patients with PNH have shown that an increase in 
granulocyte clone size leads to a greater risk of thrombosis (Moyo et al., 
2004), and that patients with different thrombotic disorders show altered clot 
structure (Bridge et al., 2014). Therefore, clot structure was analysed in 
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patients with PNH to investigate if abnormal clot structure could be an 
additional mechanism by which the risk of thrombosis is increased in PNH 
patients. Furthermore, the effects of eculizumab (treatment for patients with 
PNH targeting complement activation) on clot structure was also assessed. 
The demographics and clinical characteristics of the whole group (n = 82) of 
patients, and the distribution of patients on (n = 53) and off (n = 31) 
treatment are presented in Table 23. A significant difference was found in 
granulocyte size and LDH between patients on and off eculizumab. This was 
expected as patients with a high clone size are at increased risk of 
thrombosis, and so are more likely to be on treatment. Eculizumab prevents 
complement activation by preventing C5 activation and this leads to reduced 
inflammation. LDH is a marker of intravascular haemolysis and tissue 
damage, and so a decrease of LDH in patients treated with eculizumab is 
expected (Hillmen et al., 2013, Parker et al., 2005). 
Table 23 Demographics and clinical characteristics of all PNH patients and 
the distribution of patients on and off treatment. 
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7.2 Analysis by clone size 
Due to the effects of eculizumab treatment on inflammation levels and 
prevention of complement activation, the relationship of granulocyte clone 
size with clot formation, structure and breakdown was analysed in patients 
not on treatment. A strong positive correlation was found between increasing 
granulocyte clone size and LDH levels (r = 0.8598, p < 0.0001, Figure 64). 
This indicated that as granulocyte clone size increased, disease severity 
was increasing, indicated by increasing LDH levels. This was in agreement 
with previous studies that have shown that a higher clone size leads to an 
increase in LDH (Schrezenmeier et al., 2014), indicating an increase in 
intravascular haemolysis and inflammation. 
 
 
Figure 64 The relationship between clone size and LDH levels. The effects of 
increasing granulocyte clone size on LDH levels were assessed in patients not on 
treatment. Spearman’s rank correlation. LDH - lactate dehydrogenase. 
 
The relationship of granulocyte clone size with clot structure was 
investigated using confocal microscopy and permeation assays to assess 
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clot density. Changes in granulocyte size appeared to have no link to clot 
density, with confocal images showing no clear differences in clot structure 
between patients with different clone sizes (Figure 65A-B). Permeation 
assays supported this, showing no relationship between clone size and the 
porosity of clots (Figure 65C). 
 
Figure 65 The relationship of clone size with clot structure. The relationship of 
increasing granulocyte clone size with clot structure and porosity was assessed in 
patients not on treatment. A, Representative confocal microscopy images of plasma 
clots from patients with a < 40 %, 40-90 % or > 90 % granulocyte clone size. B, 
Correlation of clone size with fibres/100 μm. Spearman’s rank correlation. C, 
Correlation of clone size with Ks (cm2 x10-9, permeation constant). Spearman’s rank 
correlation. 
 
The relationship of granulocyte clone size with clot formation and breakdown 
was investigated using a turbidity and lysis assays. Changes in granulocyte 
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clone size appeared to have no link to clot formation, with no correlation 
found between clone size and lag time, Max OD, time to Max OD, time from 
25-75 % clotting or turbidity Vmax (Figure 66A-E). 
Similarly, changes in granulocyte clone size appeared to have no effect on 
clot breakdown either, with no correlation found between clone size and time 
to 50 % lysis, time from 25-75 % lysis and lysis Vmax (Figure 66F-H). 
Previous studies have shown correlations between increased thrombotic risk 
and increased fibrinogen levels and thrombin production (Bridge et al., 
2014). Therefore, the relationship of granulocyte clone size with fibrinogen 
levels and thrombin generation were investigated. No correlation was found 
between clone size and fibrinogen levels, endogenous thrombin potential 
(ETP) or peak thrombin generation (Figure 66I-K). 
Together, these data suggest that there are no links between granulocyte 
clone size and clot formation, structure and breakdown or fibrinogen levels. 
 
- 203 - 
 
Figure 66 The relationship of clone size with clot formation and breakdown, 
fibrinogen levels and thrombin generation. The relationship of increasing 
granulocyte clone size with different parameters of clot formation and breakdown, 
fibrinogen levels and thrombin generation were assessed in patients not on 
treatment. A, Lag time (s). B, MaxOD. C, Time to MaxOD (mins). D, Time from 25-
75 % clotting (mins). E, Max rate of clotting (δOD.min-1). F, Time to 50 % lysis 
(mins). G, Time from 25-75 % lysis (mins). H, Max rate of lysis (δOD.min-1). I, 
Fibrinogen levels (g.L-1). J, ETP (nM.min-1). K, Peak thrombin generation (nM). OD 
– optical density, ETP – Endogenous thrombin potential. Spearman’s rank 
correlation. 
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7.3 Analysis by treatment 
Treatment of PNH patients with eculizumab has been shown to drastically 
decrease thrombotic risk. To assess if changes in the clotting process may 
play a role in this reduction of thrombotic risk, the effects of treatment with 
eculizumab on clot formation and breakdown were investigated. Patients on 
eculizumab had a larger clone size of 90.1 % (IQR 71.6-99.7) than patients 
not on treatment with 33.0 % (IQR 5.6-66.2, p < 0.0001, Figure 67A). This 
was expected as studies have shown that an increase in clone size leads to 
a greater thrombotic risk, and therefore a greater need for treatment. 
Treatment with eculizumab prevents complement C5 cleavage, thereby 
inhibiting terminal complement activation. So patients on eculizumab 
presented with much lower levels of LDH, 482 U.L-1 (IQR 409-524), than 
patients not on eculizumab, 615 U.L-1 (IQR 435-1315), indicating a decrease 
in intravascular haemolysis and inflammation (p = 0.0051, Figure 67B). 
 
 
Figure 67 Granulocyte clone size and LDH levels between treatment groups. 
Granulocyte clone size and LDH levels were compared between patients on and off 
eculizumab. A, Granulocyte clone size in patients on or off eculizumab. B, LDH 
levels in patients on or off eculizumab. Mann-Whitney U test for pairwise 
comparisons. Ecu - eculizumab, LDH - lactate dehydrogenase. 
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The effects of eculizumab treatment on clot structure were explored using 
confocal and permeation assays. Patients on eculizumab treatment 
presented with clots that were less dense (Figure 68A). Clot density was 
quantified by counting the number of fibres/100 μm, and patients on 
eculizumab had significantly less dense clots (22.2 fibres/100 μm (IQR 19.7-
32.2)) than patients not on treatment (33.2 fibres/100 μm (IQR 26.4-44.9), p 
= 0.0003, Figure 68B). There was a trend towards a higher porosity of clot 
(Ks) in patients on eculizumab, 7.6 cm2 x10-9 (IQR 3.7-11.5), compared to 
those not on eculizumab, 5.66 cm2 x10-9 (IQR 4.3-9.0), but this did not reach 
significance (p = 0.2763, Figure 68C). 
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Figure 68 The effects of eculizumab treatment on clot structure. The effects of 
eculizumab treatment on clot structure and porosity were assessed. A, 
Representative confocal microscopy images of plasma clots from patients on or off 
eculizumab treatment. B, Effects of eculizumab treatment on fibres/100 μm. 
Spearman’s rank correlation. C, Effect of eculizumab treatment on Ks (cm2 x10-9, 
permeation or Darcy constant). Mann-Whitney U test for pairwise comparisons. Ecu 
– eculizumab. 
 
The effects of eculizumab treatment on clot formation and breakdown were 
investigated using turbidity and lysis assays. Treatment with eculizumab 
appeared to have no effect on lag time, time to maximum OD, time from 25-
75 % of clot formation or the maximum rate of clotting (Figure 69A, C-E). 
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However, patients on eculizumab presented with a reduced maximum OD, 
0.288 ± 0.068, compared to patients not on treatment, 0.355 ± 0.109, 
indicating the formation of less dense clots which is in agreement with the 
confocal data (p = 0.003, Figure 69B). 
Treatment with eculizumab appeared to have no effect on clot breakdown, 
with no differences in time to 50 % lysis, time from 25-75 % of clot 
breakdown and maximum lysis rate found between patients on or off 
eculizumab (Figure 70A-C). 
 
 
Figure 69 The effects of eculizumab treatment on clot formation. The effects of 
eculizumab treatment on different parameters of clot formation were assessed. A, 
Lag time (s). B, MaxOD. C, Time to MaxOD (mins). D, Time from 25-75 % clotting 
(mins). E, Max rate of clotting (δOD.min-1). Ecu – eculizumab, OD – optical density. 
Mann-Whitney U test for pairwise comparisons – A, D. Unpaired student’s t-test for 
pairwise comparison – B, C, and E.  
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Figure 70 The effects of eculizumab treatment on clot breakdown. The effects 
of eculizumab treatment on different parameters of clot breakdown were assessed. 
A, Time to 50 % lysis (mins) B, Time from 25-75 % lysis (mins) C, Max rate of lysis 
(δOD.min-1). Ecu – eculizumab, OD – optical density. Mann-Whitney U test for 
pairwise comparisons. 
 
In view of the anti-thrombotic effects of treatment on clot structure, the 
effects of eculizumab on fibrinogen levels and thrombin production were 
investigated. Patients on eculizumab were found to have decreased 
fibrinogen levels, 2.87 g.L-1 (IQR 2.30-3.38), when compared to patients not 
on treatment, 3.40 g.L-1 (IQR 2.91-4.11, p = 0.0003, Figure 71A). When 
thrombin generation was examined, no difference was found in the time 
taken to begin thrombin production (Figure 71B). However, a significant 
decrease in endogenous thrombin potential (Ecu – 2644 ± 633 nM.min-1 vs 
No Ecu – 3197 ± 625 nM.min-1, p = 0.0002, Figure 71C) and peak thrombin 
production (Ecu – 421 nM (382-479) vs No Ecu – 486 nM (382-479), p = 
0.0038, Figure 71D) was observed in the eculizumab group. This was in 
agreement with a small study on 11 patients with PNH that investigated the 
effect of complement C5 inhibition with eculizumab over 90 days (Weitz et 
al., 2012). 
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Figure 71 The effects of eculizumab treatment on fibrinogen and thrombin 
levels. The effects of eculizumab treatment on fibrinogen levels and thrombin 
generation were assessed. A, Fibrinogen levels (g.L-1). B, Thrombin lag time 
(mins). C, ETP (nM.min-1). D, Peak thrombin generation (nM). Ecu – eculizumab, 
ETP – Endogenous thrombin potential. Mann-Whitney U test for pairwise 
comparisons– A, B, D. Unpaired student’s t-test for pairwise comparisons – C. 
 
With eculizumab treatment leading to decreased fibrinogen and thrombin 
levels, the effects of eculizumab treatment time was investigated. In this 
population the length of time spent on eculizumab was independent of clone 
size, with no correlation between these two parameters (Figure 72A). As the 
length of eculizumab treatment time increased the levels of LDH decreased 
(Figure 72B).  
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Figure 72 The relationship between time on eculizumab, clone size and LDH. 
The relationships between time on eculizumab with clone size and LDH were 
assessed. A, Clone size (Granulocyte %). B, LDH (U.L-1). LDH - lactate 
dehydrogenase. Spearman’s rank correlation. 
 
Fibrinogen levels decreased as the length of time a patient had been treated 
with eculizumab increased (Figure 73A), mimicking the relationship of LDH 
with time on eculizumab. In agreement with this fibrinogen and LDH were 
also found to weakly correlate (Figure 73B) suggesting that their levels may 
be linked. In a similar manner, ETP decreased as the time spent on 
eculizumab increased (Figure 73C), with ETP also positively correlating with 
LDH levels (Figure 73D). ETP and fibrinogen levels were also correlated 
positively (Figure 73E). These data suggest that there is a link between LDH 
levels, fibrinogen levels and thrombin generation, and that the anti-
thrombotic effects of eculizumab may, in part, be through changes in clot 
structure and reduction of fibrinogen and thrombin levels. 
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Figure 73 The relationship between time on eculizumab, fibrinogen levels and 
thrombin generation. The relationships between time on eculizumab with 
fibrinogen levels and thrombin generation were assessed. A, Fibrinogen levels (g.L-
1). B, LDH (U.L-1).v Fibrinogen levels (g.L-1). C, ETP (nM.min-1). D, LDH (U.L-1).v 
ETP (nM.min-1). E, ETP (nM.min-1) v Fibrinogen levels (g.L-1). LDH - lactate 
dehydrogenase, ETP – Endogenous thrombin potential. Spearman’s rank 
correlation. 
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7.4 Whole blood analysis 
Previous studies have indicated that PNH has severe effects on blood cells 
involved in the clot formation process, including haemolysis of RBCs and the 
formation of more active platelets. We hypothesised that increasing 
granulocyte clone size resulting in increased complement activation would 
lead to a change in patient whole blood clot formation and firmness. To test 
this, exploratory experiments were carried out using ROTEM to analyse the 
mechanical properties of patient blood clots as they formed. So far, 15 whole 
blood samples from PNH patients have been analysed by ROTEM, and the 
group demographics are shown in Table 24. LDH levels in this group were 
found to correlate with clone size which was in agreement with the data from 
the whole PNH cohort presented earlier in this chapter (Figure 74). 
ROTEM was carried out in 15 patients with PNH, using ex-tem or in-tem 
assays as described in chapter 2.1.9. Parameters from these measurements 
were correlated with granulocyte clone size to explore the relationship of 
clone size with clot formation. 
Table 24 Demographics of PNH patients analysed by ROTEM. 
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Figure 74 The relationship between clone size and LDH levels in ROTEM 
group. The effects of increasing granulocyte clone size on LDH levels were 
assessed in the subset of patients that were analysed by ROTEM. Spearman’s rank 
correlation. LDH - lactate dehydrogenase. 
 
No correlation was found between clone size and lag time with both ex-tem 
and in-tem. This suggests that increasing complement activation does not 
affect the initial speed of clot formation (Figure 75A). Positive correlations 
were found between clone size and MCF, average rate of clotting and 
maximum clotting rate with both ex-tem and in-tem assays (Figure 75B, D 
and E). There was also a negative correlation between clone size and time 
to MCF with in-tem assays, and a similar trend in the ex-tem assays (Figure 
75C). This indicates that increases in clone size and complement activation 
may lead to more rapidly forming clots that are more stable and harder to 
breakdown. However, since numbers were small in this analysis, future 
studies with a larger number of patients should confirm these findings. 
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Figure 75 Ex-tem and in-tem ROTEM analysis of the relationship between 
granulocyte clone size and clot formation. The relationship between granulocyte 
clone size and ROTEM parameters of clot formation were assessed when clotting 
was initiated with ex-tem or in-tem (n = 15). Correlation of clone size with A, lag 
time (s), B, MCF (mm), C, Time to MCF (s), D, Average rate of clotting between 25-
75 % of clot formation (δ%.s-1), E, Maximum clotting rate (MaxV, mm.min-1). A, D, E 
- Spearman’s rank correlation. B, C – Pearson correlation. MCF – Maximum clot 
firmness. 
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7.5 Discussion 
In this chapter, the role of fibrin clot structure in the development of 
thrombosis in patients with PNH and its treatment with eculizumab was 
investigated. This ongoing study is one of the first to investigate clot 
structure and the role of the fibrin clot in PNH related thrombosis, and is 
based on one of the largest collections of PNH patient plasma in the world. 
Previous studies on patients with other thrombotic disorders have shown a 
link between changes in clot structure and thrombotic diseases. These 
changes include denser fibrin clots with thinner fibres that are less 
susceptible to fibrinolysis (Undas and Ariens, 2011). PNH is a pro-thrombotic 
disorder with many of the patients dying due to thrombotic complications (Hill 
et al., 2013), and a number of studies have shown that there is an increase 
in the risk of developing thrombosis with an increase in the proportion of 
PNH cells (Moyo et al., 2004, Hoekstra et al., 2009, Fowkes et al., 2003). 
PNH is particularly interesting to study with regards to thrombosis 
mechanisms, since uncontrolled complement activation appears to play a 
key role in driving thrombosis risk in these patients. Complement factors 
have previously been shown to influence clot structure (Hess et al., 2012, 
Hess et al., 2013). So it was hypothesized that an increase in the PNH 
granulocyte clone size in patients may result in a more pro-thrombotic clot 
structure.  
Patients with a larger clone size were found to have markedly increased 
LDH levels, indicating increased intravascular haemolysis and tissue 
damage. However, in platelet poor plasma assays no links were found 
between changes in granulocyte clone size and the formation, structure or 
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breakdown of fibrin clots. Furthermore, as clone size increased there were 
no differences in thrombin generation or fibrinogen levels in plasma 
samples. However, patients on eculizumab were found to have decreased 
LDH and fibrinogen levels, and reduced clot density and reduced thrombin 
generation. Analysis of whole blood samples by ROTEM suggested a link 
between increasing clone size and faster forming, more stable clots most 
likely driven by the effects of complement activation on the cellular 
components of blood.  
PNH differs from other thrombotic disorders as the increase in thrombotic 
risk is thought to be due to increased complement activation. A small 
number of studies have explored the link between the complement system 
and fibrin clot structure. One study has shown an association between 
complement activation via the alternative pathway and the formation of 
denser clots that are more resistant to lysis, but failed to uncover which 
complement proteins were involved (Shats-Tseytlina et al., 1994). Another 
study showed that MASP-1 can influence fibrin clot structure in a thrombin 
dependent manner (Hess et al., 2012). Complement protein C3 has also 
been linked to coagulation, with studies demonstrating that C3 is crosslinked 
into the fibrin clot which leads to prolonged fibrinolysis (Howes et al., 2012, 
Richardson et al., 2013). The data in this chapter helps to provide new 
information on the relationship between PNH and thrombosis, highlighting 
the potential role of intravascular haemolysis in the alteration of clot 
structure. 
ROTEM was used to analyse the mechanical properties of blood clots from 
PNH patients. Changes in these properties have been shown in patients with 
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increased thrombotic risk (Spiezia et al., 2008, McCrath et al., 2005). In this 
study, MCF and clotting rate were increased as PNH clone size increased 
when clotting was initiated via the intrinsic or extrinsic pathway. This 
suggests a more prothrombotic state as clone size increases, which is in 
agreement with previous findings (Moyo et al., 2004, Hoekstra et al., 2009, 
Fowkes et al., 2003). Increases in MCF and clotting rates have previously 
been linked to thrombin generation, fibrinogen levels and platelet 
levels/activation (Kang et al., 1985, Schneider et al., 2015, Zuckerman et al., 
1981), however there was no significant relationship seen between clone 
size and fibrinogen levels in this study. This would suggest that changes in 
MCF in PNH patients are most likely due to changes in platelet activation 
and thrombin generation. Despite the loss of CD55 and CD59, PNH platelets 
have been shown to have a normal lifespan, having increased complement 
mediated activation with increased FVa binding sites, resulting in increased 
thrombin generating capacity (Sims and Wiedmer, 1995, Wiedmer et al., 
1993). Platelets have also been shown to be able to shed the MAC complex, 
avoiding complement mediated lysis (Sims and Wiedmer, 1991). 
Alternatively, the observed changes may be due to changes in cells in the 
blood other than platelets (e.g. neutrophils, monocytes and RBCs), either 
effecting polymerization via thrombin generation or altering clotting rates and 
firmness as they were incorporated into the clot. These characteristics may 
offer some explanation for the changes seen in clot properties in this study 
and the pro-thrombotic state in PNH. 
Results from plasma assays showed no link between clone size and fibrin 
clot structure. These results may help to pinpoint where complement 
activation plays a role in clot formation. There are a few possible 
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explanations as to why no differences were seen in plasma samples, but 
changes in clot structure were seen in whole blood samples. ROTEM assays 
were carried out using whole blood, but all other clot structure assays were 
carried out using platelet poor plasma with all blood cells removed. Previous 
studies have demonstrated the multiple factors that contribute to a 
prothrombotic state in PNH and the majority of these involve blood cells 
(neutrophils, monocytes, platelets, RBCs). Therefore, most changes in clot 
structure in PNH patients may arise from changes to the cell components of 
blood. 
Another variation between experimental setups to consider is the initiator of 
clotting. In all plasma assays except thrombin generation, clotting was 
initiated with thrombin bypassing the clotting cascade. However, in ROTEM 
assays, clotting was initiated with thromboplastin or ellagic acid, activating 
the extrinsic or intrinsic pathway respectively. The use of thrombin may have 
bypassed some effects that complement activation may have had on the 
coagulation cascade. Previous studies have suggested links between the 
complement and clotting cascades that may influence thrombin generation, 
but in this study no link was found between clone size and thrombin 
generation. It should be noted that thrombin generation assays were 
performed in the absence of cells, so this could indicate that complement 
activation may play a role in cell based thrombin generation. 
A further point to consider is the presence or lack of activated complement 
proteins or mechanisms in the plasma samples. Complement proteins have 
varying half-lives ranging from 1 minute up to a couple of hours (Kirschfink 
and Mollnes, 2003). Whole blood samples were analysed within 4 hours of 
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the blood draw, so some activated complement proteins would still be 
present, and more may have been generated in the presence of complement 
affected cells or free haemoglobin (Wilson and Thomas, 1979). Plasma 
samples were generated by centrifugation of whole blood within 4 hours of 
the blood draw, and were then frozen and kept for between 2 months and a 
year before analysis was carried out. In this time there could have been 
degradation of complement proteins, resulting in absence of activated 
complement proteins or mechanisms present during the analysis of the 
samples. 
Treatment with eculizumab appeared to show clear effects on clot structure. 
Treatment of PNH with eculizumab has been shown to drastically reduce 
thromboembolic events (Hillmen et al., 2007). It imparts its effects through 
the inhibition of C5 cleavage, preventing downstream complement 
activation. In this study, treatment with eculizumab had significant anti-
thrombotic effects, with patients on eculizumab presenting with clots with 
reduced fibre density, decreased fibrinogen levels and reduced thrombin 
generation. Furthermore, as the length of time spent on eculizumab 
increased, the levels of LDH, fibrinogen and thrombin generation decreased. 
LDH is a tetrameric enzyme that is expressed extensively throughout the 
body and is released during tissue damage and intravascular haemolysis, 
and because of this it is regularly used as a marker of intravascular damage. 
Previous studies have shown that an increase in granulocyte size leads to 
an increase in intravascular haemolysis and LDH levels (Schrezenmeier et 
al., 2014), and this was corroborated in this study, with LDH levels positively 
correlating with clone size. Treatment with eculizumab led to a decrease in 
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LDH which has previously been seen in clinical trials, with eculizumab 
treatment reducing intravascular haemolysis (Hillmen et al., 2007). The 
negative correlation of eculizumab treatment time with LDH levels supported 
previous findings that eculizumab has good long term effects against 
complement mediated intravascular haemolysis (Hill et al., 2005), and 
potentially points to improved or accumulative effects over long time periods. 
The relationships found in this study between eculizumab treatment and 
changes in clot structure, fibrinogen levels and thrombin generation could be 
explained by the reduction in intravascular haemolysis brought about by C5 
inhibition. Increased intravascular haemolysis has previously been linked to 
an increased inflammatory response including amplified IL-6 release 
(Almeida et al., 2015, Conran and Almeida, 2016). In a small study, patients 
treated with eculizumab were found to present with decreased IL-6 levels 
(Weitz et al., 2012). IL-6 is a known regulator of fibrinogen synthesis, with 
fibrinogen genes being highly responsive to changes in IL-6 levels (Heinrich 
et al., 1990), and so it is possible that a reduction in IL-6 levels could lead to 
a reduction in fibrinogen production. The reduction in fibrinogen levels in 
eculizumab treated patients in this study may be explained by a reduction in 
intravascular haemolysis, leading to a drop in inflammation resulting in a 
decrease in the stimulation of fibrinogen production. 
A reduction in thrombin generation in patients treated with eculizumab has 
previously been reported (Helley et al., 2010, Weitz et al., 2012, van Bijnen 
et al., 2015), but the potential mechanisms underpinning reduced thrombin 
generation in patients on eculizumab are still unknown. The independent 
correlation of ETP with LDH and fibrinogen levels in this study suggest that 
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thrombin generation may be linked to one or both of these. Intravascular 
haemolysis is known to result in a pro-coagulant state through the formation 
of RBC fragments, which lead to increased thrombin generation (Stief, 
2007). Reducing intravascular haemolysis with eculizumab treatment may 
lead to a reduction in thrombin generation. The reduction in thrombin 
generation could also be attributed to the reduction in fibrinogen levels. A 
number of studies have highlighted links between thrombin generation and 
fibrinogen levels (Stepien et al., 2007, Kremers et al., 2013, Zentai et al., 
2016), indicating a relationship where increased fibrinogen levels lead to 
increased thrombin generation. This suggests that the opposite is possible, 
with a reduction in fibrinogen levels resulting in a reduction in thrombin 
generation. 
Fibrin clot structure is dependent on many factors including fibrinogen 
concentration and thrombin generation, with increased fibrinogen levels and 
increased thrombin generation both leading to more densely packed clots 
(Machlus et al., 2011, Wolberg, 2007). A decrease in fibrinogen levels and 
thrombin generation could help to explain the changes in clot structure in 
patients on eculizumab, with these changes resulting in a decrease in fibrin 
network density and a less thrombotic state. 
There are a few limiting factors in this study. The rarity of PNH makes it 
difficult to obtain large study numbers, with it taking four years to recruit 82 
patients for this study. A greater number of patients both on and off 
treatment with a larger spread of clone sizes would have increased the 
power of this study. Also a larger number of patients with whole blood 
ROTEM analysis is required. The low number of patients means that the 
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statistical analysis of the ROTEM data may not represent the true effects of 
PNH on clot structure. The introduction of a control group would make it 
possible to compare clot structure to individuals without PNH, but choosing 
the selection criteria for the control group may be difficult. Patients with PNH 
can be split into three groups. Classical PNH, characterized by intravascular 
haemolysis with no evidence of an underlying bone marrow disorder. A 
second group have haemolytic PNH and a bone marrow disorder, such as 
aplastic anaemia. The third group can be defined as subclinical PNH where 
they possess a small proportion of PNH cells, but they have no evidence of 
haemolysis or thrombosis (Parker et al., 2005). There is potential that two 
control groups may be required. One that contains patients with an 
underlying bone marrow disorder and one with healthy controls. A larger 
patient demographic would also help to improve the study, and highlight the 
effects of confounding factors in the disease. 
In summary, this chapter has shown that clots formed from whole blood from 
PNH patients with larger clone sizes had increased stability and formed at a 
quicker rate. However, these changes did not appear in clots formed from 
platelet poor plasma. Eculizumab treatment led to a reduction in LDH levels, 
fibrinogen levels, thrombin generation and clot density. This suggests that 
the anti-thrombotic effects of eculizumab may occur through a reduction in 
intravascular haemolysis, which in turn may lead to a less thrombotic clot 
structure. 
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7.6 Future work 
This study has highlighted that more research is needed into the links 
between PNH and clot structure, and the mechanisms behind eculizumab 
treatment. PNH has a significant effect on blood cells which appears to play 
an important role in PNH driven thrombosis. In this study there was only a 
limited number of patient samples analysed by ROTEM. To increase the 
power of this data more patient samples could be analysed by ROTEM. 
Further whole blood analysis could also be carried out, but many of the clot 
structure experiments are not possible in whole blood. To further the 
understanding of PNH mechanisms in whole blood, whole blood flow assays 
and whole blood SEM could also be carried out, and the assessment of 
fibrinolysis in whole blood could also be investigated using the halo clot 
assay (Bonnard et al., 2017). Thrombin generation in whole blood could also 
be investigated using fluorogenic thrombin generation assays (Ninivaggi et 
al., 2012), this would help to uncover if thrombin generation is increased in 
PNH patients in whole blood, and also help to uncover the mechanisms by 
which eculizumab effects thrombin generation. As the levels of thrombin 
generation were decreased in patients on eculizumab, it would be important 
to measure levels of prothrombin in these patients to assess if reduced 
levels of prothrombin are the reason for reduced thrombin production. 
Measuring haemolysis levels in patient plasma samples could also be 
carried out. This would help to investigate the relationship between 
intravascular haemolysis levels and changes in coagulation factors and clot 
structure. The development of a longitudinal study with multiple follow up 
blood samples from each patient would be of great interest, allowing 
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analysis of changes in coagulation factors and clot structure as the disease 
progresses, and permitting the study of the long term effects of eculizumab 
treatment in more detail. Another line of research that could be followed to 
improve the understanding of PNH and thrombosis would be to stimulate 
complement activation in the blood of healthy volunteers. This would help 
show if complement activation has an immediate effect in blood and if this 
results in changes in clot formation and breakdown. The role of complement 
inhibitors in blood could also be more closely explored in this in vitro setting. 
These studies would help to take a more in depth look at the link between 
complement activation and the coagulation cascade, helping to identify the 
cause of increased thrombosis in PNH. They would also help to develop new 
therapeutic targets for the treatment of PNH and improve the current 
treatments. 
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8.1 General Discussion 
The aim of this thesis was to explore the role of fibrin(ogen) in the settings of 
thrombosis and haemostasis to uncover new mechanisms that cause or 
prevent disease. Fibrin(ogen) plays multiple roles in the body, including the 
facilitation of endothelial cell spreading, tissue fibroblast proliferation, 
capillary tube formation, and angiogenesis which all aid the wound healing 
process. However, its most notable and perhaps best known role is in the 
coagulation process. The formation of a fibrin clot is an important part of 
haemostasis, combining with platelets and other blood cells to form a seal at 
sites of vascular damage to prevent blood loss. When these clots form 
intravascularly it can lead to serious complications in the tissue or organ 
affected, leading to heart attacks and strokes. The role of coagulation and 
the fibrin clot in the initiation and progression of many CVDs is not fully 
understood. Multiple studies have found links between thrombotic disorders 
and changes in clot structure, but in many cases it is still unclear if these 
changes represent cause or effect. This thesis investigated different 
pathways that are known to influence clot structure in an attempt to uncover 
mechanisms involved in the pathophysiology of thrombosis and 
haemostasis. It also explored patients with thrombotic disorders to elucidate 
if changes in clot structure contribute to the formation and progression of the 
disease. By understanding the roles and mechanisms of fibrin(ogen) in both 
haemostatic and thrombotic clots, new targets for therapeutics may be 
uncovered. 
One of the findings presented in this thesis has shown that fibrinogen γ’ 
influences clot formation, structure and breakdown at physiological 
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concentrations. However, the influence of fibrinogen γ’ on CVD is not clear-
cut and the relationship may not be as simple as increasing γ’ levels causing 
denser clots that are harder to break down. The effects of γ’ on clotting and 
fibrinolysis rates in purified systems were not always consistent with those 
seen in patient plasma samples. This may have been due to the influence of 
other components within the patient plasmas, either by these components 
having a greater effect on clotting and masking the effects of γ’, or due to 
interactions between γ’ and plasma factors that were not seen in the purified 
system. A number of these relationships between γ’ and plasma 
components, FXIII and thrombin for example, have already been 
investigated, but several of these studies disagree on the effects of these 
interactions. Without a better understanding of the interactions of fibrinogen 
γ’ with other plasma proteins it is difficult to elucidate the mechanisms of γ’ in 
thrombosis, and so further research is required to uncover this. Further 
insight into this relationship could be achieved with the use of arterial and 
venous thrombosis animal models. The preferred animal for thrombosis 
models is mice, but mice do not possess the fibrinogen γ’ variant. So to 
examine the role of γ’ in mice, thrombosis models would have to be carried 
out in Hu-γ’ transgenic mouse models previously demonstrated by 
Mosesson et al. (Mosesson et al., 2009), or in fibrinogen deficient mice 
infused with human fibrinogen γ’. These models would both have limitations, 
but would provide useful information on the roles of γ’ in a complex in vivo 
situation. 
Another finding of interest presented in this thesis was the effects of 
fibrinogen γ’ under flow and shear stress. Fibrinogen γA/γ’ clots formed 
under venous flow rates were shown to form much quicker and have much 
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greater volume and height than those made with γA/γA fibrinogen under 
comparable conditions. Yet at higher flow rates clots from both γA/γ’ and 
γA/γA fibrinogen variants formed at similar speed, with the difference in clot 
volume and height greatly reduced. These data suggest that there are flow 
rate specific changes in clot structure between fibrinogen γ’ and γA, and that 
these changes could potentially influence thrombosis via different pathways. 
This is an important finding which may provide insight into previous studies 
that have shown associations of increased levels of γ’ in arterial thrombotic 
disorders (Lovely et al., 2002, Cheung et al., 2008, Appiah et al., 2015) and 
decreased levels in venous thrombotic disorders (Uitte de Willige et al., 
2005, Mosesson et al., 2007, Nowak-Gottl et al., 2009). Could the flow rate 
dependent changes seen with fibrinogen γ’ provide an explanation for these 
apposing associations? In arterial thrombosis an increase in fibrinogen γ’ 
could lead to the formation of larger clots with more branched fibres, that 
when combined with the increased pressure of high flow rates become very 
compact and difficult to breakdown. In venous thrombosis lower flow rates 
allow for the formation of larger more voluminous clots. Without the 
increased pressure, an increase in fibrinogen γ’ in this situation could lead to 
less stable more porous clots that are more easily broken down. This 
highlights the need to explore the role of vascular flow rates on thrombosis, 
and investigate not only the role of fibrinogen γ’ in flow conditions, but also 
other factors within the blood. This could be investigated in a similar fashion 
to the animal experiments mentioned previously with the use of arterial and 
venous thrombosis models in wildtype and transgenic mouse models. 
Fibrinogen γ’ levels do not always play a role in CVD. In Chapter 6 it was 
shown that there is no difference in fibrinogen γ’ levels between AAA 
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patients and controls, suggesting that γ’ levels have no influence on the 
incidence of AAA . However, AAA patients have previously been shown to 
suffer from increased thrombotic risk (Thompson et al., 2012) and altered 
clot structure (Scott et al., 2011). This, in part, may be due to the previously 
reported increase in overall fibrinogen levels in AAA patients (Al-Barjas et 
al., 2006, Scott et al., 2011), but changes in clot structure are not normally 
due to the fibrinogen molecule alone. FXIII is known to influence clot 
structure by crosslinking fibrin molecules together, increasing clot strength 
and stiffness, and alterations to this process can play a role in the 
pathogenesis of thrombosis (Hethershaw et al., 2014, Byrnes et al., 2016). 
However, there appears to be very little research into the role of FXIII in 
AAA. Research findings regarding coding FXIII sequence variants presented 
in Chapter 6 indicate that FXIII may indeed play a role in AAA. The allele 
frequency of the sequence variant FXIII-B His95Arg was found to be 
increased in patients with an AAA, indicating a small increase in the risk of 
developing an AAA when in possession of an Arg allele. FXIII-B His95Arg 
has been reported to influence FXIII subunit dissociation and activation rates 
(Komanasin et al., 2005), which in turn may alter clot stability. This presents 
a possible mechanism for the role of this sequence variant in AAA disease, 
but will need further studies, using suitable in vitro and in vivo models. FXIII-
B His95Arg could influence ILT clot structure and/or other clots in the body 
which may contribute to the increased thrombotic risk. Further research is 
required to uncover the role of FXIII and other clot structure modulators in 
AAA. 
Combined, these data are in clear agreement with the notion that thrombosis 
is not a “single gene” disease, and that many disorders that cause or 
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associate with thrombosis are multifactorial, with differential cellular and 
humoral driving mechanisms. These mechanisms are not always induced by 
changes in the clotting process alone, with the inflammatory and immune 
systems often contributing to the pathophysiology of the disease. A prime 
example of this is thrombosis in patients with PNH. A mutation in the PIG-A 
gene leads to increased complement activation which results in a significant 
increase in thrombotic risk (Brodsky, 2014), and this appears to be driven by 
multiple factors (Peacock-Young et al., 2018). In this study patients with 
increased granulocyte clone size were found to have faster forming and 
more stable clots, in agreement with the greater thrombotic risk. Previous 
findings also suggested that changes in fibrin clot structure were not a major 
contributor to thrombosis in this disease. However, this study did find that 
PNH patients treated with eculizumab showed reduced LDH levels, 
fibrinogen levels, thrombin generation and clot density. Eculizumab is known 
to prevent end stage complement activation, which in turn leads to a 
reduction in inflammation (Hillmen et al., 2004). Could this reduction in 
inflammation be the driving force behind the anti-thrombotic effects of 
eculizumab? This, in turn, may also suggest that inflammation may be a 
major component of thrombosis in PNH, and the use of anti-inflammatory 
treatments could be explored in the treatment of this disease. These data 
indicate that increases in platelet activity, haemolysis, inflammation and 
NETs, independent of changes in clot structure, may be the driving force 
behind thrombosis in PNH. 
The lack of changes in fibrin clot structure in PNH patients may begin to 
provide insight into different types of thrombosis and their locations. PNH is 
relatively unique in that thrombosis can occur in just about any site in the 
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body, with common sites including the coronary and cerebral veins and 
arteries (Hill et al., 2012) and the hepatic vein, for reasons still unknown. 
Patients with other thrombotic disorders such as many types of 
thrombophilia (antiphospholipid syndrome, prothrombin and FV mutations 
and antithrombin, protein C and protein S deficiencies), the disease mostly 
presents as venous thromboembolism (Simioni et al., 2006). Previous 
studies data suggest that clot structure is altered in thrombophilia (Undas, 
2017), and many studies have found altered clot structure in patients who 
have suffered a VTE (Undas and Ariens, 2011). This could suggest that the 
driving force behind the thrombosis is important to its location, with 
thrombosis driven in some part by changes in fibrin clot structure occurring 
in certain places more regularly. More research is needed to explore the 
connection between locations of thrombi and the underlying cause for its 
formation. 
To fully understand the implications and mechanisms of fibrin clots in 
disease, a complete understanding of its role in normal coagulation is 
required. We have a vast understanding of many mechanisms of 
haemostasis, but it is clear that our knowledge is far from complete, with 
new information and mechanisms continually being uncovered. This thesis 
reveals a novel mechanism of haemostatic fibrin films that form at the air-
blood interface of external injuries, preventing bacterial invasion. The data 
demonstrate that fibrin films may play an important role in the protection 
against infection. This could lead to new targets to prevent infection at sites 
of injury, preventing blood borne infections, sepsis and infection induced 
thrombosis. It may also provide new therapeutics that could improve tissue 
repair by reducing infections in wounds. Further research is required to 
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uncover the complete structure of the film, fully explore how changes in 
underlying clot structure influence film formation and if fibrin films can be 
exploited to improve wound healing. This may be particularly relevant for 
patients with diabetes, who suffer impaired wound healing (Goodson and 
Hunt, 1977). Furthermore, other diseases may also be targeted for improved 
treatment, e.g. PVD (Henry et al., 2014) and Obesity (Pierpont et al., 2014) 
which result in significant complications and burden to healthcare 
organisations due to wound healing complications. 
This extraordinary finding also begins to raise questions about if these films 
may also be present in thrombosis. Do fibrin films form intravascularly? 
Previous studies with Langmuir-Blodgett experiments have shown film 
formation of fibrin(ogen) on phosphatidylcholine coated surfaces 
(Sankaranarayanan et al., 2010), suggesting fibrin film formation could occur 
on phospholipid surfaces intravascularly. My lab also already has indirect 
evidence of fibrin films forming on intravascular thrombi from murine FeCl3 
models of thrombosis. Others have also observed similar film structures at 
the clot boundaries of arterial intracranial thrombi extracted using stent-
retriever in patients with stroke (van Es et al., 2017, Autar et al., 2018). 
Together these findings begin to support the formation of intravascular fibrin 
films, but further research is required to confirm this. So what effect would 
these films have on thrombosis? Initial studies have indicated that fibrin films 
would not slow lysis directly as they were found to breakdown with plasmin 
at the same rate as fibrin fibres. However, films within thrombi may play an 
indirect role on clot breakdown potentially slowing fibrinolysis rates by 
reducing perfusion of the fibrinolytic proteins through the clot network. It is 
also possible that fibrin films may play a key role in the mechanic stability of 
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thrombi, for example through the retention of RBCs in these thrombi and 
through other mechanisms. The formation of films in thrombi could have 
implications in many thrombotic diseases. Would these films play a bigger 
role in slower forming thrombi like ILTs in AAA, forming in multiple places 
throughout the thrombus, than in the rapid forming thrombi in PNH? Would 
these films form differently in arterial and venous flow rates? These findings 
highlight tantalising new opportunities for future research in this area, with 
the potential to transform our understanding of thrombosis and thrombus 
stability, leading to future novel therapeutic or diagnostic opportunities. 
8.2 Conclusions 
In summary, there are a number of main conclusions to be drawn from this 
thesis: 
1.  Fibrinogen γ’ plays an important role in modulating clot structure at 
physiological concentrations, and it significantly influences the height 
and volume of clots produced under flow conditions. 
2. The FXIII-B Arg95 variant is associated with an increased risk of AAA, 
suggesting a possible role for FXIII in AAA pathogenesis. 
3. PNH patients with increased clone size have a more thrombotic 
phenotype, with faster forming, more stable clots. While changes in 
fibrin clot structure do not appear to be the primary cause of 
thrombosis in this disease, while complement inhibition with 
eculizumab normalises clot structure. 
4. Formation of fibrin films on the blood clot exterior reveal a mechanism 
in haemostasis that helps retain blood cells and control microbial 
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infection, and it appears to be an important physiological process that 
should be exploited in the future. 
This thesis has explored the changes, mechanisms and roles of fibrin clot 
formation, and it has demonstrated how multiple different pathways can 
lead to changes in clot structure. From small changes in the fibrin(ogen) 
molecule (fibrinogen γ’) leading to faster forming larger clots, to the 
introduction of an interface which alters the polymerization process and 
structure of fibrin. These changes have then been shown to be either 
beneficial, protecting against infection, or harmful, promoting thrombosis. 
Together these data have highlighted new mechanisms and pathways 
that can be targeted for future therapeutic treatments. They also 
demonstrate how our current knowledge of fibrin clots in haemostasis 
and thrombosis is still far from complete, and that fibrin needs to remain 
an area of research interest in the future. 
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Appendices 
Appendix 1 - Protocol  
 
Background  
An abdominal aortic aneurysm (AAA) 
is a focal dilatation of the abdominal aorta greater than three centimetres in maximal 
diameter. The condition spontaneously evolves towards rupture, which confers a 
mortality risk in the region of 80 % despite emergency surgery. The current principles 
of management involve watchful waiting with targeted intervention once the annual risk 
of rupture outweighs the mortality risks of intervention. This treatment threshold is 
currently set at 5.5 cm in otherwise fit patients. Open aneurysm repair (OAR) or 
endovascular aneurysm repair (EVAR) are both suitable treatment modalities.  
The clinical risk factors for AAA include male sex, smoking, high blood pressure and 
age; diabetes is thought to be protective. Although atherosclerosis clusters with AAA, 
its precise role in aneurysm development remains unclear. The pathobiology of AAA 
incorporates transmural inflammation, loss of vascular smooth muscle from the arterial 
media, over production of matrix metalloproteinases which destroy collagen and 
elastin. Acting in concert these factors lead to aneurysm formation, but the precise 
event that precipitates this process remains unknown. Furthermore, the factors which 
influence the ongoing growth of AAA once established are debated. It is also apparent 
that patients with AAA are at increased cardiac risk, but how this cardiac risk is related 
to the presence of AAA is also unclear.  
Aims  
The overall aim of the LEADS project is to investigate AAA development, growth and 
outcomes, and thus identify novel treatments. In order to do this, a Leeds based AAA 
database will collect demographic and diagnostic information on AAA and control 
patients and store patients‟ blood, DNA, RNA, protein, plasma and AAA tissue.  
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History  
The Leeds Aneurysm Development Study (LEADS) (Leeds East 03/142) was first 
established in 2003 as a small case-control study (AAA vs. Controls) focused on the 
differences in inflammatory and coagulation markers in male patients with AAA and 
controls. The important novel findings stemming from this work led to the continuation 
of the study and widening of the inclusion criteria. In 2005 women were invited to 
participate in the study and in 2006 the study minimum age limit was reduced from 65 
years to 55 years. As the project grew it became apparent that links should be made 
between the blood results observed at recruitment, and aneurysm tissue and post-
operative blood samples. Thus, following an amendment to the protocol in 2006, these 
samples were collected for further study.  
As the study grew in size and the findings were disseminated locally, the opportunity 
arose to collaborate with other researchers within and outside of the faculty at The 
University of Leeds. These new members of the research team offered fresh 
hypotheses relating to the development and growth of AAA. As a result, and again 
following amendments to the protocol in 2008 – 2010 data collected now includes 
aneurysm imaging and growth, genetics, survival and arterial stiffness (pulse wave 
velocity), with an aim of recruiting a total of 1500 aneurysm and 1500 control patients. 
As specified in the consent form, all participants are followed prospectively from the 
time of recruitment. This offers extensive information as to the dynamics of aneurysm 
expansion (by analysing serial USS and CT scans), AAA prognosis and patient 
survival. In addition, an application has been submitted to link to the Office of National 
Statistics data set in order to collect reliable mortality data for our cohort.  
As a result of increasing public health awareness, particularly with regard to smoking 
and changes in medications (statins and ACE-inhibitors), the number of patients with 
AAA has declined over the last ten years. As a result of decreasing patient numbers, 
but more significantly as a consequence of huge advances in endovascular aneurysm 
repair, the number of people in the UK undergoing open AAA repair has vastly 
decreased. Hence, a collection of aneurysm tissue linked to a data set which includes 
peripheral blood samples, patient characteristics and imaging is undeniably of 
importance internationally as a resource for further research in this area. Thus even 
upon completion of recruitment for this study, we will have established a valuable 
resource for continued research into the cause of AAA disease, which can be utilized 
for future medical students, BSc, MD and PhD projects through the Light Laboratories 
and the University of Leeds.  
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Study Design and Methodology  
This is a prospective observational study recruiting cases (patients with AAA) and 
control (patients with normal diameter aorta) from a variety of sources. We aim to 
recruit a minimum of 1500 AAA patients and 1500 age and sex matched controls in 
order to allow the use of multilevel mixed effects modelling as part of the growth 
analysis.  
This target will also provide sufficient patients for the genetic polymorphism analysis, 
which also requires significant patient numbers. Depending on the frequency of the 
genetic mutation of interest, in order to achieve at least 80 % power with 95 % 
confidence, at least 1000 patients are typically required per analysis. In addition, we 
aim to compare the AAA patient group with a control group to assess the overall impact 
of the risk factors such as cardiovascular disease history or e.g. smoking on the 
development of AAA. We seek to recruit 1500 controls in order to allow effective use of 
propensity score methods when applied to AAA patient subgroups.  
Recruitment of Subjects  
AAA  
Patients undergoing routine ultrasound surveillance for small AAA (3-5.4 cm AAA) and 
those admitted for elective/semi-urgent AAA intervention (> 5.4cms) will be recruited 
from a variety of sources.  
Inclusion criteria for AAA: 
 Caucasian  
 Age ≥ 55 years  
 Aortic Diameter on Ultrasound (≥30mm) 
  Able to provide informed consent.  
Exclusion criteria for AAA:  
 Non Caucasian – very low incidence 
 Age < 55 years – very low incidence  
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Control  
Controls will be recruited from a variety of sources comparable with the initial source of 
referral of the AAA. These will include Vascular Surgery Out-patients Department 
(OPD), General Surgery OPD, Urology OPD, Cardiology OPD, Neurology and 
Diabetes OPD and General Practitioners in addition to volunteers who come forward as 
a result of advertisements in Trust and local media. All controls will have imaging of 
their abdominal aorta (ultrasound or CT scan) to confirm an anterio-posterior diameter 
of less than 30 mm. From the results of previous ultrasound screening programmes, a 
normal aorta (< 30mm) at age 65 ensures that the patient is most likely to be free of an 
aneurysmal dilatation for life. The exact scanning protocol for control subjects may be 
changed in order to match with guidelines laid out by the National Abdominal Aortic 
Aneurysm Screening Programme.  
Inclusion criteria for controls: 
 Caucasian  
 Age ≥ 55 years  
 Normal Aortic Diameter on Ultrasound (< 30mm)  
 Able to provide informed consent.  
Exclusion criteria for controls: 
 Non Caucasian – very low incidence  
 Age < 55 years   
Consent   
Participants will be welcomed to take part at any time. Typically, participants are invited 
to participate at an outpatient clinic and provided with the patient information leaflet 
(enclosed). They are then given at least 24 hours (but typically one week) to consider 
participation before being contacted by the senior research nurse to arrange 
recruitment. Written, informed consent will be obtained at recruitment (usually during a 
recruitment visit or occasionally on attendance for vascular surgery inpatient treatment) 
using a standardised written consent form (as enclosed). Consent will be taken by the 
Lead Research Nurse, by the Chief Investigator and by the Chief investigators 
research fellows, as he deems appropriate. All those taking consent will have 
undergone NIHR approved Informed Consent training, as well as Good Clinical 
Practice training.  Should an individual who has given consent to take part lose 
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capacity during the study, they would be would be withdrawn from the follow up 
process. Identifiable data or tissue already collected with consent would be retained 
and used in the study. No further data or tissue would be collected or any other 
research procedures carried out on or in relation to the participant.   
Demographics, Medical History, Anthropometrics, Haemodynamics, Doppler & 
Arterial Stiffness   
At the recruitment visit, patients will complete a standard proforma (enclosed) 
documenting demographics, medical history, drug history, social history and family 
history. The questionnaire is completed via structured face  to face interview with a 
member of the research team. Following this, a full patient assessment is undertaken. 
This comprises: 
 Measurement of systolic and diastolic blood pressure with oscillometric cuff 
 Measurement of height and weight, and calculation of Body Mass Index (BMI) 
 Measurement of abdominal circumference, hip circumference and waist circumference 
 Ultrasound scan of the abdominal aorta (see below) 
 ECG 
 Palpation of peripheral pulses, Doppler of peripheral pulses and calculation of ankle-
brachial pressure index (ABI) 
 Arterial Stiffness measurement using Vicorder (see below)   
 
Blood Sampling & Analysis   
Venous blood is taken from the antero-cubital vein from the non-dominant arm. A 
tourniquet is applied to aid identification of the vein, and inflated to 40mmHg. Once the 
needle position is confirmed within the vein, the tourniquet is released, and the first 
10mls of blood are discarded, as per the laboratory protocol for all clotting studies. 
50mls of free flowing venous blood is collected.   
As part of their routine clinical care, blood samples are sent to the Leeds Teaching 
Hospitals NHS Trust Pathology Lab for routine tests. These results are then fed back to 
the supervising clinician or general practitioner. The remainder is transferred within 
30mins to the Laboratory for processing and storage prior to experiments. This consists 
of 11ml of blood on room temperature citrate, two 6ml samples on EDTA, 10ml of blood 
on cold citrate and 3ml of blood on cold heparin.  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1.2ml of the room temperature blood is put through the ROTEM device in order to elicit 
an immediate measurement of coagulation through the intrinsic and extrinsic pathways. 
The remainder is then centrifuged; the two cold samples are spun at 4000rpm for 
30mins at 4 °C and the room temperature sample at 4000rpm for 20mins at room 
temperature. The resultant plasma is aliquoted and flash frozen in liquid nitrogen, 
before being stored at -80°C.  
This plasma is used for all coagulation studies and screens for biomarkers of AAA and 
cardiovascular disease.   
The two EDTA tubes each containing 6mls of whole blood are stored at -20°C to be 
used for DNA and RNA extraction. A grade D research technician (Myself) is 
responsible for the processing and initial analysis of blood samples.   
For patients and controls who fulfil any of the following secondary exclusion criteria, 
blood is only taken for DNA, RNA and protein extraction and analysis, so as not to bias 
results of any coagulation studies. These criteria are: 
 Recent Surgery (less than 3 months)  
 Active chronic inflammatory conditions 
 Recent Thrombotic (arterial and venous) event (less than 3 months) 
 Anticoagulation treatments; Warfarin, Factor Xa inhibitors, Therapeutic Tinzaparin 
 Active malignancy   
Vicorder   
The Vicorder device will be used to measure arterial compliance and elasticity. This is 
done by simultaneously recording a pulse wave from the carotid brachial and femoral 
and ankle sites by using an oscillometric method. First a neck pad is applied over the 
carotid artery to prevent compression of the trachea and compression of both carotid 
arteries at the same time. Next the cuff is placed around the patient’s right thigh. Both 
carotid and femoral cuffs are inflated automatically to 65mmHg and the corresponding 
oscillometric signal from each cuff is digitally analysed to extract, in real time, the pulse 
delay. After acquiring several steady pulses the recording is frozen on the display and 
the transit time in milliseconds presented. The distance between the upper edge of the 
right femoral cuff and the sternal notch minus the distance between the lower edge of 
the carotid cuff and the sternal notch is recorded and entered into the computer and 
displayed as PWVcf (pulse wave velocity common femoral). The procedure is then 
repeated with the cuff at (i) brachial and femoral and (ii) brachial and ankle. If the pulse 
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wave is poor on one side the cuffs will be switched to the opposite side. Further details 
can be seen at www.dopstudio.co.uk. The recording takes just over one hour and no 
patients have reported any adverse effects.   
Imaging  
All subjects (AAA and controls) will undergo ultrasound examination of the abdominal 
aorta (maximum anteroposterior (AP) diameter, position and area of ILT) at the 
university. The results of these scans are initially stored on the hard drive of the 
ultrasound machine in an anonymised format, before being transferred to a secure 
university server for long term storage. This ultrasound examination at recruitment will 
be separate to any AAA surveillance the patient undergoes at the Leeds Teaching 
Hospitals NHS Trust. We will ensure all patients with AAA are enrolled in a suitable 
surveillance programme if they wish as part of the National Abdominal Aortic Aneurysm 
Screening programme (NAAASP). Following recruitment in the study and initial USS 
examination at the University, subsequent aortic imaging (USS, Colour Doppler USS, 
CTA, MRA, Angiography) reports will be obtained from the Leeds Teaching Hospitals 
NHS Trust secured results server and added to the anonymised database held within 
the University.   
As patients reach their intervention threshold all patients will undergo further imaging, 
usually CT, or if contraindicated, MRA, as part of the routine NHS care within the Leeds 
Teaching Hospitals NHS Trust. The images are stored on a secured, limited access 
PACS system. We will transfer anonymised CT images to CD to allow transfer of 
images to the University where they will be analysed in the department of 
Biomechanical Engineering using relevant software. This work involves the 
segmentation, mapping and ultimately geometric analysis of the AAA and the ILT in 
three dimensions. The aims of this work are: (1) compare the ultrasound and CT/MRI, 
(2) to study the force and stresses upon the wall, (3) to study the flow through the aorta 
and (4) to model the impact of a metal stent on the aorta. Non-identifiable patient 
images will be stored on the encrypted University server only. The CDs containing 
these images will be stored in a limited access locked room in the University accessible 
to the lead research nurse and the PI.   
All patients recruited as control subjects will also undergo USS at the University. They 
will be counselled as to the potential implications of finding an incidental AAA in the 
same manner as patients attending NAAASP visits at the Leeds Teaching Hospitals 
NHS Trust. Any control patients found to have an AAA will pass into the AAA group 
and will be enrolled in the Leeds Teaching Hospitals NHS Trust AAA surveillance 
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protocol.  
Growth modelling  
It is well established that once an AAA has developed it tends to grow with time, 
however, the pattern of growth is much more unclear. AAA measurements obtained 
from the Leeds Teaching Hospitals NHS Trust server from patients enrolled in the 
study will be used for this analysis by a team of biostatisticians led by Dr Paul Baxter. 
The statistics team will only have remote access to blinded data (see below) for their 
analyses. Growth modelling work will use multilevel mixed effects models to 
characterise the growth of AAAs within patients. Linear mixed models with random 
slopes and intercepts can be considered a reasonable basic model. However, more 
complex non-linear mixed models of quadratic and logistic growth are also of interest. 
As an alternative, allowing for autocorrelation in residuals from a linear mixed model 
will be used as a simple strategy for modelling non-linearity in growth. Autocorrelation 
can be addressed by Box-Jenkins autoregressive moving average (ARMA) structures 
or contrasted with a spatial autocorrelation model that allows for unequal spacing of 
observations through time. Growth mixture modelling will provide an alternative, 
experimental strategy, for characterising growth. Modelling with propensity score 
matched controls is likely to use techniques including linear and generalised linear 
models with multilevel and latent variable techniques, where appropriate, to respect 
complex data structures.  
Operative Samples  
In those patients who require open surgery, the following samples will be taken (1) 
abdominal aortic wall, (2) Intra-luminal thrombus, and (3) blood from the AAA sac. All of 
these samples are normally discarded at the time of surgery.  
In those patients who require endovascular stenting a blood sample will be obtained 
from (i) the sheath placed in the femoral artery and (ii) a catheter placed in the AAA 
sac. The sheath and passage of the catheter through the AAA are part of the normal 
procedure; blood is normally aspirated from these sheaths /catheters and then flushed 
with heparinised saline.  
Follow-up 
1. Control patients  
There is no routine follow up for the purposes of this study.  
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2. Small AAA 30-54mm  
In addition to the NHS follow up US scans (see above), those patients with a small 
AAA 30-54mm will be invited to return at yearly intervals (until the AAA exceeds 55mm) 
to update their demographic data and medications and to give a repeat blood sample.  
3. Large AAA > 55mm at recruitment in those suitable for elective repair  
Those patients who undergo a successful AAA operation (Open or Endovascular) will 
be recalled back to the LIGHT, University of Leeds (if they are fit and well) or we can 
visit them at home after 3 and 12 months for a repeat blood sample and a repeat 
ultrasound examination of the AAA repair site. Previous large scale studies have 
demonstrated that patients return back to a normal quality of life after 3 months and as 
such the majority would be fit enough to travel. Post-operative imaging undertaken as 
part of routine clinical care as outlined by LTHT protocols will be accessed 
electronically by the research team.  
4. Large AAA > 55mm in patients who have declined/been turned down for 
intervention  
The medical results server held by the LTHT will be accessed annually for blood results 
(including Hb, WCC, Plts, Clotting, U&E, CRP and Creatinine and Lipid Profile) and/or 
any subsequent relevant imaging in order to track AAA growth. In addition, should they 
wish to return, these patients are also invited back on a yearly basis in order to update 
their demographic data and medications and to give a repeat blood sample.  
At recruitment, consent is taken for all patients and controls to be followed up through 
Hospital Episode Statistics (HES), Office of National Statistics mortality data (ONS) and 
The Myocardial Infarction National Audit Project (MINAP) to allow collection of relevant 
information regarding patient outcomes, specifically relating to cardiovascular 
morbidity, and mortality.  
Laboratory Methods  
Plasma levels of TAT, F1+F2, D-dimer, TAFI, PAI-I AG, tPA Ag, plasminogen, alpha2-
antiplamin, MMP‟s, insulin and proinsulin are be measured using ELISA kits as well as 
commercially available antibodies, and fibrinogen is assayed using the Clauss Method. 
Thrombin generation is measured using the Calibrated Automated Thrombogram 
(CAT). Other coagulation factors (FVII, FIX, vWF, FXI, FXII) may also be measured by 
ELISA.  
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Cardiovascular Disease (CVD) biomarkers would be analysed using relevant 
biochemical and immunological methods.  
Measurement of plasma glucose and lipid sub-fractions are carried out in the routine 
laboratories of the Chemical Pathology department of the LGI.  
Insulin resistance is assessed using the HOMA model with fasting insulin/glucose 
product, which we have found to be a subtle indicator of insulin resistance in relatives 
of type 2 diabetic subjects compared to controls. In addition there is evidence that 
proinsulin is inadequately processed in the presence of insulin resistance and that the 
insulin: proinsulin ratio is a good indicator of underlying insulin resistance. This will be 
investigated as a marker of insulin resistance in these subjects.  
Factor XIII activity is assayed by a method which employs cadaverine incorporation as 
a surrogate for fibrin cross-linking and which has been developed in the Unit of 
Molecular Vascular Medicine in Leeds. Factor XIII A and B subunit antigens will be 
assayed by in house ELISA. These assays have a sensitivity of 0.4ng/ml of Factor XIII 
A and B subunits with an intra-assay coefficient of variation of 4 % and 6 % 
respectively.  
Assessment of fibrin structure/function; Fibrin permeation characteristics 
Measurement of the permeability of fully polymerised and cross-linked fibrin provides 
structural data regarding fibre thickness and the mass-length ratio. This is done by 
assessing the permeation or Darcy constant Ks. The Ks represent the surface of the 
gel allowing flow through a network and thus provides information on the pore structure 
will be calculated using the following formula: Ks = 
Q. L .η 
/A t ∆P where Q Is the 
volume of liquid (ml) with the viscosity η (10
-2 
poise) flowing through a clot with length 
L (1.3 cm) and a cross-sectional area A (0.049 cm
2
) in time t (sec) under pressure ∆ P 
(dyne/cm
2
). Duplicate clots are formed for each plasma sample, using human thrombin 
and calcium. Samples are incubated in a moist atmosphere for 2 hours to allow for full 
clot formation and cross-linking. The fibrin clots will be washed with 0.05 mol/L Tris-Cl, 
pH 7.5, 0.1 mol/L NaCl, and permeated with the same buffer at a pressure drop of 4 
cm. Flow rate of the buffer through the clots is analysed by measuring total buffer 
filtrate at 30minute intervals.  
Fibrin polymerisation  
Fibrin polymerisation will be studied by following generation of turbidity at 350 nm over 
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the time course of clot formation. Turbidity analysis provides kinetic information 
regarding the lag period and rate of fibrin polymerisation, in addition to fibre thickness, 
which can be calculated from the maximum absorbency at complete clot formation. 
Clot formation of each sample will be triggered in duplicate with thrombin and calcium 
in microtiter plate. Immediately upon addition of thrombin/calcium, absorbency will be 
read every 7 seconds at 350 nm for 15 minutes using a Dynex MRX-TC2 plate reader 
in kinetic mode. Parameters such as lag phase before start of fibrin polymerisation 
slope of the polymerisation curve (A/min) and maximum absorbency at full 
polymerisation will be recorded. The addition of a fibrinolytic agent (tPA) allows for 
analysis of lysis of the fibrin clot, again reading the absorbency every 7seconds over a 
period of up to 8 hours until full lysis has occurred.  
Visco-Elastic properties  
Fibrin cross-linking by FXIIIa is a strong determinant of the elasticity of the fibrin clot. 
We have recently purchased ROTEM equipment. The ROTEM provides a fully 
automated method to measure visco-elastic properties of the fibrin clot in whole blood 
samples or in blood plasma. In collaboration with physics (Leeds University) we have 
also developed magnetic tweezers equipment which we may use to investigate visco-
elastic properties in more detail.  
Confocal Microscopy  
Fibrin clot structure will be imaged using confocal microscopy. In brief, thrombin and 
FITC fibrinogen will be added to plasma samples, and placed into a 6 channel confocal 
microscopy plate. After an incubation period to ensure full clot formation and fibrin 
cross linking, the clots can be imaged using the confocal microscope. This provides 
both 2dimensional and 3 dimensional images. In addition to providing detailed pictorial 
representations of the clot, this will also allow accurate measurement of fibre thickness 
and pore size (by taking relevant measurements at known magnifications).  
Scanning electron microscopy 
Fibrin clot structure will be further investigated by scanning electron microscopy. We 
will make use of electron microscopes (Camscan Series 4 and Camscan CS-44-EX) 
available in the microscopy suit of the Department of Material Sciences at the 
University of Leeds. Clots will be made as previously described. The clot will be 
extensively washed with 0.067 mol/l Na-cacodylate buffer pH 7.2, fixed with 2 % 
glutaraldehyde in cacodylate buffer overnight. Samples will be further processed 
dehydration using a stepwise acetone gradient, critical point drying and sputter coating 
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with palladium-gold. Each sample will be observed in at least 6 different areas for 
digital image analysis. Overall clot structure will be analysed, in addition to 
measurement of fibre image analysis. Overall clot structure will be analysed, in addition 
to measurement of fibre thickness and number of branch points per area using Image 
software version 1.24 (Wayne Rasband, National Institutes of Health, USA).  
Molecular Biology  
DNA extraction  
DNA is extracted from the whole blood samples taken at recruitment. Prior to 
extraction, samples are defrosted in a room temperature water bath.  
The process uses a commercially available DNA extraction kit (QIAGEN maxi spin kit). 
In brief, protease and a lysis buffer are added to the whole blood samples, and then 
incubated at 75°C for 10minutes. 100 % ethanol is added, and following a thorough 
mixing stage, the samples are decanted into the QIAGEN spin column. They are 
centrifuged at 3000rpm for 2minutes, and the filtrate discarded. The column is then 
washed in a two-stage process, before being transferred into a clean centrifuge tube. 
The elution buffer is added, the column incubated to ensure DNA binding, and two final 
centrifugation stages are undertaken.  
The concentration of the resulting DNA sample solution is elicited using the Nanodrop 
reader, at an absorbance of 260nm. Samples are diluted to a final concentration of 
10ng/μL using DNAase and RNAase free TBS, and stored at 4°C. Long term storage of 
concentrated DNA for future work is at -20°C.  
RNA Extraction  
RNA will be extracted using a standardized TRIreagent protocol. Total RNA is 
extracted from VSMC using Tri- reagent (Sigma), bromocriptine and glycogen. RNA 
precipitates were re-suspended in water followed by DNase 1 turbo digestion at 37oC 
for one hour. RNA can be quantified using Ribogreen® (Molecular Probes, Invitrogen). 
0.6ug of RNA is reverse transcribed to cDNA using the Applied Biosystems High 
Capacity RNA to cDNA kit (RT+). 0.6ug is also used for a genomic DNA control in a 
reaction without reverse transcriptase (RT-). Real time PCR is performed using SYBR 
Green I on a LightCycler (Roche). The specificity of PCR is confirmed by performing 
RT negative control experiments and melt curve analysis of PCR products. PCR cycle 
crossing points (Cp) are determined using a fit points methodology (Light Cycler 
Software 3.5). Relative abundance of target RNA is quantified as compared to the 
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housekeeper gene beta actin.  
Protein Extraction  
Vascular smooth muscle cells are collected on ice cold phosphate buffered saline and 
pelleted at 4oC before lysis using Laemmli sample buffer supplemented with complete 
protease inhibitor (Roche). The lysate is centrifuged to remove particulate matter and 
equal amounts of protein are separated by 8 % sodium dodecyl sulphate 
polyacrylamide gel electrophoresis and transferred onto nitrocellulose membrane. 
Membranes are incubated with blocking buffer for two hours at room temperature 
followed by incubation with primary antibodies of interest overnight at 4oC. Membranes 
are washed and incubated with the secondary antibody of interest. Signals are 
detected using super signal west pico chemiluminescent.  
Genotyping  
Currently, DNA samples are genotyped for known polymorphisms of Fibrinogen, Factor 
XIII and TAFI. Commercially available probes are used (Taqman Genotyping Assays). 
Genetic polymorphisms in other coagulation and fibrinolysis related proteins will also 
be investigated.  
In brief, the probe is added to TaqMan Genotyping MasterMix in a 20:1 ratio 
(henceforth referred to as MasterProbe). 2.7μL of MasterProbe and 2.2μL of the diluted 
DNA (10ng/μL) are added to each well of a 384 well plate. Two no template controls 
(containing only MasterProbe) are included on each plate. A LightCycler480 is used for 
programming the real time PCR. Each run consists of 50 amplifications, with end-point 
genotyping following cooling.  
Operative Samples  
Participants undergoing open aneurysm repair at Leeds Teaching Hospitals NHS Trust 
as part of their usual care will be given the opportunity to donate tissue samples as part 
of the study. All tissue taken as part of this process would usually be discarded during 
the operation.  
Aortic Wall  
A segment of anterior aortic wall will be biopsied at the time of surgery and divided into 
different transport media as follows: (1) Dulbecco‟s Modified Eagle Medium 
supplemented with 10 % foetal calf serum and 1 % penicillin/streptomycin transported 
on ice to Dr Porter’s primary tissue culture lab and (2) sterile 0.9 % saline, transported 
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at room temperature to the lab for histological analysis.  
Dr Porter and her team will undertake Smooth muscle cell isolation & culture. An 
explant technique will be used to acquire primary vascular smooth muscle cells 
(vSMC). The media will be isolated and dissected into small fragments (1mm
3
) and 
transferred in 2ml of culture medium to tissue culture flasks and maintained at 37
o
C in 
a humidified incubator in 5 % CO2 in air. After 1-2 weeks, vSMC will be observed to 
migrate out from the explants and passaged in order for experimentation. The primary 
cells will be confirmed as SMC by staining for intracellular smooth muscle-actin and 
myosin heavy chain-2 fibres. Isolated vSMC can be used for DNA, mRNA and protein 
characterisation, in addition to functional and phenotypic analysis studies. Functional 
studies include proliferation, invasion, migration and apoptosis assays. Secretory 
function can be demonstrated with the use of zymography. Phenotypic studies will 
allow the identification of extracellular markers that will help characterise the vSMC.  
Our early work suggests that vSMC isolated from AAA exhibit poor proliferation, 
reduced migration and we have observed a flatter more rhomboid phenotype compared 
to vSMC isolated from internal mammary artery in use in the lab. To further understand 
the driving forces behind this altered phenotype, the vSMC will be used for calcium 
signalling experiments in conjunction with Prof. Beech using a range of 
pharmacological agents, RNA interference strategies and antibodies. This work will 
involve isolation of mRNA/protein from the cultured vSMC in addition to functional 
assays as previously described.  
Intraluminal Thrombus  
The material will be fixed in formalin before sectioning on a microtome to allow 
immunohistochemical analysis of blood coagulation and fibrinolysis related proteins. 
Blood and tissue samples taken from the same patient will be appropriately coded to 
allow them to be matched during analysis.  
Data Management  
The LEADS database itself is managed by Thomas Fleming, Data Management 
Technology Group, University of Leeds. All information stored on this database is 
anonymised. The master database of information is stored on a password protected 
computer in an access-limited area of the university. Access to the original database is 
limited to the database manager, the lead research nurse, and the vascular research 
administrative assistant who works alongside her (David Watson). Access-only use is 
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granted to members of the research team at the discretion of the principal investigator.  
Identifiable patient information is held only as paper copies, and is kept in a secure, 
locked drawer in a limited access area of the University of Leeds. The lead research 
nurse (Mrs Anne Johnson) acts as the custodian for this information, and is the only 
one to have access to the identifiable data. Personal identifiable information will be 
destroyed five years after the end of the study.  
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Appendix 2 - Patient Information Sheet  
 
 
A Study of risk factors in patients with Abdominal Aortic Aneurysms (AAA)  
You are being invited to take part in a RESEARCH study. Before you decide, it is 
important for you to understand why the research is being done and what it will involve. 
Please read the following information carefully and discuss it with friends, relatives and 
your GP if you wish. Ask us if there is anything that is not clear, or if you would like 
more information. A leaflet is produced by INVOLVE (Promoting public involvement in 
NHS, public health and social care research) - www.invo.org.uk gives information about 
medical research and looks at some questions you may want to ask. 
What is the purpose of the study? 
Aortic aneurysm is a common condition where the major blood vessel (aorta) in the 
tummy dilates like a balloon. The vast majority of patients have no symptoms. There is 
some evidence that abdominal aortic aneurysms (AAA) run in families and it is unclear 
whether this risk is due to environmental factors (e.g. diet, smoking, high blood pressure 
etc.) or whether a person’s genes may contribute.  
Given time, however, the aneurysm expands and may burst. Of all the cases of ruptured 
AAA only 10 % survive emergency surgery compared to 95 % who survive elective 
surgery. The wider availability of ultrasound scans as a simple non-invasive method to 
accurately assess the presence of aneurysms and the National Aortic Aneurysm 
Screening means that in future it is likely that we will identify large numbers of subjects 
with early disease. 
At the present time patients with small Aortic Aneurysms (3.0 – 5.0cm) are followed up 
by routine ultrasound scans every 6-12 months depending upon their size. Once the 
Aortic Aneurysm exceeds 5.0cms patients are referred by their consultants for more 
specialised scanning to assess the suitability for treatment. This can be either a CT or 
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MRI/MRA scan. A CT (Computerised Tomography) scan is a type of x-ray examination 
where a cross sectional picture of the area scanned is produced. Magnetic Resonance 
Scanning (known as MRI/MRA)) is a way of looking inside your body without the use of 
x-rays. Instead it uses a large magnet, radio waves and a computer to scan your body 
and produce a detailed picture. 
Surgery in the form of open or stenting (minimally invasive) is reserved for those patients 
in whom the abdominal aortic aneurysm exceeds 5.5cms in diameter. 
The aim of this project is to investigate the cause of abdominal aortic aneurysm, and in 
particular the proteins that cause weakening of the wall of the aorta and the genes for 
those proteins. 
The project should provide us with important information about the cause of abdominal 
aortic aneurysms and may identify relatives at risk of developing the condition. 
The study may also identify further areas of study in the development of new drug 
treatments to stop the abdominal aorta from increasing in size. 
Why have I been chosen? 
You have been chosen because you have an Abdominal Aortic Aneurysm so called 
“triple A” 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part, you will 
be given this information sheet to keep and be asked to sign a consent form. If you do 
decide to take part, you are still free to withdraw at any time and without giving a reason. 
This will not affect the standard of care you receive. 
What will happen if I take part? 
If you are happy to help us with this research project this is what will happen 
You will have nothing to eat or drink after midnight before your visit. 
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You should try not to smoke during this period. 
You will be asked some simple questions about your health. 
You will have cuffs placed around your arm, leg and a pad on your neck which will be 
used to measure the stiffness of your blood vessels. 
You will have a heart tracing. 
You will give a sample of blood (50mls, about 4 tablespoons). These samples will allow 
us to study the levels of blood sugar, fat and factors in the blood, which cause it to clot. 
We will also look at the genes which are involved in the development of aortic 
aneurysms and the formation of new blood vessels and blood clotting 
You will have a simple ultrasound test (very similar to the scans that pregnant women 
have) to measure the size of the abdominal aorta. This is painless and takes 5-10 
minutes. In those cases where it is difficult to see the aorta we will arrange a separate 
ultrasound scan at St James’ Hospital, this will be undertaken by Dr Michael Weston, 
Consultant Radiologist. 
The above tests will take place in the clinical research unit of the LIGHT laboratories of 
the University of Leeds. You will be asked to attend for an appointment with a research 
nurse, which will last about one hour. We will write to you to confirm a suitable day and 
time for the assessment. We will send you details of how to get to the LIGHT building 
either by local transport or taxi. 
We will access your electronically held medical records annually. We will register your 
data with the NHS Information Centre and the NHS Central Register so that we can 
track your progress over the study time period. As such your data will be identifiable to 
us.  
We will write to you on a yearly basis to ask if you would be prepared to return for a 
further a repeat assessment. 
- 277 - 
  
 If your aortic aneurysm is larger than 5.0cms your consultant will arrange for you to 
have either a CT scan or an MRI scan. This is part of the normal workup to assess how 
best to treat your aortic aneurysm. We would like to have your permission to store 
these anonymised images and use them at a later date to study (1) the comparison 
between ultrasound and CT/MRI, (2) the force and stresses upon the aortic wall, (3) the 
flow through the aorta and (4) the impact of a metal stent on the aorta. This work will be 
undertaken by Dr Peter Walker (Department of Mechanical Engineering, University of 
Leeds) 
If you are having an operation for your aortic aneurysm we would ask permission to 
collect the following samples: 
Fluid between the aortic aneurysm wall and the blood clot 
A blood sample (20 ml) from the aneurysm sac, 
A sample of the wall of the aortic aneurysm and 
The blood clot within the aneurysm. 
 All of these tissues are usually discarded at the time of surgery 
Post operation 
You will be seen in the outpatient department at approximately six weeks following 
surgery. 
At this stage we will ask if you would be happy for a further sample to be taken at 3 to 6 
months post operatively. This could be arranged as a home visit. 
You will have nothing to eat or drink after midnight before your visit. 
You should try not to smoke during this period. 
You will give a sample of blood (50mls, about 4 tablespoons). These samples will allow 
us to study the levels of blood sugar, fat and factors in the blood, which cause it to clot.  
What are the potential risks from taking part? 
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Taking a blood sample is unlikely to cause any problems, although some people 
experience minor discomfort or bruising. 
What are the potential benefits from taking part? 
There are no direct benefits to you for taking part. In the future we hope that the 
information we get from this study may help us to improve the treatment of patients 
with abdominal aortic aneurysms. We will be able to assess whether life-style changes 
and or new drug treatments may help those patients with small abdominal aortic 
aneurysms and relatives at highest risk of developing abdominal aortic aneurysms. 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available. In your case this may be an increase in the size of your abdominal aorta. If 
this happens, your research nurse will tell you about it and discuss with you whether 
you want to continue in the study. If you decide to withdraw, arrangements will be 
made for your care to continue. If you decide to continue in the study you will be asked 
to sign an updated consent form and the necessary information passed onto your 
consultant surgeon and general practitioner. 
What if something goes wrong? 
If taking part in this research project harms you, there are no special compensation 
arrangements. If you are harmed due to someone’s clinical negligence, then you may 
have grounds for a legal action but you may have to pay for legal advice. Regardless of 
this, if you wish to complain about any aspect of the way you have been approached or 
treated during the course of this study, the normal National Health Service complaints 
mechanisms should be available to you. 
Will my taking part in this study be kept confidential? 
All information, which is collected, about you during the course of this research will be 
kept strictly confidential. Any information that leaves the laboratory will have your name 
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and address removed so that you cannot be recognised from it. The blood, fluid and 
tissue samples taken to look at the proteins and genes will be given a study number so 
that it is impossible in any way to identify you from them. 
You should be aware that the samples of blood, fluid and tissue will be stored in a 
freezer and may be used for future studies at a later date. 
Any abnormalities detected in your blood sugar or fat will be forwarded to you and your 
general practitioner. 
What will happen to the results of the study? 
The results of the study will be published in a variety of surgical journals and discussed 
at surgical meetings. Please note that you will not be identified in any report or 
publication. 
Who is organising and funding the research? 
The study is based in the Division of Cardiovascular and Diabetes Research at the 
Leeds Institute of Genetics, Therapeutics and Health at the University of Leeds. The 
study is currently funded by The Garfield Weston Trust, Circulation Foundation, British 
Heart Foundation and Wellcome Trust. 
Who has reviewed the study? 
Leeds (East) Research Ethics Committee has reviewed the study. 
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Contact for further information. 
Any further questions regarding the study can be easily answered by calling Anne 
Johnson Vascular Research Nurse 0113 343 7702 or by writing to Professor Julian 
Scott, Leeds Vascular Institute, Leeds General Infirmary, Leeds LS1 3EX Version 10 
01/02/2012 
Thank you for considering whether to take part in this research 
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Appendix 3 - Patient Consent Form  
 
Subject Identification Number:  Name of researcher: Prof D J A Scott       
        Anne Johnson 
I confirm that I have read and understand the study information sheet dated.../../…., and have had the 
opportunity to discuss it with relatives and friends, and ask any questions.  
I understand and accept that if I take part in the study I may not gain any direct personal benefit from it. 
I understand that all information collected in the study will be held in confidence and that, if it is presented 
or published, all my personal details will be removed from it. 
I confirm that I will be taking part in this study of my own free will. I understand that I may withdraw from it, 
at any time and for any reason, without my medical care or my legal rights being affected. 
I understand that any blood and tissue samples collected as part of the study are given freely as a gift. I 
consent to my samples being examined for genetic factors which are thought to influence the formation of 
aneurysms. I agree to transfer any property rights to the samples I provide to the University of Leeds on 
the understanding that it is only used for research. 
I agree to my electronically held medical records being accessed annually by the research nurses 
assigned to the study 
I understand my details will be registered with the NHS Information Centres 
I agree to participate in this study. 
 
Name     Signature    Date 
Name of Person taking consent Signature    Date 
One copy for patient, 1 copy for researcher, 1 copy to be kept with hospital records 
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Appendix 4 – Purification of fibrinogen γA/γ’ and γA/γA - Concave gradient for 
elution 
Sample elution: Gradient from 0 % to 100 % Buffer B1, over 13.4CV, 2ml/min (3.5ml 
fractions, +6°c) 
5 %   Buffer B1, 3.16 CV 
10 % Buffer B1, 3.63 CV 
15 % Buffer B1, 3.63 CV 
20 % Buffer B1, 3.63 CV 
25 % Buffer B1, 3.63 CV 
30 % Buffer B1, 3.63 CV 
40 % Buffer B1, 3.63 CV 
10 % Buffer B1, 3.63 CV 
10 % Buffer B1, 3.63 CV 
10 % Buffer B1, 3.63 CV 
10 % Buffer B1, 3.63 CV 
10 % Buffer B1, 3.63 CV 
10 % Buffer B1, 3.63 CV 
Column wash: Buffer B1, 5 CV, 2 ml/min 
Column equilibration: Buffer A1, 5 CV, 2 ml/min 
Run time ~ 350 min 
Pool peaks fractions and store at -80 °c 
Store column at +4 °c 
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Appendix 5 – In-house fibre density macro 
I produced a macro using image J (v2.0, NIH), which runs through the following steps: 
Maximum intensity projection of a 20 μm (all layers of Z-stack flattened into one), and 
subtraction of background (Figure 76A). 
The resulting image is made binary (Figure 76B) 
A vertical line is drawn across the image (Figure 76C) 
All parts of the image are removed except for the sections of the clot fibres that cross 
the yellow line (Figure 76). 
The number of points that crossed the line is quantified and this represents the number 
of fibres that crossed the yellow line 
This is repeated 9 more times vertically at different points across the image, and then 
10 times horizontally down the image. 
From this the average number of fibres/100 μm can be calculated. 
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Figure 76 Fibre density macro. The multiple stages of the macro have been 
separated. A, Z-stacks are flattened. B, Images are made binary. C, 10 vertical 
and 10 horizontal lines are drawn across the image at different points. D, For 
each line all areas of the image are deleted except the sections of fibre that 
intersect the line. These are then quantified. 
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Appendix 6 - DNA extraction from whole blood using the QIAGEN Maxi-Column 
Kit  
Before starting  
Prepare a 70°C water bath 
Buffer AW1 should be prepared (mixed with ethanol as indicated on the bottle) 
Stored at room temp 
Buffer AW2 should be prepared (mixed with ethanol as indicated on the bottle) 
Stored at room temp 
QIAGEN protease should be prepared (Add 5.5mls of distilled water) 
Blood should be defrosted in a room temperature water bath   
Procedure  
Pipette 500μL QIAGEN protease into the bottom of a 50ml centrifuge tube (each vial of 
protease will be enough for 11 blood samples)    
Add 6ml of blood (one full pink topped tube)    
Add 4ml of PBS    
Mix briefly    
Add 12ml of Buffer AL (provided in kit), mix thoroughly by inverting the tube 15 times 
then shaking vigorously for a minute.    
Incubate at 70°C for 10minutes (incubating for longer will not adversely affect the DNA 
yield)    
Add 10ml of ethanol (96-100 %) to each sample    
Mix by inverting 10 times and then shaking vigorously again    
Transfer half of the solution into the QIAamp maxi column within a 50ml centrifuge 
tube. 
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Ensure the rim is dry and close the cap   
Centrifuge at 1850 x g or 3000 rpm for 3 minutes    
Remove the maxi-column from the centrifuge tube, discard the filtrate, ensure the tube 
is dry and replace the column    
Transfer the remaining solution into the maxi-column    
Centrifuge again at 1850 x g or 3000 rpm for 3 minutes    
Remove the maxi-column from the centrifuge tube, discard the filtrate, ensure the tube 
is dry and replace the column    
Add 5ml of Buffer AW1 to the QIAamp maxi column. Pipette carefully, without 
moistening the rim. Pipette to the side of the column (not directly onto the membrane) 
   
Centrifuge at 4500 x g or 5000 rpm for 1 minute.    
Without discarding the filtrate, add 5 ml of buffer AW2 to the QIAamp maxi column.    
Centrifuge at 4500 x g or 5000 rpm for 15minutes    
Place the QIAamp maxi column in a clean 50 ml centrifuge tube.    
Discard the collection tube containing the filtrate    
Pipette 1 ml of Buffer AE directly onto the membrane of the QIAamp maxi-column. 
Incubate at room temperature for 5 minutes.    
Centrifuge at 4500 x g or 5000 rpm for 2 minutes.    
Two final steps:  
For maximum concentration of DNA – reload the eluate containing the DNA onto the 
maxi column. Incubate for 5 mins at room temperature. Centrifuge at 4500 x g or 5000 
rpm for 5 minutes. 
